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ABSTRACT 
Microbiomes are communities of bacteria. These communities exist in a variety 
of places ranging from soil and the ocean to various locations on the human body. Next 
generation sequencing technologies have made it possible to catalog the bacteria that 
live in these communities as well as the metabolic functions which they are capable of. 
Now that the studies of what microbes are present or what functions are present has 
become routine, questions of why these communities exist in certain compositions as 
well as why they shift with disease are being explored. 
One way to understand the functional interactions among bacteria with their hosts 
is through metabolomics. Untargeted metabolomics approaches catalog the milieu of 
small compounds that exist within a sample. Associations between the microbiome and 
the metabolome give a functional understanding of the interactions in a microbial 
community. Integrative analyses of the microbiome and metabolome often take two 
approaches: 1. Correlate between the data types and 2. Use knowledge of microbial 
genomics to understand the metabolism in the community. Both approaches have 
limitations. Correlative approaches involve large numbers of statistical tests which limits 
power. Integrative analyses tend to be very manual, requiring either consultation with 
domain experts or searching for information in databases and literature. 
To address these issues, I have developed a variety of methods and tools to better 
integrate microbiome and metabolome data. To improve correlation network analyses, I 
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have developed a tool for Sparse Correlation Network Investigation for Compositional 
data (SCNIC). SCNIC builds correlation networks, detects modules of highly cooccurring 
features and summarizes them into singular features. By binning features into modules 
there are statistical advantages, an increase in statistical power and decrease in 
dependence between features, and groups of correlated features can provide insight 
into the relationships between features. I show that SCNIC modules, from 16S rRNA 
sequencing data, are consistent in their associations with outside metadata with 
microbes that make up the modules. Modules also are enriched in biological signal. I 
applied SCNIC to metabolome data and found that  many modules seem to be made up 
of near identical compounds and are likely technical artifacts. 
I developed methods to ease integration of microbiome and metabolome data via 
microbial genomic databases. I used this approach in a study of children with autism 
spectrum disorders with specific metabolites of interest and then generalized it to create 
a tool for Annotation of Metabolite Origin via Networks (AMON). AMON can predict the 
origin of compounds based on provided gene sets and I found that the compounds 
predicted to be produced by a microbial gene set was enriched in microbial functions 
and the compounds predicted to be produced by the human gene set was enriched in 
human functions. 
I used these techniques for an integrative analysis of the HIV human gut 
microbiome and plasma metabolome. I found significant associations between modules 
of microbes, detected by SCNIC, and compounds detected using metabolomics. Some 
modules had predicted direct productive and consumptive relationships, as predicted 
with AMON. Additional metabolic relationships were predicted based on enriched 
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pathways in modules of microbes. Modules with enriched pathways were correlated with 
compounds that are members of the enriched pathways. 
Together, these methods and results advance the state of the art in microbiome 
and metabolome integration studies. SCNIC and AMON both allow microbiome and 
metabolome researchers to better understand their data with free and open source tools 
designed for use by a wide audience. By integrating these data types which give 
information about the microbes present in a system, as well as the functional end 
products of metabolism, we can understand the roles and interactions between 
microbes in these systems. With this knowledge, we can advance the goal of rationally 
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Bacteria live in nearly all environments present on earth from the arctic (Thompson 
et al., 2017) to human gut (The Human Microbiome Project Consortium, 2012). These 
microbes form an integral part in the metabolism across the environments in which they 
exist including within human associated communities. The collection of microbes that 
make up a community is often referred to as a microbiome. Host associated microbiomes 
are communities associated with a separate living host such as a human. The most 
studied host associated community is the human gut. In the gut there are about .2 kg of 
bacteria including almost as many bacterial cells as human cells (Sender et al., 2016). 
Dysbiosis, changing of a microbiome from the healthy state, has been detected 
(Duvallet et al., 2017), but currently association-based studies are most common. 
Associating the abundance of a microbe or gene with disease has become easier with 
newer sequencing technology as well as comprehensive software packages such as 
QIIME (Caporaso et al., 2010). Transitioning from associative studies to functional will 
provide insights into the mechanisms that will drive microbiome science to have real 
impacts on the treatment of disease. 
This chapter introduces the technologies as well as the current state of the art in 
generating microbiome data as well as metabolome data. I start by introducing methods 
for measuring various characteristics of the microbiome via sequencing technologies. The 
efforts for measuring and analyzing the metabolome are explained before a deeper 
exploration of the current work in microbiome and metabolome data integration. 
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1.1 Measuring Microbial Communities 
The measurement of microbial communities has been happening for more than 40 
years (Tiedje, 2000). The microbial ecology of human associated microbiomes has been 
studied just as long (Savage, 1977). It was the initial usage of ribosomal RNA (rRNA) 
genes with oligonucleotide cataloging approaches that showed the huge diversity of 
microbe present in many natural environments (Woese, 1987). The 16S rRNA gene is 
present across all bacteria and only slowly mutates because of the strong conservation 
pressure. Because of this, the 16S gene can be used to make phylogenetic trees which 
can be used to measure the relatedness of bacteria. 
Additionally, the 16S rRNA gene is composed of conserved and variable regions. 
The conserved regions can be targeted by PCR primers. The design of universal primers 
meant that large amounts of bacterial diversity could be measured via sequencing 
approaches (Pace, 1997). The advent of next generation sequencing changed the 
landscape of microbiome research allowing for high throughput sequencing of the 16S 
gene in microbial communities (Hamady et al., 2008). 
Shotgun sequencing provides insight into the functional potential of a community. 
The functional data, in terms of the abundance of genes in a community, is key to 
understanding the roles of specific microbes in their communities. 16S sequencing data 
cannot directly give this functional information but is cheaper to produce and gives a more 
direct measurement of the relative abundance of bacterial taxa. 
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 1.2 Genomic Databases and Prediction of Function from Phylogeny 
Progress has been made in culturing microbes from the environment, especially in 
well studied communities such as the human gut (Browne et al., 2016). Culturing 
microbes has allowed for wide scale whole genome sequencing and so functional 
analysis of genes. Genomic and functional databases such as KEGG (Kanehisa et al., 
2017) and MetaCyc (Caspi et al., 2014) have been developed. These databases contain 
information linking genomes to genes, to chemical reactions, to compounds, which makes 
possible a metabolic understanding of these well understood genomes. 
Because gene content of a microbe is associated with phylogenetic relatedness, 
genome content of a 16S sequence can be imputed. Tools such as PICRUSt (Langille et 
al., 2013) and Tax4Fun (Aßhauer et al., 2015) have been developed for this task. These 
algorithms generally follow the same working principles. Closely related bacterial taxa 
tend to share a higher percentage of genes. These algorithms use data relating the 
phylogenetic distance between microbes, measured via 16S alignment, and the genomes 
of well characterized taxa to predict the gene content of 16S sequences that do not have 
fully sequenced genomes. The power of these tools is limited by the availability of 
annotated genome sequences. Since human microbiomes, especially the gut 
microbiome, are well cultured and annotated, functional analysis of microbiomes from 
16S data is possible. 
1.3 Metabolomics as a tool to understand microbial function 
The primary limitation of 16S sequencing studies is the difficultly of linking the 
abundance of a microbe to functional changes in the. Metabolites are the functional end 
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point of biological systems and give an understanding of functionality within a microbial 
community. The abundance of small compounds in a biological sample can be measured 
using untargeted mass spectrometry or NMR. These compounds can be annotated and 
then understanding of the possible role of microbes in a metabolome can be inferred. 
 1.4 Current efforts in microbiome and metabolome data integration 
By integrating 16S microbiome data and untargeted metabolomics there is 
potential to find microbial taxa associated with disease and metabolites. There are two 
primary ways these analyses are done: 1. Correlation based analyses and 2. Knowledge 
based integration analyses. 
In correlation-based analyses, correlations are calculated between metabolites 
and microbes. Significant correlations are interpreted as potentially interacting partners 
that could represent a productive, consumptive or other indirect relationship. These 
analyses are limited by statistical power because of the large number of comparisons 
between hundreds to thousands of microbes and hundreds to thousands of metabolites. 
Interactions are difficult to confirm because while a correlation may suggest a relationship 
it does not prove its existence or biological relevance. 
This gap can be filled by knowledge-based integration analyses. Genomic 
information can be used to find potential relationships between the data types. The data 
backing these relationships can be found in genome and metabolism databases 
(Kanehisa et al., 2017; Caspi et al., 2014), or by consulting domain experts.  
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 1.5 Contributions 
This work is focused on increasing the power of microbiome and metabolome 
integration analyses via both correlation and knowledge based techniques (Figure 1.1). 
1.5.1 Finding and Summarizing Modules of Highly Cooccuring Features 
Correlation analysis of ‘omics data is a common technique, including in 16S based 
microbiome analyses. This is especially true in microarray and sequencing based RNA 
expression studies where the weighted gene correlation network analysis (WGCNA) tool 
is commonly used (Langfelder and Horvath, 2008). WGCNA is a tool for finding modules 
based on traditional correlation metrics and a module finding technique centered on 
finding hub and spoke patterns in correlation networks and summarizing the modules. 
Some microbiome studies have utilized WGCNA but it is not designed for the data 
properties of microbiome data, such as compositionality. I developed and validated 
SCNIC to make correlation networks, find modules in the networks and summarize the 
highly correlated groups of features (Figure 1.1A). SCNIC is available as both a 
standalone python package (https://github.com/shafferm/SCNIC/) and QIIME 2 plugin 
(https://github.com/shafferm/q2-SCNIC/). 
1.5.1.1 Modules of microbes are consistent and enriched with biological signal 
The microbes in modules detected should be all positively cooccurring with each 
other and associate with metadata in the same direction as the module. To validate that 
modules were biologically relevant, I set the assumption that biologically interesting 
modules would be more closely phylogenetically related than uncorrelated pairs of 
features. These tests were used to validate the module detection methods used and their 
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parameters. I additionally tested if modules share more functionality than expected based 
on their phylogeny. Therefore, I used linear regression to determine if pairs of bacteria in 
modules had more shared gene content, in terms of KEGG Orthology units (KOs), than 
pairs of bacteria that were not correlated with each other. 
1.5.1.2 Modules increase power in 16S sequencing analyses 
The relative abundances of the bacteria in microbiomes are not independent as 
can be measured by correlation analyses. Correlation analyses are commonly limited by 
statistical power due to the large number of features, in this case bacteria, present. By 
summarizing the modules where all taxa correlated with each other, statistical power is 
increased since the number of features has been decreased. The increase in power is 
demonstrated across multiple datasets. 
1.5.1.3 Preprocessing of sequencing data affects the content of detected modules 
The methods used for generating representative sequences from microbiome data 
is rapidly changing. Where operational taxonomic unit (OTU) picking methods grouped 
sequences at a set percent identity of sequences, new methods, such as DADA2 
(Callahan et al., 2016), can differentiate sequences that are separated by a single 
nucleotide. When DADA2 is used, as either a preprocessing step before OTU picking or 
alone, the modules detected by SCNIC tend to be phylogenetically diverse. 
1.5.1.4 Modules of metabolites show signatures of technical error in an LC/MS system 
SCNIC was applied to metabolomics data to find modules of highly cooccurring 
compounds. Large modules of compounds were found when very stringent parameters 
were used to determine edges in the correlation network. Deeper investigation of these 
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modules revealed that they were composed of compounds with very similar mass and 
retention times that likely represent technical error in the peak calling step. SCNIC could 
be used as a quality control step to eliminate some noise. 
1.5.2 Tools for Integrative Analyses of the Microbiome and Metabolome via Databases 
To integrate microbiome and metabolome data, genomic information is used to 
understand the metabolic potential of the microbiome and its effect on the metabolome. 
Consulting domain experts with knowledge of microbes of interest and their metabolism 
or by manually genomic databases is common to understand these interactions are 
common approaches. We have developed a tool to predict metabolic products of 
microbes, as well as their hosts, to find compounds potentially produced by the 
microbiome, which automates this process (Figure 1.1B). 
1.5.2.1 Including putative metabolite origin in a microbiome/metabolome integration 
analysis provides insight into disease 
In a data set that includes NMR metabolomics and 16S rRNA sequencing from 
feces in a cohort of individuals with Autism Spectrum Disorders (ASD), we identified 
metabolites of interest that are potentially produced by bacteria present in the samples. 
We used PICRUSt to predict metagenomes. Then we used KEGG to predict the 
metabolites that the metagenome could produce. Metabolites that were associated with 
ASD were able to be traced to a potential bacterial origin. 
1.5.2.2 AMON: Annotation of Molecular Origins via Networks 
To generalize the ability to predict the metabolites which can be generated by a 
microbe or set of microbes, we developed the tool Annotation of Molecular Origins via 
Networks (AMON) (Shaffer et al., 2018). This tool takes one or more gene sets that are 
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used to predict metabolites that could be produced by those genes based on metabolic 
information in the KEGG database. Additionally, the user may provide a list of 
compounds, such as those detected in a metabolomics analysis, to find compounds that 
have been produced by any provided gene sets. As output, the list of compounds and 
their origins is given, in addition to files for visualizing the origins of these compounds 
using KEGG mapper. AMON is demonstrated on a data set where the metagenome 
predicted by PICRUSt is used as a gene set and the human genome as another. 
Xenobiotic degradation pathways were enriched in compounds detected in the 
metabolomics and predicted to be produced by microbes. Human associated pathways 
including bile secretion were enriched in metabolites detected in the metabolomics and 
predicted to be produced by the human host. 
1.5.3 Demonstrating a thorough integration of microbiome and metabolome data to 
investigate HIV and associated comorbidities 
HIV is associated with a large shift in the composition of the gut microbiome, 
although this effect may be influenced by other confounding factors such as men having 
sex with men (Noguera-Julian et al., 2016; Armstrong et al., 2018). With a data set 
including fecal 16S microbiome data and LC/MS metabolome data I demonstrate a 
thorough integrative analysis of the effect of HIV as well as lipodystrophy, a metabolic 
disease which is a comorbidity of HIV, on these data types (Figure 1.1). This serves as a 
preliminary analysis for what will become a much larger cohort. 
1.5.3.1 Metabolites are associated with both HIV and Lipodystrophy 
LC/MS untargeted metabolomics was done on the plasma of all individuals in the 
cohort. Differential abundance of compounds was tested for between HIV+ individuals 
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who were not undergoing antiretroviral therapy (ART) and HIV- individuals to find 
associations with HIV. Differential abundance was also measured in HIV+ individuals 
undergoing ART were compared to HIV+ individuals undergoing ART with lipodystrophy 
to find associations with lipodystrophy. Compounds were found that associated with both 
HIV and Lipodystrophy and when used in a pathway enrichment analysis multiple 
enriched pathways were found. 
1.5.3.2 Significant correlations exist between the microbiome and metabolome which 
are supported by pathway enrichment of microbial genomes 
SCNIC was used to find modules in 16S data from the feces before correlating 
with metabolomics data. Multiple correlations were found between SCNIC modules from 
the microbiome and the metabolome. To test the ability of modules to potentially break 
down or produce these metabolites we measured the enrichment of KEGG pathways with 
genes, unexpected to occur across modules by chance, predicted to be encoded by the 
16S sequences in each module. Significant microbiome-metabolome correlations were 
found where the modules were enriched in genes of the same pathway of the correlated 
compound even when the compound was not well annotated in KEGG. 
1.5.3.3 Metabolites associated with HIV and Lipodystrophy could come from bacterial 
sources 
To determine if metabolites with significant correlations with the microbiome as 
well as those associated with HIV or lipodystrophy could have been produced by 
bacteria, we used AMON to predict the metabolites which could be produced by the 
fecal microbiomes. One metabolite was found to have potentially been able to be 
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produced by the module which it was associated with and multiple significant 
metabolites were of possible bacterial origin. 
 1.6 Outline of Dissertation 
This dissertation aims to develop better methods for integration of microbiome 
and metabolome data in order to better understand the effects of microbial metabolism 
on disease. Chapter II provides a survey of the literature on integrating microbiome and 
metabolome data as well as background information on both data types. Chapter III 
outlines SCNIC, a tool for finding and summarizing modules of highly cooccurring 
microbes. Chapter IV uses database information to more easily understand links 
between microbial presence and metabolome composition. Chapter V, shows a 
thorough integrative analysis with the goal of uncovering the possible microbial 
contribution to a metabolic comorbidity associated with the antiretroviral therapy. Finally, 
chapter VI explores the future potential of integrating microbiome and metabolome data 




An overview of the work in this thesis where tools have been developed for improving 
both correlation and knowledge-based analyses. These methods can be integrated to 
find correlations and explain them with metabolic databases. (A) SCNIC was developed 
to build correlation networks and find modules of highly correlated features. This can be 
applied to a variety of data types. Correlations can then be done between data types. 
(B) Genomic databases can be used to identify if genes can produce or degrade a 
metabolite of interest. This can also be used to determine if a microbe or host can 




2.1 The Microbiome 
An important concept for understanding the state and challenges of microbiome 
research was articulated by Donald Rumsfeld in 2002, when he said, “There are known 
knowns; there are things we know we know. We also know there are known unknowns; 
that is to say we know there are some things we do not know. But there are also unknown 
unknowns – the ones we don't know we don't know…. it is the latter category that tend to 
be the difficult ones (Rumsfeld and Myers, 2002).” 
The modern microbiome field began with a great discovery of “unknown 
unknowns”. Starting in the mid-1980s researchers began using targeted sequencing of 
ribosomal RNA (rRNA) genes to survey microbial populations (Stahl et al., 1985). Studies 
began to reveal deep branches of the tree of life previously unknown either because the 
organisms were invisible to the naked eye or uncultivable in the laboratory (Pace, 1997). 
Considering how many “unknown unknowns” there were about the microbes that live in, 
on and around us just 30 years ago, the progress made in the field of microbiome 
research is remarkable.  
Several key aspects of microbiome research have contributed to this rapid 
progress. First, the early adoption of the highly conserved small subunit rRNA gene as a 
phylogenetic marker allowed for relating all cellular life on earth onto one phylogenetic 
                                                        
 
1 Parts of this work was previously published in the journal Translational Research as Shaffer et al. 
“Microbiome and metabolome data integration provides insight into health and disease.” 189:51-64 
(2017). Reprinted with permission. 
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tree (Pace, 1997, 2009). Examining novel environmental 16S rRNA gene sequences in 
an evolutionary context allowed for some properties of uncultivated organisms to be 
predicted. Even when such functional predictions were not possible (e.g. because the 
16S rRNA gene sequence was extremely different from any previously characterized 
organism), simply moving our understanding of microbial biology from one of “unknown 
unknowns” to “known unknowns,” allowed for the identification of key gaps in 
understanding. For instance, the 16S rRNA sequences from an uncultivated group of 
bacteria in the α-proteobacterial lineage called SAR11 was found in nearly every pelagic 
marine bacterioplankton community, accounting for 26% of all rRNA genes in sea water. 
Targeted efforts led to the isolation and biological characterization of SAR11 isolates 
(Rappé et al., 2002). Using other –omics techniques coupled with experimental validation, 
the diverse and complex functions of the SAR11 (Huse et al., 2008) lineage in the world’s 
oceans continue to be elucidated (Tsementzi et al., 2016). 
A second factor that has contributed to rapid progress in microbiome research is 
next-generation sequencing. These technologies were used for 16S rRNA targeted 
characterization of microbial communities through use of the 454 sequencing platform in 
2008 (Dethlefsen et al., 2008; McKenna et al., 2008; Huse et al., 2008). Starting in 2011, 
the 454 platform was largely replaced with the more high-throughput Illumina platforms 
(Caporaso et al., 2011). Coupled with development of bioinformatics pipelines for 16S 
rRNA targeted microbiome analysis such as QIIME (Caporaso et al., 2010) and of 
taxonomic databases for linking 16S rRNA gene sequences to named 
organisms/lineages (e.g. Silva (Quast et al., 2013) and greengenes (DeSantis et al., 
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2006a)), deep sequencing of microbial populations in many different environments, 
including many human body sites in disease contexts, has occurred. This has led to a 
plethora of papers describing associations of human microbial communities with diseases 
including obesity (Raman et al., 2013; Martinez et al., 2017), depression (Evrensel and 
Ceylan, 2015), inflammatory bowel disease (IBD) (Halfvarson et al., 2017; Dickson, 2017) 
heart disease (Kitai et al., 2016; Wang et al., 2011; Haiser et al.) and  autism (Clayton, 
2012; Buie, 2015; Rosenfeld, 2015). Next generation sequencing has also enabled the 
sequencing of shotgun metagenomes and transcriptomes. Shotgun metagenomes 
survey the “functional potential” of a microbial community by mapping the genes present. 
The metatranscriptome adds an extra layer of information of the genes actively 
expressed. Effective functional analysis of microbial communities using shotgun 
metagenomic and metatranscriptomic data is highly dependent on our underlying 
knowledge of how gene sequences relate to enzymatic or other functions, which is 
summarized in databases such as KEGG (Kanehisa et al., 2017) and MetaCyc (Caspi et 
al., 2014). However, as for 16S rRNA databases where many known sequences 
represent organisms of unknown characteristics, the genes detected in shotgun 
metagenomes and metatranscriptomes contain many genes of unknown function. As an 
example, only a median of 18.9% percent of the genes present in bacterial genomes in 
KEGG can be mapped to a KEGG Orthologue (KO) of known function based on 
homology. In some cases, only a general function is known for a given gene. For instance, 
Bacteroides thetaiotaomicron has 280 genes predicted to be glycoside hydrolases in the 
Carbohydrate Active EnZyes database (CAZY) because they have sequence domains 
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related to families of structurally-related catalytic and carbohydrate-binding modules, but 
only 44 of them are in KEGG. 
As described for the SAR11 cluster and 16S rRNA, identifying “known genes of 
unknown function” that may be of particular relevance due to their ubiquity or a strong 
correlation with disease can focus targeted efforts to elucidate their functional roles. In 
one study, a family of nonribosomal peptide synthetase gene clusters in gut bacteria was 
targeted for functional analysis because they were present in 88% of the National 
Institutes of Health Human Microbiome Project stool samples and transcribed under 
conditions of host colonization (Kanehisa et al., 2017). By expressing a subset of these 
clusters in Escherichia coli or Bacillus subtilis, it was determined that their gene products 
lead to the production of peptide aldehydes with protease inhibitory activity that selectively 
targets a subset of cathepsins in human cell proteomes(Guo et al., 2017). The ubiquity of 
these enzymes indicates that they have the potential to be an important mediator of gut 
microbiome/host interactions. 
While there have been many advances in microbiome sequencing workflows, the 
key challenge for the microbiome field, and essential for translational research, is to move 
beyond associations to an understanding of mechanism. One challenge for generating 
testable hypotheses regarding mechanistic links between microbial communities and 
disease is a lack of understanding of microbial function in disease causality. A potential 
way to address fill this gap is through the application of metabolomics with microbiome 
analysis. 
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2.2 The Metabolome 
An important tool for understanding microbial community function is metabolomics. 
Metabolomics is a growing field that comprises the measurement of hundreds to 
thousands of small molecules in a system (Wishart, 2016). It encompasses metabolite 
profiling, lipidomics, and metabolic flux measurements (Sethi and Brietzke, 2017; Wishart, 
2016) and can also include the targeted analyses of specific small molecules, including 
sex hormones, lipid mediators (Armstrong et al., 2009), and amino acids (Armstrong et 
al., 2007).  
While genomics, transcriptomics, and metadata provide valuable information 
regarding phenotypes and molecular mechanisms, metabolomics provides a real-time 
view of dynamic changes as they occur through the quantitation of small molecules. Small 
molecules play several roles in the cell including membrane structure (lipids), signaling 
(lipid mediators, neurotransmitters), and building blocks (amino acids). They are also 
involved in many processes affected by exogenous influences; these include response to 
oxidative stress (redox potential), inflammatory response, and energy metabolism, to 
name a few. Overall metabolomics can be thought of as a functional measurement of 
dozens to hundreds of molecules. This functional knowledge is essential for 
understanding the links between microbial communities and disease. 
Metabolomics can be conducted using either mass spectrometry-based or nuclear 
magnetic resonance (NMR)-based platforms. NMR offers reproducible, quantitative 
measurement of approximately 125 small molecules, including carbohydrates, nucleic 
acids, and fatty acids (Spratlin et al., 2009; Markley et al., 2017). NMR is highly robust, 
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can be performed in vivo, for instance to obtain biochemical information about the tissues 
of the human body in a non-invasive way (without the need for a biopsy), and is non-
destructive. However, due to the relatively lower sensitivity of NMR, mass spectrometry-
based platforms have become increasingly adopted by clinical and research laboratories 
wishing to conduct metabolomics.  
One advantage of metabolomics is that it is agnostic to the nature of the sample 
type or treatment group; hence, it is a valuable tool for both hypothesis generation 
(untargeted approaches) and testing (targeted approaches). However, numerous 
challenges exist (Kohler et al., 2016) including multiple compound name assignments to 
a single mass, lack of database search scoring algorithms, limited coverage of important 
pathways using a single technology, uncharacterized metabolic and degradation 
products, and lack of standardized nomenclature and analytical methods that compare 
datasets. High throughput sampling and analysis as well as data interpretation pose 
additional challenges; traditionally, the interpretation step has been challenging for 
researchers when only long lists of potential biomarkers or compound masses (MS) are 
provided as the final results. Despite the availability of sophisticated pathway analysis 
programs (Persicke et al., 2012; Xia et al., 2016), a thorough interpretation of the data 
has often been beyond the scope of many metabolomics studies; this is especially 
emphasized in the context of microbiome/host studies, where the origin of metabolites is 
unclear. 
However, metabolomics is still limited by several “known unknowns”. Due to their 
chemical diversity, it is impossible to quantitate every species or even class of small 
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molecule using a profiling approach. Therefore, targeted small molecule analysis (based 
on robust mass spectrometry assays) are used to quantitatively pinpoint the roles of 
individual molecules. For example, inflammatory responses can be elucidated by 
measuring individual lipid mediators that are part of the arachidonic acid pathway (Spite 
and Serhan, 2010). Examples of targeted small molecule analyses are most often found 
in newborn screening, where small molecules are used to determine the presence of 
many metabolic and genetic disorders (Kohler et al., 2016). While a precise and accurate 
means of quantitating small molecules, targeted assays require knowing the molecule of 
interest and are often limited in the numbers of molecules that can be quantitated. 
Additionally, many metabolomics “known-unknowns” and “unknown-unknowns” 
cannot be mapped to current pathways. Even knowing the chemical class or species of 
these molecules may not be enough to deduce their function. Overall, the challenges in 
both microbiome and metabolome data interpretation highlights the need for efforts to 
further develop our knowledge so that the results of multiple ‘omics studies can be used 
to understand mechanisms and phenotypes in human health and disease. 
2.3 Microbiome Effects on Host Metabolism 
Metabolomics has been applied to a variety of human sample types where 
bacterial metabolites may be found. These include sites where the bacteria reside and 
are active, including nasal passages, feces, and skin (Garg et al., 2017; Donia and 
Fischbach, 2015), as well as peripheral sites without resident bacterial communities such 
as blood (Wikoff et al., 2009; Marcobal et al., 2013; Martin et al., 2007a), urine (Marcobal 
et al., 2013; Martin et al., 2007b) and liver (Martin et al., 2008). The latter are of interest 
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because these metabolites have translocated through host barriers (e.g. skin or mucosal 
sites) and have potential for more systemic health effects. Metabolomics analyses of 
microbiome-influenced samples often have a primary aim to measure well-characterized 
metabolites such as short chain fatty acids (SCFAs), siderophores, and biotransformation 
products from host metabolites and xenobiotics (Gilbert et al., 2016; Clarke et al., 2014; 
Sridharan et al., 2014; Ursell et al., 2014; Wishart, 2016). Untargeted analyses aimed at 
understanding microbiome effects on the metabolome of host-derived samples are 
complicated because the compounds detected represent a complex milieu of 
environmental compounds as well as those produced by microbes and/or the host.  
Determining the origins of metabolites that cause or influence disease is important 
for developing targeted therapies. Microbes have highly enhanced metabolic capabilities 
compared to humans; the gut microbiome encodes an estimated ~ 10 million genes (Li et 
al., 2014) compared to an estimated 19,000 in humans (Theriot et al., 2014). Microbiomes 
have the genetic capacity to produce a wide variety of structurally diverse specialized 
metabolites including natural products, small molecule virulence factors, and signaling 
metabolites including quorum sensors and autoinducers (Donia et al., 2014; Donia and 
Fischbach, 2015; Garg et al., 2017). Most specialized metabolites, their biosynthetic 
origins, and their roles in microbiome related disease remain understudied (Garg et al., 
2017).  
A broad understanding of how the presence of a microbiome affects the host 
metabolome has come from comparing germ free (GF) mice, (i.e. mice with no associated 
microbial communities), to mice with colonizing microbes including 1) conventional mouse 
 23 
microbiota (Wikoff et al., 2009) 2) the microbiota of different humans (i.e. humanized 
mice) (Marcobal et al., 2013) or 3) specific individual bacterial species (Wikoff et al., 2009; 
Marcobal et al., 2013). Similarly, other studies have compared the metabolomes of mice 
treated with antibiotics to non-antibiotic treated controls (Theriot et al., 2016; Antunes et 
al., 2011). These studies have found that microbial colonization/composition has a 
profound influence on both the presence and relative abundances of many metabolites in 
various sites including the blood (Wikoff et al., 2009; Marcobal et al., 2013; Martin et al., 
2008), urine (Martin et al., 2008; Marcobal et al., 2013), feces (Marcobal et al., 2013), 
liver (Martin et al., 2008), and ileum (Martin et al., 2008). Differences observed in GF 
and/or antibiotic treated mice in the various studies include changes in amino acid 
metabolism pathways (e.g. a loss of transformation of tryptophan into tryptamine and 
indole derivatives (Wikoff et al., 2009; Martin et al., 2007b; Marcobal et al., 2013; Antunes 
et al., 2011)), polysaccharide metabolism (e.g. increases in non-digestible plant-
polysaccharides in feces (Marcobal et al., 2013)), decreases in SCFAs, increases in 
primary bile acids and decreases in secondary bile acids (Antunes et al., 2011) and 
elevation of creatine and creatinine (Swann et al., 2011; Romick-Rosendale et al., 2009; 
Marcobal et al., 2013). Microbiota colonization also results in differences in many small 
compounds of unknown identity/function (Marcobal et al., 2013). 
Another way to estimate which metabolites in host samples originate from host 
versus microbial metabolism is to use metabolic networks described in databases such 
as KEGG (Kanehisa et al., 2017). These networks capture the relationship between 
metabolites, the enzymes that produce them, and the organisms (both host and microbial) 
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that contain genes encoding those enzymes (Figure 2.1A). These networks can, in 
principle, provide a framework for relating the genes/enzymatic reactions present in the 
colonizing bacteria (genome/shotgun metagenome), the expression of those genes 
(metatranscriptome), and presence of the encoded proteins (meta-proteome), and the 
metabolites (metabolome) in a sample (Figure 2.1B). They also provide a framework for 
investigation of microbiome/host co-metabolism (Figure 2.1C).  
2.4 Linking Microbiome/Metabolome with the Exposome  
Another important level of complexity is how the metabolome and microbiome are 
linked with the exposome (e.g. exogenous factors such pollutants, hygiene products, and 
the diet). One of the most studied facets of the exposome is diet. Diet composition 
substantially alters the human microbiome (David et al., 2013; Ruengsomwong et al., 
2014) and diet induced changes can occur as rapidly as within a day (Turnbaugh et al., 
2009; David et al., 2013). This change is accompanied by alteration in bacterial gene 
expression (David et al., 2013), suggesting that the microbiome is elastic and poised to 
quickly respond to varied diet exposures. 
Studies in both humans (Wu et al., 2016; Scalbert et al., 2014; Edmands et al., 
2015; De Angelis et al., 2015) and animal models (Marcobal et al., 2013) have shown 
that consumption of different diets is associated with changes in microbially-produced 
metabolites. For instance, high fiber diets have been associated with the increases in 
both fecal (Heinritz et al., 2016; Russell et al., 2011) and circulating (Trompette et al., 
2014) levels of SCFAs. Another study of humans on a high protein diets saw an increase 
in levels of the carcinogenic N-nitroso compounds compared to a maintenance diet, 
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thought to be driven by increased protein fermentation and decreased carbohydrate 
fermentation by colonic microbiota (Russell et al., 2011). Broader effects of fiber 
consumption on the fecal and urine metabolome were observed in a study comparing 
mice on a standard low fat (LF) to a high fat (HF) diet (Montoliu et al., 2016) which 
suggests that lack of complex polysaccharides may be a large contributor to the HF-diet 
associated microbiome/metabolome.  
Though a significant facet of the exposome, daily exposures extend beyond diet. 
A large area of exposure is the skin which is composed of a diverse and rich microbiome, 
varying by body site (Grice et al., 2009). Spatial mapping of the microbiome and 
metabolome across 400 sites of the human body revealed associations between 
microbes and the metabolites present (Bouslimani et al., 2015). Most notably 
Propionibacterium was associated with sebaceous sites and highly correlated with 491 
metabolome features, 73% of which were lipids. Further in vitro analysis revealed that 
Propionibacterium acnes can oxidize oleic acid, the breakdown products of which have 
were found in sebaceous sites (Bouslimani et al., 2015). These findings suggest that the 
skin microbiome influences the chemical landscape of the skin metabolome.  
The host microbiome is also important in xenobiotic degradation. Gut microbes 
can metabolize a range of environmental chemicals in ways that can affect their toxicity 
to the host, including polycyclic aromatic hydrocarbons (PAHs), nitrotoluenes (which are 
important intermediates in the manufacture of dyes and plastics), and pesticides (Claus 
et al., 2016). PAH degrading microbes have also been observed on human skin (Sowada 
et al., 2014). Additionally, gut microbes have also been associated with breakdown and 
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reactivation of a variety of drugs including the cardiovascular drug, digoxin and the cancer 
drug, irinotecan (Spanogiannopoulos et al., 2016). 
2.5 Identifying Important Microbially-Produced Metabolites for Health and Disease 
Studies aimed to explore an association between microbial metabolism and 
disease states often focus on well-characterized microbial metabolites such as 
SCFAs(Lee and Hase, 2014). However, approaches that can identify novel bio-active 
microbial metabolites as mediators of microbiome-host or microbe-microbe interactions 
are increasingly being applied (Wilson et al., 2017). These include: 1) Bioactivity-guided 
screening, in which a phenotypic bioassay is performed by testing a collection of 
microbes, chemical extracts, or cosmid libraries generated from metagenomics DNA 
against a panel of host pathogens or signaling pathways (Cohen et al., 2015; Zipperer et 
al., 2016). 2) Candidate molecule workflows, which mine existing (meta)genomics data 
to identify Biosynthetic Gene Clusters (BGCs) that may produce metabolites of interest 
because they are prevalent or correlate with disease (Donia et al., 2014). 3) Integrative 
analysis of microbiomes and untargeted metabolomes in disease contexts (Elaine Y. 
Hsiao et al., 2013; Neis et al., 2015; Koeth et al., 2013; Theriot et al., 2016; Wang et al., 
2011). All of these approaches can identify molecules with potential roles in mediating 
host-microbe interactions that can be further validated in in vitro or in vivo systems. 
Bioactivity-guided workflows have led to the identification of several metabolites 
that mediate interactions between microbes and the host or other microbes. For instance, 
commendamide, which activates the G-protein-coupled receptor G2A/GPR132 (G2A has 
been implicated in disease models of autoimmunity and atherosclerosis), was discovered 
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initially in a screen of 3,000 megabases of metagenomic DNA for effectors that activate 
NF-κB, a transcription factor that plays a role in mediating responses to environmental 
stimuli (Cohen et al., 2015). Lugdunin, a novel antibiotic that prohibits colonization by 
methicillin-resistant Staphylococcus aureus (MRSA), was discovered by screening for the 
mechanism by which Staphylococcus lugdunensis, a microbe that occupies the same 
niche as MRSA, could inhibit the growth of MRSA in vitro (Zipperer et al., 2016). 
Bioactivity-guided workflows can also include random mutagenesis of the microbe of 
interest combined with high-throughput phenotypic screening for loss of function, and 
imaging mass spectrometry of competing microbes in vitro (Harvey et al., 2015; Moree et 
al., 2012; Cohen et al., 2015). 
Candidate molecule workflows identify BGCs that allow microbes to produce 
metabolites and capitalize on knowledge of the core enzymatic machinery responsible for 
their biosynthesis, which has been well-characterized for many classes of specialized 
metabolites (Donia et al., 2014). This knowledge has been used to develop and 
implement bioinformatics platforms, such as anti-SMASH and related platforms, to detect 
widely distributed and closely related gene cluster families, identify potential metabolite 
producers, and guide purification workflows (Blin et al., 2013; Medema et al., 2011; Weber 
et al., 2015; Blin et al., 2017; Zierep et al., 2017; Khater et al., 2017). Candidate molecule 
methods have also led to the identification, structural elucidation and/or synthesis of 
metabolites that mediate interactions between microbes and the host and/or other 
microbes. These include colibactin, a secondary bacterial metabolite with genotoxic 
properties (Balskus et al., 2015), lactocillin, a potent thiopeptide antibiotic made by 
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a prominent member of the vaginal microbiota (Donia et al., 2014; Guo et al., 2017), 
(dihydro)pyrazinones, which are prevalent in the human gut and that release a peptide 
aldehyde that inhibits cathepsins in human cell proteomes, and humimycins, antibiotics 
with activity against MRSA (Chu et al., 2016). Candidate molecule workflows can also be 
combined with tandem mass spectrometry (MS/MS) data to link MS/MS spectra of 
unknown metabolites to their biosynthetic origins, simplifying compound isolation and 
characterization (Kersten et al., 2013, 2011). 
Integrative analysis of microbiomes and untargeted metabolomes in disease 
contexts have also allowed for the identification of microbially produced compounds found 
to mediate disease upon further functional characterization. For example, one study used 
a maternal immune activation (MIA) murine model that developed symptoms commonly 
associated with Autism Spectrum Disorders (ASD). These MIA mice also had altered gut 
microbiome and serum metabolome profiles compared to control mice. Oral treatment of 
the MIA mice with the human commensal Bacteroides fragilis ameliorated ASD-like 
behaviors. The metabolite 4-ethylphenylsulfate (4EPS) was focused on for functional 
study because its levels were increased in the MIA mice and restored to control levels 
by B. fragilis treatment. Interestingly, systemic administration of naïve wild-type mice with 
4EPS potassium salt was sufficient to induce anxiety-like behavior similar to that 
observed in MIA offspring (Elaine Y. Hsiao et al., 2013). 
In another study that characterized the fecal microbiome and serum metabolome 
of non-diabetic Danish individuals, serum levels of branch-chain amino acids (BCAAs) 
were higher in insulin-resistant individuals and also correlated with fecal microbiomes with 
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higher biosynthetic potential for BCAAs conferred by the species Prevotella copri and 
Bacteroides vulgatus. These predictions, made based on correlative analyses and 
functional predictions, were further validated by showing that P. copri could induce insulin 
resistance while increasing circulating BCAA levels when introduced into High Fat Diet 
(HFD)-fed mice (Pedersen et al., 2016a). 
In some cases, associations between microbially produced metabolites and 
disease have also been linked with the exposome, including diet. One study showed that 
a dietary fiber associated reduction in allergic lung inflammation was driven by the SCFA 
propionate, which exerted its health effects through G protein–coupled receptor 41 
mediated signaling in bone marrow (Cohen et al., 2015). Other work demonstrated that 
risk of cardiovascular disease and atherosclerosis was linked with trimethylamine-N-
oxide (TMAO), which is produced by host enzymes from trimethylamine (TMA). TMA is a 
metabolite of dietary phosphatidylcholine and L-carnitine that can be produced by 
intestinal bacteria but not host enzymes and whose production is associated with 
particular human gut microbiome compositions (Koeth et al., 2013; Wang et al., 2011).  
Metabolites from non-targeted metabolomics can be prioritized for functional 
exploration using various analytic techniques. As mentioned above, correlative analyses 
link the presence of a specific metabolite to genotypic and/or phenotypic data and may 
suggest that a metabolite is produced or induced by the presence of a specific microbe 
(Faust and Raes, 2012; Faust et al., 2012; Kelder et al., 2014; Lozupone et al., 2012; 
Weiss et al., 2016). Other methods include Self Organizing Map generation, which applies 
multivariate statistics to differentiate samples by identifying the largest changes in 
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metabolite abundance between case and control (Derewacz et al., 2015; Goodwin et al., 
2015, 2014), and dereplication, or the identification of known molecules. Dereplication by 
molecular networking uses MS/MS data to visualize the chemical space of samples to 
pinpoint an in vitro producer of a metabolite produced in vivo (Quinn et al., 2016; Wang 
et al., 2016; J. Y. Yang et al., 2013; Bouslimani et al., 2015). Molecular networking 
measures relatedness between MS/MS spectra as a proxy for molecular similarity. 
MS/MS metabolomics data derived from in vitro cultivation of members of the microbiota 
can be used to seed molecular networks in order to identify either known compounds 
produced by those members of the community or close analogs (Jeramie Watrous et al., 
2012; Wang et al., 2016; J. Y. Yang et al., 2013). 
2.6 Functional Validation 
Once associations between microbiomes and metabolomes in disease have been 
identified, the roles of specific metabolites or metabolomics patterns must be validated. If 
a compound is characterized and commercially available, validation is most 
straightforward. For uncharacterized compounds, molecular biology workflows can be 
used; for instance, metagenomics-derived BGCs can be expressed in heterologous hosts 
as was recently used to characterize the (dihydro)pyrazinones from human gut microbiota 
(Guo et al., 2017). Additionally, if the microbe that produces the metabolite can be grown 
in pure culture and genetically manipulated, regulators of BGCs can be removed, 
replaced, or enhanced to increase in vitro metabolite production to levels necessary for 
isolation, as was recently demonstrated during the characterization of lugdunin (Rutledge 
and Challis, 2015; Zipperer et al., 2016).  
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Despite recent success characterizing a handful of individual metabolites, many 
specialized metabolites of interest are understudied, in part due to limitations of 
cultivation. To circumvent these limitations, conventional approaches for microbiota 
growth have been modified to include environment specific media (Browne et al., 2016; 
Stewart et al., 2002; Goodman et al., 2011; Oberhardt et al., 2015), optimization of growth 
conditions based upon (meta)genomic information (Oberhardt et al., 2015), inclusion of 
helper organisms (Bertrand et al., 2014; D’Onofrio et al., 2010) and higher throughput 
cultivation strategies (Barkal et al., 2016; Lagier et al., 2012; Ling et al., 2015; Zengler et 
al., 2002; Goodman et al., 2011). Efforts are also underway to cultivate both native and 
designer microbiome communities using in vitro and in vivo model systems (Stewart et 
al., 2002) and new model systems continue to be developed (Fritz et al., 2013; Shah et 
al., 2016). 
Animal models are widely used to explore the functional attributes of microbes and 
their metabolites, including both conventionally raised and GF models of zebrafish, mice, 
rats, and pigs (Fritz et al., 2013). While GF models have been a powerful tool for 
experimental validation of microbial contributions to disease, use of these models has 
sometimes been criticized as these animals have alterations in essential physiological 
processes (Rooks and Garrett, 2016; Fritz et al., 2013). Treatment of conventionally 
raised animals with broad-spectrum antibiotics cocktails followed by repopulation with 
chosen microbes is a commonly used alterative (Lundberg et al., 2016; Winston and 
Theriot, 2016; Theriot et al., 2016, 2014) and may circumvent some issues with GF animal 
model systems, but have the limitation that antibiotics never completely remove 
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indigenous microbes and also may have other effects on the host. Successful use of 
animal models to functionally validate the effects of microbially-produced metabolites in 
disease were described above for studies of atherosclerosis (Wang et al., 2015; Koeth et 
al., 2013; Wang et al., 2011), ASDs (Elaine Y. Hsiao et al., 2013), and diabetes (Russell 
et al., 2011). Another elegant example of using molecular biology in conjunction with 
animal models to identify key metabolites is the elucidation of the role of microcins 
produced by probiotic E. coli strains in modulating Enterobacteriaceae in the inflamed gut 
(Sassone-Corsi et al., 2016). 
While animal models are most often chosen to explore functional activity of 
microbes and their metabolites, in vitro systems can provide an intriguing alternative(Fritz 
et al., 2013) due to their higher throughput, flexibility, scaling, and ability to simplify the 
system for high-resolution molecular analyses. These in vitro models include independent 
cultivation of the microbiota and interfacing the members of the microbiota with host cell 
lines using Transwell systems or, eventually, organ-on-a-chip microfluidic devices (Fritz 
et al., 2013). While a number of groups are attempting to systematically construct artificial 
communities for robust evaluation of microbiome modulation by both organisms and 
metabolites, such as probiotics and pharmaceuticals, respectively, development of 
environment-specific media has led to some success recapitulating in vivo microbiome 
communities in vitro for similar purposes (Tan et al., 2015; Browne et al., 2016; Stewart 
et al., 2002; Goodman et al., 2011; Lagier et al., 2012; Zengler et al., 2002). For example, 
stable oral microbial biofilm communities representing 60-80% of the taxonomic diversity 
of the original sample has been accomplished (Edlund et al., 2013), while fecal 
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communities were recapitulated at 65-95% (Auchtung et al., 2015). Miniaturized 
bioreactors and chemostats may provide opportunities to maintain continuous culture of 
communities removing concerns about sample limitation from patient donors, particularly 
of microbiome niches that are not as easily accessible as stool (Robinson et al., 2014; 
Fritz et al., 2013). To incorporate host cells, co-culture systems have been developed and 
models for the context of gut microbiome investigation have been recently reviewed (von 
Martels et al., 2017). These models include co-culture in tubes (HoxBan system), 
Transwell systems, and microfluidic devices. While microfluidic systems, such as the 
HuMiX model, are more compatible with multi-omics analyses, it suffers from poor 
chemical compatibility, challenges with parallelization, and lack of widespread availability 
(Fritz et al., 2013; Shah et al., 2016; von Martels et al., 2017). 
2.7 Towards Microbiota-targeted Therapeutics 
 Microbiome/metabolome targeted therapies include both those that inhibit 
detrimental microbes/metabolites and those that promote beneficial microbes/metabolites 
(Figure 2.2). The microbiome/metabolome can also potentially inform personalized 
medicine, if the treatment of an individual is tailored based on the composition or 
metabolic capabilities of their microbiome. The complicated and diverse roles in disease 
of the microbiome are only beginning to be elucidated; thus, most promising research 
directions have yet to reach their full potential in the clinic.  
2.7.1 Targeting detrimental bacteria and metabolites 
Although antibiotic treatment can be valuable for discouraging growth of bacteria 
that produce detrimental metabolites, broad effects on other (beneficial) microbes and 
 34 
rapid acquisition of antibiotic-resistance limits their utility. Thus, another promising 
approach is competitive exclusion by other “probiotic” bacteria. Perhaps the best 
evidence that this approach can be successful clinically is the 92% success rate of fecal 
microbiota transplantation (FMT) for the treatment of recurrent Clostridium difficile 
infection (Rao and Young, 2015). However, understanding metabolic mechanisms of 
inter-species interaction can allow for better “precision microbiome reconstitution” (Buffie 
et al., 2015) for treatment of C. difficile and potentially of diseases where FMT has had 
more variable success such as IBD (Paramsothy et al., 2017; Moayyedi et al., 2015). In 
the case of C. difficile, protection in mice has been conferred by introducing specific 
bacteria (e.g. Clostridium scindens) that can produce key metabolites (secondary bile 
acids) that affect C. difficile sporulation and growth and thus infection (Buffie et al., 2015); 
however, efficacy and safety trials in human populations still need to be conducted. 
Another mechanism for preventing detrimental microbial metabolic activity is to 
inhibit the metabolic pathway rather than the bacteria that contain it. This can be 
accomplished by limiting inputs to the pathway (e.g. by altering dietary intake) or by 
inhibiting bacterial enzymatic activity (Figure 2.2). One promising example is the 
treatment of cardiovascular disease by inhibiting microbial production of TMA using a 
structural analog of choline that can inhibit microbial TMA lyases (Wang et al., 2015). In 
another example, the amino acid arginine can inhibit enzymatic conversion of the cardiac 
drug digoxin into an inactive form by the gut microbe Egerthella lenta, indicating that co-
administering this drug with arginine may prevent its de-activation by microbial enzymes 
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(Haiser et al.). However, both enzyme-targeted treatment strategies still require validation 
in clinical cohorts. 
2.7.2 Promoting beneficial bacteria and metabolites: 
Therapies that promote the prevalence/activity of beneficial microbes and their 
metabolites also have promise for clinical applications that has likely yet to be fully 
realized. Current probiotic treatments use a small number of intestinal microbes (e.g. 
various Lactobacillus or Bifidobacteria species, the yeast Saccharomyces boulardii, or E. 
nissle) that have already been approved for use in humans and that only represent a 
small component of bacteria that can colonize the human gut. In some cases, specific 
probiotics have been shown to affect both microbiome and metabolome composition 
while promoting health; for instance, a trial in patients with liver cirrhosis found 
supplementation with Lactobacillus GG improved outcomes (decreased 
endotoxemia and TNF-α levels) with concomitant changes in microbiome composition 
and metabolite/microbiome correlations pertaining to amino acid, vitamin and secondary 
BA metabolism (Bajaj et al., 2014). As the literature on these probiotics is vast, consensus 
opinion regarding their utility in the clinic are valuable; the Triennial Yale/Harvard 
Workshop on Probiotic Recommendations (Floch et al., 2015) gives A-C evidence ratings 
for the use of specific probiotics in necrotizing enterocolitis, childhood diarrhea, IBD, 
irritable bowel syndrome, C. difficile diarrhea and liver disease.  
There are several bacteria that have shown positive effects in mouse models that 
may represent a “next generation” of probiotics once safety and efficacy studies in 
humans can be conducted. For instance Bacteroides uniformis and Akkermansia 
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muciniphila both reduce weight gain and metabolic disease pathology in HFD-fed mice 
(Gauffin Cano et al., 2012; Everard et al., 2013); Bacteroides fragilis, Bacteroides 
cellulosilyticus, and cocktails of T regulatory cell inducing, spore-forming Clostridia have 
all been shown to protect against intestinal inflammation in mouse models (Neff et al., 
2016; Mazmanian et al., 2008; Atarashi et al., 2013). The mechanism by which probiotics 
may confer a health benefit are often not completely understood and include other 
functions besides the production of small molecules, such as the production of immune-
modulatory capsular components (Neff et al., 2016).  
Probiotic applications can be challenged by colonization resistance; This challenge 
can potentially be circumvented by promoting growth and metabolic activity of beneficial 
bacteria using prebiotics or synbiotics. Prebiotics are broadly defined as any compound 
that affects the composition or function of the microbiome to exert a beneficial effect upon 
the host following bacterial metabolism (Bindels et al., 2015). Prebiotics are typically 
fibers and starches extracted from plants or post-fermentation processes with SCFAs 
being one desirable metabolic product of their digestion (Tzortzis et al., 2005; Depeint et 
al., 2008; O’Mahony et al., 2005; Whorwell et al., 2006; Guyonnet et al., 2007; Silk et al., 
2009). Synbiotics are formulations that contain both probiotics and prebiotics together. 
Understanding the metabolic environment necessary for the successful growth of 
microbes can lead to the intelligent design of prebiotics and synbiotics. For instance, 
galactooligosaccharide mixtures defined in laboratory culture experiments to have 
particularly strong prebiotic properties for Bifidobacteria, effectively increased the 
proportion of Bifidobacteria in the gut in a dose dependent manner when given to healthy 
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human volunteers (Depeint et al., 2008). Use of genomic and metabolic data to design 
prebiotic strategies that target specific microbes and metabolites will become more 
powerful as our knowledge bases of microbial enzymes and metabolites expand. 
Beneficial microbial metabolites can also be directly introduced to the host to 
circumvent the need for microbial production from dietary substrates, a process referred 
to as “microbiome-based metabolite treatment” or “postbiotics” (Suez and Elinav, 2017) 
(Figure 2.2). For instance, the anti-inflammatory microbial fermentation product, butyrate, 
has been added directly to the colonic environment via enema in efforts to ameliorate 
inflammation in patients with ulcerative colitis (Canani et al., 2011; Zimmerman et al., 
2012), although only minor improvements were observed (Hamer et al., 2010). The 
exploration of “postbiotic” therapies are in their infancy and potentially challenged by 
unintended effects of the compound on gut microbiome composition and activity, and 
difficulty in determining and delivering physiologically important levels of the metabolite 
to its active site in the body (Suez and Elinav, 2017). 
2.8 Personalized medicine 
Finally, microbiome/metabolome information has the potential to inform 
personalized medicine. In one elegant example, gut microbiota composition was included 
in machine learning-algorithms that also considered blood parameters, dietary habits, 
anthropometrics, and physical activity, to predict personalized glycemic responses to 
meals. This model was used to perform personalized dietary intervention to lessen 
elevated postprandial blood glucose and its metabolic consequences (Zeevi et al., 2015). 
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 Another promising direction of microbiome/metabolome informed personalized medicine 
is to consider the role of the microbiome on drug metabolism/ pharmacokinetics for proper 
drug dosing. For instance, evaluation of the presence of digoxin-deactivating strains of 
the gut bacterium E. lenta has the potential to inform proper administration of this cardiac 
drug (Haiser et al., 2014). Another study suggested that urinary levels of the microbial 
product p-cresol sulfate (as determined by (1)H NMR spectroscopy) could indicate the 
metabolic fate of acetaminophen (Clayton et al., 2009) 
2.9 Summary and Conclusions 
Progress is being made in methods for the integration of microbiome and 
metabolome data and there is evidence of potential to translate these discoveries into 
treatment of disease. In this thesis, I present new methods to improve and automate the 
types of studies outlined here. By making these methods more accessible it will be 
possible to accelerate this translation process. Correlational analyses show potential 
relationships between microbes and compounds. Using genomic data to explain the 
correlations can generate mechanistic explanations. These mechanisms, when paired 
with a disease association, can be used to identify targets for treatment with drugs, 






(A) The central dogma of molecular biology is the information flow of genes to transcripts 
to proteins. In the –omics age, we can observe this information flow through the 
characterization of genomes, transcriptomes and proteomes. The metabolome, the 
collection of small compounds present in a biological sample, is a natural extension of the 
central dogma. These metabolites can be associated with disease and we can work back 
from metabolites, to proteins that catalyze the reactions that produce them, to the 
transcripts that are translated to the genes that encode those transcripts. (B) This model 
can be extended to include multiple organisms as would be present in a microbial 
community and the reactions and metabolites that are produced and consumed form 
connections between the community members. (C) The host can be added back into this 






Microbiome-targeted therapies can target detrimental microbes and/or their metabolites 
(red) or promote beneficial microbes and the production of their metabolites (green). In 
principle, the presence of beneficial microbial metabolites in the host can be promoted by 
adding the metabolite itself (dietary intervention or supplementation), the microbe that 
produces the metabolite (probiotics), the substrate the microbe uses to produce the 
metabolite (prebiotics) or the beneficial metabolite itself (postbiotics). The presence of 
detrimental microbial metabolites can be reduced by targeting the microbe that produces 
it directly (antibiotics) or through competitive exclusion (probiotics/fecal microbiota 
transplant), by inhibiting the enzymes (shown in pink) that produce the metabolite, or by 




FINDING AND SUMMARIZING GROUPS OF HIGHLY CORRELATED FEATURES IN 
MICROBIOME AND METABOLOME DATA 
The advent of next generation sequencing ushered in the ‘omics revolution. In 
‘omics data a number of features are made in each sample and often an association is 
measured according to metadata. Because of the large number of features multiple 
testing corrections must be applied which limits the power of these associations. 
Additionally, all features are not independent of each other. Correlation structure is often 
strong in ‘omics data and so correlation network creation is a common task. One way to 
handle the dependence of correlated features and increase statistical power is to find 
cooccurring groups of features and treat them as a single feature. 
The most common approach applied to address this goal is weighted gene 
correlation network analysis (WGCNA) (Langfelder and Horvath, 2008). WGCNA was 
created for use with gene expression microarray data and adapted for use with mRNA 
(transcriptome) sequencing data but has also been applied to both microbiome (e.g. Tong 
et al., 2014; Castillo et al., 2017; Yin et al., 2017; Younge et al., 2017) and metabolome 
data (e.g. DiLeo et al., 2011; Roede et al., 2013; McHardy et al., 2013; Su et al., 2014; 
Johnson et al., 2018). WGCNA uses Pearson, Spearman or midweight bicorrelation to 
build correlation networks and then a custom algorithm to detect modules of highly 
correlated features and to summarize them. The technique for finding modules depends 
on the network having a scale-free network topology. A network is scale free when the 
degree distribution of the network follows a logarithmic distribution (Barabasi and Albert, 
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1999). This means that a small number of nodes are highly connected to many other 
nodes while most nodes only have a few connections. To summarize modules of features, 
WGCNA takes the eigenvalue of the abundance of all features that are in the same 
module. 
Recent papers have critiqued the use of WGCNA on both microbiome (Jackson et 
al., 2018) and metabolome data (Pei et al., 2017). This criticism centers on microbiome 
and metabolome data not fitting the assumptions about data properties that WGCNA 
makes, which are based on gene expression data. First, the correlation metric used in 
WGCNA to identify correlated features does not take into account compositionality of data 
which can be very important for microbiome data (Gloor et al., 2017) and creates spurious 
correlations. Second the scale free network topology assumption of the WGCNA module 
detection algorithm may not be relevant to microbiome/metabolome data. The hub and 
spoke nature of this topology is relevant in gene expression systems where a small 
number of master regulators, transcription factors, will be highly correlated with many 
other features which each may not be highly correlated with each other. In microbiome 
and metabolome systems, no such master regulators may exist and there may be other 
community structure constraints. Generally, evidence is emerging that scale free 
networks are not as common as was once thought (Broido and Clauset, 2018). 
To address these concerns, I have developed a tool for Sparse Correlation 
Network Investigation for Compositional data (SCNIC). SCNIC provides a variety of 
methods for both correlation network construction and module detection. Here, I outline 
this method and apply it to microbiome and metabolome data. I performed extensive 
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optimization to determine the module detection method and parameters that maximize 
both statistical relevance and enrichment of biological signal in modules in two 
microbiome data sets. I also show that SCNIC can be used on LC/MS metabolome data 
and find that modules are enriched in similar compounds. 
3.1 SCNIC: Sparse Correlation Network Investigation for Compositions 
SCNIC addresses the concerns that microbiome and metabolome data do not fit 
the assumptions of WGCNA while providing flexibility so that users can use appropriate 
techniques for their data sets. SCNIC has three steps: 1. a correlation network is built, 2. 
modules are selected from the network and 3. modules are summarized into a single 
feature for use in downstream statistical analysis (Figure 3.1A). As input, SCNIC takes a 
table in BIOM format (McDonald et al., 2012). The provided outputs are a correlation 
table, correlation network, module membership file and a table in which modules have 
been collapsed, also in BIOM format (Figure 3.1B). 
The correlation network can be calculated with a variety of metrics and then the 
network can be made based on a correlation R-value cutoff. The traditional correlation 
metrics of Pearson, Spearman and Kendall-Wright correlation are all available. SparCC 
(Friedman and Alm, 2012), which is a compositionally aware correlation metric developed 
for microbiome data, is available via fastspar (Watts et al., 2018). This provides an 
advance over WGCNA for the analysis of microbiome data because it provides a 
compositionally aware correlation metric as well as other measures. In the output 
correlation network, nodes are features from the input table and edges represent 
correlations which are stronger than the R value cutoff. Only positively correlated features 
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are included when making modules. The network is output as a graph modeling language 
file (GML) which can be used for visualization in Cytoscape (Shannon et al., 2003). 
There are two methods implemented in SCNIC to detect modules. Both module 
detection methods do not make assumptions about network topology and so are not 
reliant on modules fitting the scale free topology requirement of WGCNA. The first is a 
novel method called the shared minimum distance method (SMD). Unlike many module 
detection methods, SMD guarantees that all individual features included in a module are 
correlated with each other at a minimum R value threshold. In SMD, the R values from 
the correlation analysis are transformed into distances (d) with the following equation: 𝑑 =
(−1 ∗ 𝑅 + 1)/2. With this transformation, a correlation with an R value of 1 has a distance 
of 0 and a correlation with an R value of -1 has a distance of 1. Complete linkage 
hierarchical clustering is applied to a pairwise distance matrix to create a tree of 
relationships between features. The nodes in the tree are then traversed from the root to 
the tips and pairwise correlations between all descendants of each internal node are 
examined. If all pairwise correlations between tips descending from a node have an R 
value greater than the user provided minimum, then that node is defined as a module and 
all tips in the module are marked as being seen. If the current node is a tip then it is not 
included in any module and is marked as seen. This process is repeated for each node 
until all tips are marked as seen. The benefits of this method are that it only relies on a 
single parameter (the R value threshold) and all pairs of features in all modules are 
guaranteed to be correlated with each other. 
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Because a prior study had also recommended the Louvain modularity 
maximization (LMM) algorithm (Blondel et al., 2008) for module detection in microbiome 
data (Baldassano and Bassett, 2016), we also implemented this algorithm in SCNIC. The 
LMM algorithm picks modules that optimize modularity; modularity is a measure of the 
number of edges that exist between modules compared to within modules. With high 
modularity, many edges join the features within modules and few edges join features in 
different modules. LMM works by first assigning each feature to its own module of one. 
The change in modularity if two modules are joined is calculated for each pair of adjacent 
modules, and the pair which increases the mean modularity of the network the most is 
joined. This process is repeated until the modularity of the network is not increased by 
combining more modules. LMM uses two separate parameters. The first is the parameter 
used to define the edges between features to create the network: in SCNIC this is the 
minimum R value provided by the user. The second is the gamma parameter which 
controls the size of the modules detected, where large values lead to larger modules and 
smaller values lead to smaller modules. 
In SCNIC, the modules that are detected with either method are summarized by 
summing the abundances of all features in each module per sample. This preserves the 
total counts per sample. Tools which make assumptions based on total sample counts 
such as ANCOM (Mandal et al., 2015) for 16S rRNA sequencing analyses can be used 
with the collapsed tables created by SCNIC, which would not be possible with other 
methods that may be used to summarize modules, such as use of eigenvectors from 
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features in a module as is conducted in WGCNA, or by only considering hub taxa, which 
is another common approach. 
The source code for SCNIC is available on GitHub 
(https://github.com/shafferm/SCNIC). SCNIC is available as both a standalone python 
program via bioconda (Grüning et al., 2018) and the in python package index. It is also 
available as a QIIME 2 plugin (Bolyen et al., 2018) which allows QIIME 2 users to easily 
incorporate SCNIC into microbiome data analysis workflows. 
3.2 SCNIC with 16S Data Reveals Modules with Consistent Associations and 
Biological Enrichment 
Correlation network analyses are common in 16S rRNA sequencing based 
microbiome studies (e.g. Tong et al., 2014; Castillo et al., 2017; Yin et al., 2017; Younge 
et al., 2017). The goals of these studies are to discover community structure within the 
data (Greenblum et al., 2012; Fisher and Mehta, 2014; Gevers et al., 2014; Kurtz et al., 
2015). Edges represent an association between microbes, which may be driven by factors 
such as a shared metabolism or a preference for an environment factor. Therefore, 
modules have potential functional meaning as well as decreasing dependence between 
features and increasing power by decreasing the total number of features. 
WGCNA is commonly used for this type of analysis but its assumptions are not 
satisfied by microbiome data. A recent paper outlined an alternate procedure for finding 
modules in 16S sequencing data (Jackson et al., 2018). Jackson et al. used an ensemble 
approach for correlation detection recommended by Weiss et al. (Weiss et al., 2016). 
They looked across p-value thresholds and found the p-value which created the most 
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scale free network. This decision was justified by purporting that many biological networks 
are scale free, but this may not be true of microbial co-occurrence networks. Louvain 
modularity maximization (Blondel et al., 2008) was used as it had been done in a previous 
microbiome study (Baldassano and Bassett, 2016). The Louvain modularity maximization 
method was not designed to find modules in scale free networks and so may not be the 
ideal algorithm for networks optimized to be scale free. There was no measure of the 
biological relevance of the modules which were detected. 
De novo clustering of 16S rRNA sequences was used to generate operational 
taxonomic units (OTUs) on human gut 16S rRNA sequencing samples but this is not 
considered state of the art. Importantly, Illumina sequencing data is known to have noise 
that results in the production of many spurious OTUs (cite PMID:20534432). Noise OTUs 
will have the tendency to co-occur with the true OTU across samples, which has the 
potential to inflate estimates of the degree to which co-occurring microbes may be 
phylogenetically related. More recently, OTU picking methods have been supplanted by 
methods which generate amplicon sequence variants (ASVs) such as DADA2 (Callahan 
et al., 2016) and deblur (Amir et al., 2017). When analyzing 454 sequencing data, using 
denoising followed by OTU picking was the recommended process (Quince et al., 2009; 
Reeder and Knight, 2010; Gaspar and Thomas, 2013). OTU picking following denoising 
may have the benefits in co-occurrence analysis for multiple reasons: First, OTU picking 
may removing residual noise OTUs that still may persist despite the application of 
denoising algorithms. While DADA2 can control for sequence quality information there 
are other potential sources of error which are not accounted for in sequencing quality 
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scores, such as PCR errors. 99% OTU picking can somewhat control for these errors by 
merging these low abundance errors into singular features while not merging too much 
phylogenetic diversity into a single feature as may be done with more common 97% OTU 
picking. Second, OTU picking may decrease sparsity while binning highly related and 
potentially functionally redundant ASVs. While the strain level information of DADA2 may 
be more representative of true biological variation this also causes an increase in sparsity 
which limits the ability to use traditional statistical techniques without further 
summarization of the data using data such as taxonomic rank. 
Jackson et al. outlined an approach and demonstrated a way to select parameters 
for healthy gut data sets but did not release a software package which could do this 
analysis and did not show that this approach was applicable across data sets. To address 
these concerns, I have applied the SCNIC method to 16S rRNA sequencing data with 
sparCC correlations and used WGCNA, Louvain modularity maximization and the shared 
minimum distance algorithm. I show that the modules created by my method are 
consistent in correlation direction, consistent in association with phenotype data and 
enriched in biological signals as measured by phylogenetic distance and that there is an 
association between shared gene content and phylogenetic distance. I have optimized 
these parameters on two publicly available16S rRNA datasets: 1) data from a study that 
characterized the gut microbiome of men who have sex with men (MSM) as well as those 
who only partake in heterosexual sex with and without HIV (Noguera-Julian et al., 2016) 
and 2) a dataset analyzing the microbiome of water samples at various depths in two of 
the Great Lakes. I have also tested SCNIC on both DADA2 ASVs and OTUs as created 
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from DADA2 ASVs to investigate the effect of OTU picking and DADA2 on SCNIC 
modules. 
3.2.1 HIV Gut Microbiome Dataset  
I applied SCNIC to a dataset from a previously published study of the gut 
microbiome where associations with HIV and MSM status were measured (Noguera-
Julian et al., 2016). There were four groups: HIV+ and MSM (N=77), HIV+ and non-MSM 
(N=37), HIV- and MSM (N=23), and HIV- and non-MSM (N=4). To determine the best 
module picking approach and parameters, I tested WGCNA, the SMD algorithm and LMM 
(Table 3.1). Several SCNIC parameter sets were tested where a parameter set is defined 
as a module picking algorithm and the parameters for running that algorithm in SCNIC. 
For WGCNA the recommended workflow for choosing a soft threshold was used. For both 
the SMD method and LMM a variety of parameters were tested. Both methods require a 
minimum correlation R value cutoff for module making: R values between 0.05 and 0.75 
separated by 0.05 increments were tested. LMM also requires a gamma parameter which 
controls module size; values between 0.05 and 1, separated by 0.05 were tested. This 
led to a total of 281 tested parameter sets. These parameters were tested on two methods 
of preprocessing the data: DADA2 denoising and 99% OTU picking on DADA2 denoised 
sequences. 
3.2.1.1 Picking WGCNA soft threshold values and making modules 
The recommend protocol for selecting WGCNA parameters was used. The 
correlation values determined by sparCC were used for both the DADA2 and DADA2 with 
OTU picking data sets. WGCNA requires the user to select a soft threshold parameter 
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based on the data. This parameter is selected by minimizing mean connectivity while 
having a high correlation between node degree and logarithm of the count of nodes with 
that degree. Based on the threshold of a R squared value of .9 for the node degree 
distribution and desired lower mean connectivity a soft threshold of 4 was selected for the 
DADA2 data (Figure 3.2A) and 5 for DADA2 with OTU picking (Figure 3.2B). Modules 
were selected on signed hybrid networks and a minimum modules size of 2 was set. With 
DADA2 only there were 139 modules which contained all 1256 ASVs (Figure 3.2C). In 
the data set with OTU picking 2 modules were selected which contained a total of 1239 
out of 1256 total OTUs (Figure 3.2D). 
3.2.1.2 Eliminating redundant parameter sets and those with negative correlations 
To determine which parameters and tools made the best modules, all methods 
were used to analyze the HIV gut microbiome datasets with the full range of parameters. 
Parameters which formed sets of modules that were identical to those formed with other 
parameter sets were removed. This occurred in LMM parameter sets with high R values 
and small differences in gamma values. The networks with such stringent edge thresholds 
were small and so similar gamma values would produce identical module sets. For 
redundant parameter sets the set with the smallest gamma value was retained. This 
reduced the number of parameter sets from 281 to 208 for the DADA2 only data and 211 
for the data with OTU picking. 
One property we wanted to minimize was the selection of modules in which pairs 
of features with negative correlations, may become a part of the same module because 
of their relationships with other features in that module.  Since features will be summed 
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for subsequent statistical analysis, features that negatively correlated with each other are 
too distant such that they should never be summed for subsequent statistical comparison. 
Therefore, methods and parameters which produced modules where any pair of ASVs or 
OTUs within a module were negatively correlated were eliminated. Any members with 
negative associations with any other members of that module will negatively affect 
summarization. Removal of parameter sets that resulted in modules with negatively 
correlated pairs of features led to the reduction of parameter sets from 208 to 40 for the 
DADA2 only data and from 211 to 35 when OTU picking was used. For both data sets 
this eliminated the WGCNA parameter set. The large modules found by WGCNA included 
negative correlations between feature pairs. For the DADA2 only data set all LMM 
parameter sets with a minimum R value lower than 0.5 were eliminated by this step and 
for the OTU picked set all LMM parameter sets with a minimum R value less than .45 
were eliminated. None of the parameter sets from SMD were removed as the method 
guarantees that all correlations within a module are greater than the set minimum R value. 
3.2.1.3 Finding parameters where associations with HIV and MSM are consistent 
Next, we reasoned that modules should not result in the binning of features that 
had inconsistent associations with the same experimental metadata.  To test association 
between features and both HIV and MSM status, a 2-way ANOVA was used on the 
original unmodified tables as well as all collapsed tables produced by SCNIC from 
parameter sets which were not previously eliminated. Before the 2-way ANOVA was 
applied each table was rarefied to 10,181 sequences per sample and features that were 
not present in more than 71 samples were removed from the analysis (50% of samples). 
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In the 2-way ANOVA there are p-values for the two effects, HIV and MSM status, 
and an interaction term. If the p-value for a factor was less than 0.05 then it was 
considered significant. When the interaction term is significant then the other effects are 
difficult to interpret. As a result, if the interaction term changed in significance between 
the module and feature then this was considered a negative result as the association did 
not stay consistent. If the interaction term was positive in both then this was a positive 
result and marked as the significances staying the same. If the interaction term was not 
significant in both, then both effects were checked for significance. If the significance was 
not the same then the direction of that change, either from significance to insignificance 
between the feature to the module or from insignificance to significance from the feature 
to the module, was recorded. 
These measures of directional changes of association were measured across 
parameter sets to evaluate the consistency of modules to match the associations of 
individual features which make them up. In the DADA2 processed dataset the number of 
associations that are in the same direction decreases as the minimum R value increases 
(Figure 3.3A) and conversely the number of negative results goes down (Figure 3.3B). In 
DADA2 and OTU picking processed data, the number of associations in the same 
direction also increases with higher R values (Figure 3.3C) but there is no decrease in 
the number of negative events (Figure 3.3D). 
With LMM the total number of features which pass the filtering steps is very stable 
across gamma values and changing the minimum R value has a much larger effect on 
number of features in a module. The gamma value has a large effect on the total number 
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of modules with it ranging from 38 when using a minimum R value of 0.45 and a gamma 
value of 0.1 to 12 when using the same minimum R value and a gamma value of 0.95. 
With both processing methods, LMM with a minimum R value of 0.05 and a gamma value 
of 0.10 there are no features in any module which pass the minimum sample threshold. 
Further investigation of these modules shows that this is a result of all these pairwise 
correlations being between features where values are mostly zero. These are not 
removed by the filtering criteria used in the sparCC manuscript but are removed by the 
minimum sample filter. 
3.2.1.4 Biological enrichment in modules in terms of phylogeny and functionality 
Modules were tested for biological enrichment in terms of both phylogeny and 
shared functionality. To measure enrichment of phylogeny the phylogenetic distances, as 
measured by tree distance between pairs of features within a module, were compared to 
the distances between pairs of uncorrelated features. A pair of OTUs was considered 
uncorrelated if its R value was less than the minimum R value used to make the network. 
A subsampling procedure was used to randomly select uncorrelated features equivalent 
to the size of the module being tested. The distribution of distances among pairs of 
selected features was used to calculate a one-sided t-statistic with the alternative 
hypothesis being that the mean distance between OTUs from the selection was less than 
the mean distance between all uncorrelated OTUs. This was repeated 14,000 times to 
create a null distribution. The t-statistic from the same test but comparing the distribution 
of distance between OTUs within a module to all uncorrelated modules was compared to 
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the null to calculate a p-value. This controls for the size of the module as using a 
conventional test biases significance to large modules. 
In the DADA2 preprocessed data more than 75% of modules with all parameter 
sets are significantly enriched in phylogeny (FDR adjust p-value < .05) (Figure 3.4A). 
When OTU picking was done after DADA2 a wider spectrum of p-values was observed. 
The median p-value was less than 0.05 for all modules with a minimum R value of 0.35 
or greater (Figure 3.4C). Generally, the SMD method found modules which were more 
enriched than those with the LMM method at the same minimum R value. 
Modules were also tested for enrichment in shared functionality relative to 
phylogenetic distance. A regression was done between phylogenetic distance and the 
logarithm of the percent of KOs shared between pairs of features which were uncorrelated 
, as predicted by PICRUSt 2. The residuals were used to test for positive enrichment of 
feature pairs in shared functionality. The same subsampling procedure was used as in 
the phylogenetic enrichment test but with residuals from the regression instead of 
phylogenetic distance. The alternative hypothesis was also changed to testing if the set 
of residuals from the group of features were greater than the residuals from uncorrelated 
features. For both preprocessing approaches there were some modules significantly 
enriched in function found in almost all parameter sets but there was no clear pattern in 
p-value distribution (Figures 3.4B, C). 
3.2.1.5 Selecting a module picking method and parameters 
Based on these analyses the SMD method with a minimum R value of .35 was 
selected for both analyses. When using only DADA2 a minimum R value of .35 provided 
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for large modules with a small number of errors in terms of association with outside 
metadata. The phylogenetic enrichment seen with DADA2 and OTU picking reached a 
median p-value of less than .05 at .35 while providing the other benefits for using only 
DADA2. This also aligns with the suggested parameters from the sparCC manuscript 
(Friedman and Alm, 2012) and the R level at which I have found all larger R values are 
significant when using a permutation test on the sparCC R values. 
3.2.1.6 SCNIC analysis increases ability to detect significant associations 
When looking for differential association with 2-way ANOVA for the DADA2 
processed data there are 36 significant results (FDR p-value < .05). When using SCNIC 
with the SMD method and a minimum R value of .35 there are 25 significant results of 
which 23 are modules. In total these modules represent 97 unique ASVs and so the total 
number of significant results is 99. This is a 4x increase in the number of significant results 
indicating an increase in power. When using DADA2 with OTU picking there were 30 
significant OTUs when using the 2-way ANOVA on the original table. After using SCNIC 
to collapse modules with the SMD method and minimum R value of .35 there were 25 
significant results of which 20 were modules. The significant modules represented 85 
OTUs for a total of 90 significant OTUs across those that are significant in modules and 
not in modules. This represents a 3x increase in the number of significant OTUs. 
SCNIC results also represents organisms that are taxonomically different from 
when not using SCNIC. When only DADA2 is used there are 5 genus level taxonomic 
assignments of significant ASVs that were not seen in the significant results when not 
using SCNIC. These are Anaerovibrio, Butyrivibrio, Clostridium, Desulfovibrio, and 
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Megasphaera. When using DADA2 with 99% OTU picking there are 9 new genera 
represented in the significant results: Anaerovibrio, Bifidobacterium, Bilophila, Bulleidia, 
CF231, Holdemania, Megasphaera, Ruminococcus and Slackia. 
3.2.1.7 SCNIC summarized modules show the effect of MSM on the gut microbiome 
The results of the 2-way ANOVA on data processed using only DADA2 were 
analyzed to look for patterns in association of modules with MSM and HIV. The most 
significant associations were with MSM (Table 3.2). Modules 49, 2, 156, 1, 5 and 297 and 
seq 146 have decreased relative abundance in individuals who are MSM. Of these, 
modules 1, 2, 5, and 49 are at least half Bacteroides while modules 49 and 156 are at 
least half from the genus Ordoribacter and module 297 is made up of two ASVs of the 
Parabacteroides genus (Table 3.4). The significance of seq 146 seems to be outlier 
driven. Modules 0, 175, 25, 47, 118, 22, 160, 91, 12, 360 and 21 are increased in 
abundance in MSM. Of these modules 0 and 175 are made up of Prevotella genus 
bacteria with most being Prevotella copri. In many modules all ASVs have the same 
taxonomic assignments module 47 is all Dialister, 118 is Sutterella, 22 is Anaerovibrio, 
91 is Eubacterium biforme, and 360 is Catenibacterium. Module 21 is made up of a set 
of five ASVs all with Bacteriodales order level taxonomic assignments. The only 
significant models with a significant interaction between the HIV and MSM status are seq 
146 and module 158. Significant interactions mean that the effects of HIV and MSM are 
not additive and therefore had effects that are not applicable to HIV or MSM in general 
but are specific to some number of subgroups. 
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The same trend of associations with MSM being more robust than any associations 
with HIV was true when the data set was processed with OTU picking after DADA2. 
Modules 1, 3, 7, 25, 98, 13 and 5 are increased in abundance with MSM (Table 3.4, Figure 
3.6). Module 1 is made up of a combination of Bacteroides and Parabacteroides ASVs 
and modules 5 and 7 are primarily made up of Bacteroides ASVs. Module 13 contains 
ASVs from the Rikenellaceae family (Table 3.5). The inverse association was seen in 
modules 2, 0, 14, 12, 6, 26, 17, 4 and 34 as well as OTUs 849311 and 827313. Modules 
2, 0, 12, are primarily made up of Prevotella OTUs and modules 14 and 6 contain both 
Paraprevotella and Prevotella. There is a wider diversity of bacteria taxa present within 
modules when OTU picking is done in addition to DADA2. 
The two features with a significant interaction term are the OTU 842596, which 
appears to be driven by an outlier, and module 72. Although seq 146 from the DADA2 
processed data and OTU 842596 from the DADA2 and OTU picking analysis both have 
a significant interaction term and an outlier in the MSM- and HIV+ group they are assigned 
to different taxa, the Ruminococcaceae family and Coprococcus respectively. 
The modules produced by DADA2 alone tend to be more significantly enriched in 
phylogeny compared to when DADA2 and OTU picking was applied. The heatmaps of 
phylogenetic distances within the modules of the top results for DADA2 show this pattern 
(Figure A.1). All have significantly lower phylogenetic distances compared to random sets 
of uncorrelated ASVs of the same size. This distance seems to be driven by patterns like 
in modules 49 and 2 (Figure A.1A). In module 49 there are 4 ASVs. Of the ASVs seqs 32 
and 265 have near zero phylogenetic distance between them as do seqs 480 and 121 
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while between members of the separate pairs there is a greater distance. A similar pattern 
emerges in module 2 (Figure A.1B). In module 2 seqs 18, 79 and 247 all have near zero 
phylogenetic distances as do seqs 96, 21, 29 and 9, but there is a greater distance 
between the two groups.  Modules 0 has a larger amount of diversity (Figure A.1C) while 
in module 156 all distances are near 0 (Figure A.1D). The phylogenetic distance between 
these pairs is much higher. The significant phylogenetic enrichment result is likely driven 
by the small distances. When 99% OTU picking is applied after DADA2 these sets of near 
zero phylogenetically distant ASVs would be summarized and the resulting modules 
would not be significantly phylogenetically enriched. 
3.2.2 Great Lakes Dataset Analysis 
3.2.2.1 Great Lakes samples separate based on lake of origin and pH 
This data was previously published as part of the Earth Microbiome Project 
(Thompson et al., 2017). The goal of this data set was to investigate patterns of microbial 
relative abundance across depths in Lake Michigan (N=16) and Lake Superior (N=33). 
Based on a principle coordinates analysis of unweighted Unifrac the data forms four 
clusters. The split along the first principle coordinate separates samples by the lake that 
they come from with Lake Michigan on the left side of the plot and Superior on the right 
(Figure 3.7A). The Lake Michigan samples split into two groups based on sampling site 
in the lake and the Lake Superior samples primarily group together apart from two 
samples from a single site. The depth of the sampling had little effect on clustering (Figure 
3.7B) while pH and salinity both increase along the first principle coordinate (Figure 3.7C, 
D). 
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3.2.2.2 Picking WGCNA soft threshold values and making modules 
As with the Noguera-Julian dataset the WGCNA tutorial was used to select for the 
soft thresholding parameter. For the DADA2 processed data a soft threshold of 4 was 
selected (Figure 3.8A) and for the data that was also OTU picked a soft threshold of 3 
was selected. The gene dendrograms have more structure with the Great Lakes dataset 
compared to the HIV dataset for both data processing strategies (Figures 3.8C, D). Both 
have two large modules in addition to many smaller ones. 
3.2.2.3 Eliminating parameter sets with negative correlations within modules 
Correlation values were more extreme in the Great Lakes data set than the 
Noguera-Julian data for both data processing methods. This created more complex 
network structures at higher R value cutoffs and as a result of this there were no 
redundant modules created by different parameter sets when only DADA2 was used. 
When DADA2 was used with OTU picking the number of parameter sets was reduced 
from 281 to 276. All parameter sets eliminated were using the LMM method. 
Modules were analyzed to find negatively correlated features in modules with both 
preprocessing methods. When only DADA2 was used all LMM parameter sets were 
eliminated with a minimum R value of .45 or below except for a minimum R value of .05 
with gamma values of .10, .15 and .20 and with a minimum R value of .1 with a gamma 
value of .05. These data sets were similar to the low minimum R value sets that passed 
this filter in the Noguera-Julian data set, in that they primarily consisted of ASVs where 
more than half of values were zeroes. A total of 27 parameter sets passed this filter. The 
WGCNA data set did not pass this filter. 
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The elimination of data sets with negatively associated pairs of OTUs data 
processed with both DADA2 and OTU picking removed all LMM data sets with a minimum 
R value cut off below .6 aside from the minimum R value .05 with gamma .15 and .2 
parameter sets and the minimum R .1 and minimum gamma value .05. These parameter 
sets produced modules primarily make up of OTUs with a majority of values across 
samples being 0. The WGCNA module set was eliminated in this step. 
3.2.2.4 Determining direction of association with Lake Michigan or Superior 
To test that associations with each lake were consistent between the original data 
and the summarized modules, the Mann-Whitney U test was used on a rarefied and 
filtered feature table for both the original tables and all the parameter sets that passed the 
previous filtering steps. Direction of association was determined based on significant 
associations. If an ASV, OTU or module had a p-value of less than .05 then there was no 
significance association. If the p-value was less than .05 and the median was greater in 
the Lake Michigan samples then it was considered Lake Michigan associated and if the 
median was greater in the Lake Superior samples then it was considered Lake Superior 
associated. 
Then, as with the Noguera-Julian data set, for each module in each parameter set 
all the associations of all features which make up that module were compared to the 
association of the module itself. In the DADA2 processed set the pattern of total ASVs 
with associations went down with increasing minimum R thresholds across both the SMD 
and LMM methods (Figure 3.9A). There is a strong trend in the decrease of negative 
events with increasing minimum R values with the SMD method (Figure 3.9B). With LMM 
 61 
there does not seem to be a strong association between minimum R value or gamma and 
number of failures. When OTU picking was done after DADA2 the same patterns were 
seen (Figures 3.9C, D). 
3.2.2.5 Finding biological enrichment in modules in terms of phylogeny and 
functionality 
I attempted to measure the biological meaningfulness of modules using the same 
methods as with the Noguera-Julian et al. data set. In terms of phylogenetic enrichment 
in the DADA2 processed data there was no clear pattern in the p-value distribution across 
both the SMD and LMM methods. Using the SMD method modules are seen which are 
significantly enriched in phylogeny with minimum R values above .1 but the median p-
value never goes below .55. With LMM the median p-value as low as .33 and at least one 
module is enriched with phylogeny in all parameter sets except for the minimum R value 
of .7 and gamma of .4. When the data was processed with DADA2 and OTU picking there 
was also a lack of a clear pattern of p-values across parameter sets. Across all parameter 
sets at least one module was significantly phylogenetically enriched. 
Functional enrichment was not able to be measured in this data set. The microbes 
in these samples were not on average closely related enough to sequenced organisms 
in the PICRUSt 2 database. The small or unable to be predicted genomes meant no 
calculations of percent shared content could be made that produced regressions between 
phylogenetic distance and percent of shared KOs. 
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3.2.2.6 Selecting a module picking method and parameters 
Based on the results of the consistency of associations between individual features 
I selected the best parameter sets for both processing methods. For the DADA2 
processed set the SMD method was chosen with a minimum R value of .45 as at this 
point negative events in association started decreasing and the number of ASVs in 
modules is maximized. When OTU picking was done after DADA2 the SMD method was 
chosen with a minimum R value of .3 for the same reasons. 
3.2.2.7 Differences in results with and without SCNIC in analysis 
When looking for differential association between Lake Michigan and Lake 
Superior for the DADA2 processed data there are 126 significant results (FDR p-value < 
.05). When using SCNIC with the SMD method and a minimum R value of .45 there are 
70 significant results of which 50 are modules (Table 3.7). In total these modules 
represent 308 unique ASVs and so the total number of significant results is 328. This is 
a 2.5x increase in the number of significant results indicating an increase in power. When 
using DADA2 with OTU picking there were 164 significant OTUs when using the 2-way 
ANOVA on the original table (Table 3.7). After using SCNIC to collapse modules with the 
SMD method and minimum R value of .30 there were 57 significant results of which 52 
were modules. The significant modules represented 415 OTUs for a total 420 significant 
OTUs across those that are significant in modules and not in modules. This represents a 
2.5x increase in the number of significant OTUs. 
SCNIC results also represent organisms that are taxonomically different from when 
not using SCNIC. When only DADA2 is used there are 25 genus level taxonomic 
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assignments of significant ASVs that were not seen in the significant results when not 
using SCNIC. These are Polaromonas, Roseomonas, Cytophaga, Leptolyngbya, 
Saprospira, Gemmatimonas, Candidatus Solibacter, HTCC, Gemmata, Methylibium, 
Armatimonas, Symbiobacterium, Phaeospirillum, Peredibacter, Rhodoplanes, 
Alkalimonas, Mycobacterium, Brevundimonas, Polynucleobacter, Synedra, Aquirestis, 
Novosphingobium, Ochromonas, A17 and Phenylobacterium. When using DADA2 with 
99% OTU picking there are 19 new genera represented in the significant results: 
Phenylobacterium, Roseomonas, Polynucleobacter, Aquirestis, Beijerinckia, 
Leptolyngbya, Simkania, Mycobacterium, Armatimonas, Polaromonas, Candidatus 
Solibacter, Phaeospirillum, Gemmatimonas, Gemmata, Peredibacter, Synedra, 
Alkalimonas, HTCC and Phaselicystis. 
3.2.2.8 Results of analyzing the Great Lakes Data 
With both processing methods the modules found are more phylogenetically 
diverse than those found in the Noguera-Julian et al. data set. In the DADA2 processed 
data set modules 16, 22 of the Stramenopiles family and modules 33 and 35 from the 
ACK-M1 family are more than half from the same family. In the DADA2 and 99% OTU 
picking processed data modules 21, 22, 45 and both module and modules 21 and 45 
were more than half from the family ACK-M1. None of the significant modules with either 
processing method are a majority from any one taxa at the family level or below. This is 
in line with the trend toward a lack of significant enrichment of phylogeny across modules 
from the Great Lakes. 
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3.2.3 Discussion 
Across both studies and both processing techniques optimal parameters for use 
with SCNIC on 16S microbiome data were found. These parameter sets decrease the 
size of the output table while minimizing inconsistencies between modules and the 
features that make them up and creating modules which are enriched in biologically 
relevant markers. The increases in the number of significant features are driven by an 
increase in power because of the decrease in number of tests and the increase in power 
for individual features that would not individually be significant but when grouped with 
other features which follow similar trends, as measured by correlation, become 
significant. 
When selecting the optimum parameter set the SMD method proved superior in 
both data sets with both processing techniques. LMM gave a small increase in the total 
number of features in modules but does so at a sacrifice of both consistency of 
association and, in the Noguera-Julian data set, a reduction in phylogenetic enrichment 
of modules. It is interesting that the minimum R value used to determine whether or not 
an edge is present has a much stronger effect than the gamma value with the LMM 
method. When the gamma method is changed and the minimum R value remains 
constant there is not a large degree of change in the total number of features contained 
in modules but there is a change in the number of modules. This parameter seems to be 
controlling whether larger modules are split into many smaller modules more than 
including features that were not in modules at smaller gamma values into modules at 
larger gamma values. 
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Modules are present with low minimum R values and low gamma values that pass 
the test of all features within all modules being positively correlated with each other. This 
seems to be driven by features where most features have zero values across samples. 
These features make it past the initial filtering as it is an average abundance filter of 2 
reads per sample. This is the filter used in the original sparCC paper. A more traditional 
filter would be to remove features that have 0 values in more than 50% or more of 
samples. Features which are highly abundant in a few samples would pass the sparCC 
filter but may not produce valid correlations. The sparCC manuscript suggests this filter 
because removing features with high abundances, even in a few samples, will upset the 
ability of the method to control for the number of reads per sample in its compositionality 
adjustment. Therefore, it may be helpful to filter as recommended by the sparCC 
manuscript and then filter again after sparCC has been run to remove correlations 
involving features which have zeros in 50% or more of samples. 
The results of analysis of the Noguera-Julian et al data set, with both processing 
methods, yielded results that are in line with what was found in their original analysis as 
well as another recent study (Armstrong et al., 2018). The primary result is the lack of any 
significant associations with HIV status and many strong associations with MSM status. 
Taxonomically the primary difference was an increase in Prevotella species and a 
decrease in Bacteroides in individuals who participate in MSM. Many other examples 
exist showing the same associations between bacterial taxa and MSM. Ordoribacter was 
associated with MSM in both the Armstrong et al and Noguera-Julian et al studies. The 
associations in the Noguera-Julian et al study were done at the genus level which 
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obscures some of the complexity in the data. Some genera, such as some Bacteroides, 
have had OTU specific associations with MSM status where some were positively and 
some negative associated, which was also seen in the Armstrong study. 
A benefit SCNIC gives in interpretation of microbiome data is finding new 
significant OTUs as well as investigating the other features they are correlated with. Of 
the 89 new significant OTUs in the DADA2 and 99% OTU picking processed data 21 were 
of the Prevotella genus and 13 were of the Bacteroides genus. The previous HIV 
microbiome studies all found these genera most associated with both HIV and MSM 
status (Lozupone et al., 2013; Dillon et al., 2014; Noguera-Julian et al., 2016; Armstrong 
et al., 2018). In module 0, which was more abundant in MSM samples, Prevotella species 
are correlated with an OTU identified as Eubacterium biforme. Prevotella copri has 
previously been associated with increased inflammation in the intestinal mucosa of HIV 
patients. (Dillon et al., 2014). However, other studies have indicated that this relationship 
may not be causal, as in vitro stimulation of human immune cells with P. copri did not 
produce higher levels of production of pro-inflammatory cytokines than other gut 
commensal bacteria tested (Lozupone et al., 2013). In contrast, E. biforme did appear to 
be particularly pro-inflammatory in these same assays. The observation of a positive co-
occurrence between Prevotella and E. biforme demonstrated here may indicate that a 
positive correlation between Prevotella and intestinal inflammation, as has been reported 
previously (Palmer et al., 2014; Gianella et al., 2012), may be indirectly driven by co-
occurring microbes. 
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Also interesting are novel taxa that we only had the power to associate with 
disease after applying SCNIC. Module 25, which was associated with MSM status, is the 
fourth most significant feature and is made up of Bilophila and Odoribacter OTUs. Neither 
of these OTUs, or any other members of those genera, were significant when SCNIC was 
not used. Both of these are sulfidogenic bacteria which may partially explain their 
correlation (Devkota et al., 2012; Nagai et al., 2010). Meat and saturated fat consumption 
was up in individuals with increased Bacteroides abundance in the Noguera-Julian et al 
study (Noguera-Julian et al., 2016) Both Bilophila and Odoribacter are bile associated 
(Devkota et al., 2012; Nagai et al., 2010) and up in abundance in the non-MSM grouped 
which was associated with higher Bacteroides abundance. This gives a possible dietary 
explanation of the association found with module 25. 
With the Great Lakes data set, we see in an increase in power from running 
SCNIC. Unlike in the gut data set, there was no trend in phylogenetic enrichment across 
parameter sets. There were modules that were phylogenetically enriched but there was 
no increase in percent of modules which were significantly phylogenetically enriched with 
increasing R values.  This was reflected in the tendency of modules to be uniform in terms 
of taxonomy in the analysis of the Noguera-Julian data set, while modules in the Great 
Lakes data set were much more taxonomically diverse. This result was surprising as 
closely related organisms should thrive on similar substrates across environments. 
Application of SCNIC across more environments is necessary to see if the phylogenetic 
enrichment of modules is specific to gut or host associated communities or if some other 
pattern exists. Due to the increased nearest sequenced taxon index, relative to the 
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Noguera-Julian data set, predicting genome content with PICRUSt less accurate and 
therefore functional enrichment could not be measured. 
An additional aspect of this analysis was the comparison between using only 
DADA2 or using DADA2 and 99% OTU picking when processing microbiome data. 
DADA2 is powerful in that it can use sequence quality information to determine 
sequences down to a single nucleotide difference. Combining DADA2 with 99% OTU 
picking seems to combine the benefits of the strain resolution of DADA2 with the control 
for other sources of error and decrease sparsity when using a stringent identity threshold 
for OTU picking. This benefit is seen in the Noguera-Julian dataset where when DADA2 
plus 99% OTU picking is used, a pattern of increasing phylogenetic enrichment is seen 
with increasing minimum R values while nearly all modules are phylogenetically enriched 
when only DADA2 is used, which could be an artifact of true sequences co-occurring with 
artifactual sequences. Deeper investigation of modules shows that the true distribution of 
phylogenetic distances in the modules is often bimodal with two centers around near 
identical sequences that would likely be collapsed by 99% OTU picking (Figure A.1). This 
creates a significantly phylogenetically enriched module that is driven to significance by 
what is either a set of noisy ASVs or what should be a single biological unit. It is interesting 
that this pattern is not observed in the Great Lake data set. This could indicate that 
species and strain level variants have differential correlations while closely related 
features have the same relationships in the gut data. Overall DADA2 with 99% OTU 
picking seems to provide the best solution in the gut data while the ideal method is less 
clear in water samples. 
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SCNIC modules open new opportunities for analysis. When a module is found to 
associate with metadata of interest, such as disease state, it becomes particularly 
interesting to predict functional relationships between correlated microbes as we have 
done informatically. These functional relationships may indicate the biological factors that 
lead to their co-distribution with the metadata factor of interest. These functional 
hypotheses can be further investigated with in vitro and in vivo experiments. The 
functional properties of co-occurring modules of microbes can be evaluated by co-
culturing them or, in the case of host-associated microbiomes, they can be used to 
inoculate germ free mice. These groups may grow better than individual microbes and 
may show different phenotypes than when grown separately. 
These analyses show that optimal SCNIC parameters can be found. All together it 
seems that the SMD method performs optimally and the best R value threshold falls in a 
range between .3 and .45. Once parameter sets that produce modules that include 
negative correlations are discarded, associations with outside metadata are very 
consistent and biological enrichment is seen in gut data, if not in lake water data. R levels 
between .3 and .45 all seems to give good results and are in line with statistical 
significance levels found using a permutation test with sparCC R values. 
3.3 SCNIC with LC/MS Metabolomics Data Finds Modules Driven by Technical 
Error 
Correlation network analysis is also common in metabolomics studies and 
WGCNA is a popular tool for this (e.g. DiLeo et al., 2011; Roede et al., 2013; McHardy et 
al., 2013; Su et al., 2014; Johnson et al., 2018). A recent study showed the limitations of 
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using WGCNA and proposed modifications to the standard workflow to make it more 
appropriate for GC/MS metabolomics data (Pei et al., 2017). Because of the flexible 
nature of SCNIC I sought to use it with a LC/MS metabolomics data set to see if the 
modules detected were useful. Using Spearmen correlation was used with a strict R value 
cutoff, the modules found tended to be of compounds with very similar masses and 
retention times which are likely a result of technical error. 
3.3.1 SCNIC with Untargeted LC/MS Metabolomics from Blood Plasma 
The samples used for this analysis were from a set of individuals with and without 
HIV. There were 59 samples which will be analyzed as a single group. The metabolome 
of these samples was measured via electron spray ionization LC/MS measuring the 
aqueous positive fraction. To preprocess the data, the compound table was filtered so 
that only compounds present in at least 20% of samples were kept. This left 1811 
compounds present across the 59 samples. For these data I used the SMD algorithm for 
module picking in SCNIC and needed to select an R value cutoff for making the network. 
If the correlation network was made based on pairs of compounds where the p-value was 
less than .05 then the network would have 250,907 edges and would include all 
correlations with an R value greater than .341. This network is too large to be feasibly 
analyzed and so a stricter minimum R value threshold was used. At .75 there were 1017 
compounds included in 306 modules (Figure 3.13A). The max module size was 24 and 
163 modules had only 2 compounds in them (Figure 3.13B). 
To investigate the content of these modules the masses and retention times of the 
compounds in each module was analyzed. For each module I measured the maximum 
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and minimum mass and retention time differences for all pairs of compounds in each 
module. Modules where the minimum mass difference was less than .1 and the minimum 
retention time difference was less than .01 were recorded (Table 3.8). There were 107 
modules that fit this requirement. Of those modules, 58 had a maximum mass difference 
less than .1 and maximum retention time difference less than .01. Of these 58 and 52 are 
made up of 2 compounds and the maximum size was 4 compounds (Figure 3.13C). This 
represents 123 compounds as determined by the peak calling procedure which seem to 
represent only 58 compounds in highly correlated compounds with near identical masses 
and retention times were merged. 
Next, modules were tested for functional enrichment in terms of KEGG pathways. 
Of the 1811 compounds detected only 747 had an assigned KEGG ID and only 437 had 
a unique KEGG ID. The module with the most compounds with assigned KEGG IDs had 
7 out of 13 compounds with annotations and of the 7 KEGG IDs 5 were unique. This was 
the most unique KEGG IDs in a module tied with 8 other modules. Only 23 modules had 
more than 3 unique KEGG IDs assigned. Across all module KEGG ID and pathway pairs 
the maximum overlap was 2 compounds and so enrichment could not be calculated with 
the hypergeometric test. 
3.3.2 Discussion 
Using SCNIC on LC/MS metabolomics data shows that modules of highly 
intercorrelated compounds can be found. Compounds measured via LC/MS are generally 
highly intercorrelated as measured with Spearman correlation. 250,907 pairs of 
compounds are correlated with an FDR adjusted p-value less than .05 which is 15% of 
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all correlations. The median correlation value was .12 and almost 5% of correlations had 
an R value above .5. There were 7,121 correlations had an R value above .75. To build 
our modules with the SCNIC SMD method we used an R value cutoff of .75. The high 
level of correlation indicates that compound abundances are very interrelated. A high 
level of interrelation is expected because compounds are present in pathways and 
intercorrelated areas of the network may indicate reservoirs of compounds that are being 
built from others. 
In about 1/3 of modules all compounds had very similar mass and retention times. 
It is likely that each of these modules represents a single true compound. SCNIC is 
therefore acting equally as a quality control tool as a network analysis tool. A future 
direction for this application of SCNIC would be to use it as a preprocessing tool to find 
these modules of the same mass and retention time and summarize only them. These 
results could then be used with SCNIC again to find modules which are potentially more 
biologically relevant or to be directly used in associational studies. This is another 
explanation for the high abundance of strong correlations. 
Expanding on the use of mass data, another possible examination of these 
modules would be possible. If correlated compounds within a module had mass 
differences which were different by the mass of common functional groups such as a 
hydroxyl, methyl or phosphate, this could indicate that one compound is a modification of 
another. If the masses of two compounds added to another, this could indicate that those 
two compounds were broken down from the larger compound, and thus may be the 
product of an in source fragmentation or a break down into smaller compounds. 
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Annotation of compounds is a difficult process when using only exact mass, 
isotope ratios and isotopic distribution. This limits the ability to find biological enrichment 
of modules. Even though modules were found with up to 24 compounds, at most only 5 
unique KEGG compound IDs were found per module. The max overlap between KEGG 
pathways and these modules was 2 which made it impossible to calculate enrichment of 
these modules as even an overlap of size 0 would cause significant enrichments with the 
hypergeometric test and smaller KEGG modules. A domain expert may be able to use 
the names of compounds present in a module and ascertain some level of understanding 
of the role of the modules but it is not possible with common enrichment statistics due to 
the lack of annotation. 
Using SCNIC on a data set of MS/MS spectra, which gives structural information 
about the compounds measured as well as better annotation, would increase the ability 
to detect functional enrichment of modules. While we were able to use the mass and 
retention time data to find modules which were made of highly similar compounds, with 
structural information it would be possible to find structural similarity between members 
of modules as is done in molecular networking approaches (Wang et al., 2016). 
3.4 Limitations 
While SCNIC provides a variety of methods for building correlation networks and 
finding modules, it does have limitations. SCNIC calculates correlations across a data set 
and does not consider factors which could cause changes in correlations. Because of this 
a correlation will not be detected if it is strong in a subset of samples and not present or 
changed in direction in another set. A user could calculate correlations separately on 
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subsets of the data but this limits power, by reducing sample size per run, and eliminates 
the ability to make and summarize modules across the cohort that could be used in 
downstream analyses. A future direction would be to use more complex linear modeling 
techniques which can detect differential correlations. These models complicate module 
detection and summarization, but would give a more complete picture of the relationships 
that exist within a data set. 
One aim of this investigation of SCNIC was to validate that the modules detected 
with microbiome data were relevant.  In addition to seeing that modules were consistent 
I looked for biological enrichment in modules of microbes. To see the effect of modern 
denoising techniques on the results of correlation network analyses all module validations 
were done on the results of running the 16S rRNA sequencing data both with DADA2 and 
with DADA2 and 99% OTU picking. There is a difference in the modules created as seen 
in the biological enrichment measures. A better way to analyze the effect of these different 
data processing techniques would be to test the effects of these methods on ASV or OTU 
inflation on synthetic data sets. Additionally, the noise that seems to exist around ASVs 
in phylogenetic space seems to create multimodal distributions of phylogenetic distances. 
The consistent enrichment seen in modules from DADA2 in the gut samples could be 
driven by this. These patterns are not well controlled by the test used to measure 
phylogenetic enrichment of modules. 
Measuring functional enrichment was more difficult. Here I used the residuals to 
measure if the Jaccard index between genomes was higher than expected based on the 
phylogenetic distance. The genome lists are imputed using PICRUSt 2 and are likely 
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missing genes and may have genes which are not actually present. Additionally in the 
Great Lakes data set sufficient genomes could not be predicted as NSTI was too low. 
Using shotgun metagenomics and assembly of genomes will provide lists of the genes 
which are known to be present in the sample and assemble into a specific genome. This 
could provide a more accurate and complete list of the genes present in each genome 
and remove the restriction to only well studied microbiomes. 
Relatedly comparing the lists of genes in pairs of genomes complementary 
metabolism will not be detected. Complementarity of genomes means that sharing of 
metabolites could be occurring. In this case a correlation was found between genomes, 
but the percent of shared genes would be smaller. This could be measured using metrics 
like those in NetCooperate which can measure complementarity and parasitism (Levy et 
al., 2015). Quality of modules could be measured by the metabolic complementarity index 
between pairs of microbes within a module compared to that of uncorrelated pairs. This 
avoids the relationship between Jaccard index and phylogenetic distance and includes 
complementary metabolism. The metabolic networks as generated from PICRUSt 
predicted genomes may be incomplete and therefore affect the complementarity 
measure, but this could be improved using shotgun sequencing. 
When using SCNIC with metabolomics data our results are confounded by the 
large number of modules driven by what are being called separate compounds but seem 
to be the same. To avoid this, a dereplication strategy could be used. This may eliminate 
these peaks before SCNIC would be run. SCNIC could be used for this task when 
combined with looking for mass and retention time distances as was done to detect 
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redundant modules. Alternatively, other strategies for measuring the metabolome could 
be used such as running tandem mass spectroscopy across all peaks. The increased 
structural information given by this would limit the number of redundant features by 
improving compound identification as well. The modules detected in that data could then 
be used with molecular networking techniques to more thoroughly investigate the 
functionality of modules. 
3.5 Summary 
SCNIC is a generalized tool for finding modules of features which are correlated 
across a set of samples. The modules are summarized to create a data table that can be 
used with downstream analyses. This tool is flexible in that it provides a variety of 
correlation metrics including sparCC which is designed for use with compositional data 
sets such as microbiome data. There are two methods provided for creating modules: 
Louvain modularity maximization and a SMD algorithm which generates modules were 
all features are more strongly correlated than a given threshold. SCNIC was then used 
with 16S rRNA sequencing data from the gut microbiome and a dataset of water columns 
from the great lakes as well as an untargeted LC/MS metabolomics data from plasma. 
To validate which parameter set and module detection algorithm performed best 
with microbiome data a variety of tests were done. The modules generated by SCNIC 
were also compared to the modules created when using WGCNA with sparCC as the 
correlation metric. To test for the quality of modules all sets which had any negative 
correlations were eliminated and the consistency of association with outside metadata 
between modules and the features which made them up were measured. Biological 
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enrichment was also measured in terms of both phylogeny and functionality. Phylogenetic 
enrichment was measured by comparing the phylogenetic distance between pairs of 
features in a module to the distance between uncorrelated pairs. Functional enrichment 
was measured by comparing the residuals of the logarithmic regression between 
phylogenetic distance and the Jaccard index of the lists of genes present in each genome 
as predicted by PICRUSt. 
The gut data set used to validate SCNIC was previously published by Noguera-
Julian et al. On this data set, the use of the SMD module detection algorithm with a 
minimum R value of .35 was selected when using DADA2 or DADA2 and 99% OTU 
picking. This produced modules which were phylogenetically enriched in around half of 
the time which were consistent with metadata. There was no clear pattern of functional 
enrichment which was consistent across parameter sets. In the great lakes data set the 
SMD module detection algorithm was selected with minimum R values of .45 and .3 when 
using DADA2 and DADA2 with 99% OTU picking respectively. A range of minimum R 
values could be justified with the SMD algorithm as appropriate across both data sets 
with values between .3 and .45. This is in line with the values suggested in the sparCC 
manuscript. The modules found allowed for an increase in the number of features 
associated with variables of interest compared to when SCNIC was not used. 
SCNIC was applied to plasma metabolomics samples using the SMD method and 
a minimum R value of .75. The modules detected via this method often had very similar 
mass and retention times among metabolites in the modules. These seem to be driven 
by technical errors that should have been detected by earlier processing steps. This 
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suggests that SCNIC could be used along with the mass and retention time information 
as a processing step before reapplying SCNIC to find more biologically relevant modules. 
Because of this trend among modules, no functional enrichment could be found. 
3.6 Methods 
3.6.1  Noguera-Julian et al. data set retrieval and preprocessing 
The Noguera-Julian et al. data set was retrieved from NCBI SRA accession 
number SRP068240. Only the samples from the BCN0 cohort were used in this analysis. 
Reads were error corrected, quality trimmed and primers were removed using BBTools 
using default values. DADA2 was used to find amplicon sequence variants (ASVs) with 
reads trimmed from the left by 30 base pairs and truncated at 269. The reads were then 
used for OTU picking using USEARCH (Edgar, 2010) at 99% identity via QIIME 1 
(Caporaso et al., 2010). A tree was made using the SEPP protocol (Janssen et al., 2018) 
via QIIME 2 (Bolyen et al., 2018) for both the DADA2 sequences as well as the 99% 
OTUs. Genome content in terms of KEGG Orthology (KOs) was predicted for each 
sequence, from both DADA2 and 99% OTU picking, using PICRUSt 2 (Langille et al., 
2013) with HMMER (Eddy, 1998), EPA-NG (Barbera et al., 2018),  gappa (Czech and 
Stamatakis, 2018) and castor (Louca and Doebeli, 2018). 
The Great Lakes data set was retrieved from QIITA accession number 1041 
(Gonzalez et al., 2018). ASVs were found using DADA2 with a left trim of 30 and a 
truncation length of 135. OTUs were picked on the data using VSEARCH (Rognes et al., 
2016) with a 99% identity threshold. All these analyses on the Great Lakes data set were 
done with QIIME 2 (Bolyen et al., 2018). Tree making and genome prediction was done 
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using the same methods as with the Noguera-Julian data set. For the remaining methods 
in microbiome analyses OTUs and ASVs will be collectively known as features. 
3.6.2 SCNIC Parameter Sets Tested 
To determine optimal parameters for running SCNIC, a variety of parameter sets 
were used. SparCC was used as the correlation metric based on the analysis of Weiss et 
al. (Weiss et al., 2016). Three module picking methods were used. For the Paredes data 
set weighted gene correlation network analysis (WGCNA) was used with soft thresholds 
of 4 and 5 and a weighted hybrid network for DADA2 and DADA2 with OTU picking 
respectively. Modules were found using dynamic tree cut with deepsplit values of 2 and 
4. For the SMD method R values between .05 and .7 were used with steps of .05 
separating each value used (no correlations existed which were stronger than .75). For 
the Louvain method the same spread of minimum R values was used as the SMD method 
and the resolution parameter of the Louvain method was set between .05 and 1 with steps 
of .05 separating each value used. 
For the Great Lakes data set WGCNA was used with a soft threshold of 4 without 
OTU picking and 3 with OTU picking and a weighted hybrid network. The same parameter 
sets as with the Noguera-Julian data set were used for the SMD and Louvain methods. 
3.6.3 Validating Modules are not Identical and module Members are not anti-correlated 
All parameter sets were checked to identify if all modules were the same in terms 
of feature content compared to other module sets. If modules were the same, then the 
module set which had smallest parameter values was retained and all others were 
discarded. For each set of parameters for each module making approach, the modules 
were evaluated to determine if all pairs of features were positively correlated. All pairs of 
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features within a module were checked to see if their pairwise correlation had an R value 
> 0. Any parameter set which had any module with 1 or more pairs of OTUs which were 
negatively correlated was thrown out of further analyses. 
3.6.4 Determining if Association with Metadata is Consistent 
Modules were evaluated by determining whether associations with metadata were 
the same for entire modules and the features which made up the modules. In the Paredes 
study the primary finding was the association of microbes with HIV and MSM status. 
Association with these parameters was measured via a two-way ANOVA for each feature. 
This was done on the original feature table where SCNIC was not applied as well as each 
parameter set which passed the previous tests. If the interaction parameter was 
significant (p-value < .05) in the feature or module but not both this was considered a 
negative event. If the interaction was not significant in both then the HIV and MSM factor 
p-values were analyzed. If the p-value was significant in both or not significant in both the 
feature and module then a value of .5 was added to the same counter. If the p-value went 
from significant to insignificant from the feature to the module then it was considered from 
significant and that counter was increased by .5. If the value went from insignificant to 
significant from the feature to the module then it was considered to significant and that 
counter was increased by .5. This was done for HIV and MSM p-values. 
A similar procedure was followed for the Great Lakes data set. The test used was 
a Mann-Whitney U test to test for differential abundance of features between samples 
from Lake Michigan and Lake Superior. Here there was only one association direction 
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per feature. The same alpha value and direction measure was used as well as the same 
evaluation of change in association direction between the modules and original features. 
3.6.5 Finding Biological Enrichment of Modules in Terms of Phylogeny 
Modules were tested for phylogenetic enrichment by testing if pairs of features 
within a module were more closely related than random pairs of features. For each 
module in each parameter set the phylogenetic distance between each pair of features 
was measured via the tip to tip distance on the generated tree. To test if this distance was 
significantly smaller than the distance between random features, a subsampling 
procedure was used to build a null distribution. A group of features the same size as the 
module being tested was selected and the distribution of phylogenetic distances was 
taken over 14,000 iterations to build a null distribution for that module size. From these 
distributions t-statistics were calculated with the alternative distribution being that the 
mean of the distribution of phylogenetic distances was lower within the selected group 
than average among the distribution of all uncorrelated pairs of features. Then the t-
statistic for the real module was compared to the t-statistics from the null distribution and 
the p-value was calculated by measuring the percent of permutation t-statistics which 
were less than the module t-statistic. This is done for each module for each parameter 
set. Only modules with three or more features were included. The p-values are multiple 
testing corrected using the Benjamini-Hochberg procedure per parameter set. 
3.6.6 Finding Biological Enrichment of Modules in Terms of Functionality 
To test if modules were functionally enriched in the Noguera-Julian data set a 
regression was done between the phylogenetic distance and the log of the percent of 
genes shared between the pair of features. To test if significantly more genes were shared 
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between pairs of features in a module than expected by chance a one-sided t-test with a 
subsampling procedure was done to test if the residuals between the pairs of features in 
a module was significantly greater than between pairs of uncorrelated features. The same 
procedure for this was followed as with the phylogenetic enrichment except the alternate 
hypothesis was that the module statistic was greater than the uncorrelated statistic. 
3.6.7 Plasma Sample Preparation:  
A modified liquid-liquid extraction protocol was used to extract hydrophobic and 
hydrophilic compounds from the plasma samples (Y. Yang et al., 2013).  Briefly, 100 µL 
of plasma spiked with internal standards underwent a protein crash with 400 µL ice cold 
methanol.  The supernatant was dried under nitrogen and methyl tert-butyl ether (MTBE) 
and water were added to extract the hydrophobic and hydrophilic compounds, 
respectively.  The upper hydrophobic layer was transferred to a new tube and the lower 
hydrophilic layer was re-extracted with MTBE.  The upper hydrophobic layer was 
combined, dried under nitrogen and reconstituted in 200 µL of methanol.  The hydrophilic 
layer was dried under nitrogen, underwent a second protein crash with water and ice-cold 
methanol (1:4 water-methanol).  The supernatant was removed, dried by SpeedVac at 45 
°C and reconstituted in 100 µL of 5% acetonitrile in water.  Both fractions were stored at 
-80 °C until LCMS analysis. 
3.6.8 Liquid Chromatography Mass Spectrometry 
The hydrophobic fractions were analyzed using reverse phase chromatography on 
an Agilent Technologies (Santa Clara, CA) 1290 ultra-high precision liquid 
chromatography (UHPLC) system on an Agilent Zorbax Rapid Resolution HD SB-C18, 
1.8um (2.1 x 100mm) analytical column with an Agilent Zorbax SB-C18, 1.8 micron (2.1 
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x 5 mm) guard column.  The hydrophilic fractions were analyzed using hydrophilic 
interaction liquid chromatography (HILIC) on a 1290 UHPLC system using a Phenomenex 
Kinetex HILIC, 2.6um (2.1 x 50mm) analytical column with an Agilent Zorbax Eclipse Plus 
C8 5µm (2.1 x12.5mm) guard column.   The hydrophobic and hydrophilic fractions were 
run on Agilent Technologies (Santa Clara, CA) 6520 and 6550 Quadrupole Time of Flight 
mass spectrometers, respectively.  Both fractions were run in positive and negative 
electrospray ionization modes, as previously described (Heischmann et al., 2016).   
3.6.9 Mass Spectrometry Data Processing 
Compound data was extracted using Agilent Technologies (Santa Clara, CA) Mass 
Hunter Profinder Version B.08 (Profinder) software in combination with Agilent 
Technologies Mass Profiler Professional Version 14 (described previously (Heischmann 
et al., 2016)). Briefly, a naive feature finding algorithm, Find By Molecular Feature, was 
used in Profinder to extract compound data from all samples and sample preparation 
blanks.  To reduce the presence of missing values, a theoretical mass and retention time 
database was generated for compounds present in samples only.  This database was 
then used to re-search the raw sample data in Profinder using the Find By Ion algorithm.  
Quality control of samples was done on all fractions. As a control blank and mock 
samples of known composition were included in the run. First, total ion chromatograms 
for each fraction were visually inspected to check for similarity of peaks across samples. 
Both aqueous fractions and the lipid positive fraction were similar across samples. There 
was a leak during the lipid negative run, as observed in the total ion chromatogram data, 
and all samples affected were rerun with new QC samples and blanks. Second, the 
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coefficient of variation was calculated for all mock samples. All percent coefficients of 
variation from mock samples across all four fractions were less than 27% and considered 
within specifications. 
An in-house database containing METLIN, Lipid Maps, KEGG, and HMDB spectral 
data was used to putatively annotate metabolites based on exact mass, isotope ratios 
and isotopic distribution with a mass error cutoff of 10 ppm. This corresponds to a 
Metabolomics Standards Initiative metabolite identification level 2 (Sumner et al., 2007).  
3.6.10 Analyzing Module Content 
The differences in mass and retention time among compounds within modules 
were investigated. For each module the absolute differences between all pairs of mass 
and retention time of each compound was measured. Pairs of compounds were said to 
be likely technical error if the mass differences were less than .1 Daltons and if the 
retention time difference was less than .01 seconds. If all pairs of compounds in a module 
met this requirement then that module was considered a result of technical error. 
To test the enrichment of KEGG pathways in the compounds in a module, the 
hypergeometric test was used. The background was defined as the set of unique KEGG 
compound IDs across all compounds. Only KEGG pathways of size 10 or larger were 
considered. Because the max overlap size between any module and any pathway was 2 
and at most 5 KEGG compounds were identified in a module no significance could be 
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Model p-value Model FDR p-
value 
module_49 0.13177189 2.36E-07 0.16174806 2.16E-21 1.56E-19 
module_2 0.68894222 0.00178355 0.81695337 2.59E-16 9.31E-15 
module_0 0.7693628 0.0128838 0.80331004 1.41E-11 3.39E-10 
module_156 0.04098712 0.35839262 0.13016385 3.66E-10 6.59E-09 
module_1 0.03619622 0.71106736 0.0680204 2.37E-08 2.85E-07 
module_284 0.67777776 0.04149329 0.84668495 2.14E-08 2.85E-07 
module_175 0.94965465 0.01512451 0.59995736 2.92E-07 3.00E-06 
module_25 0.80964816 0.09777259 0.73653235 1.37E-06 1.23E-05 
module_47 0.82397496 0.03220835 0.73264109 6.43E-06 5.15E-05 
module_118 0.86389362 0.0356002 0.57925311 5.85E-05 0.0004211 
module_22 0.98949425 0.04715403 0.60177526 0.00010433 0.0006829 
module_160 0.95297001 0.08121973 0.84460723 0.00011939 0.00071632 
module_5 0.4041254 0.34201568 0.59777128 0.00029701 0.00164501 
module_161 0.99160105 0.03708596 0.23030153 0.0004615 0.00237345 
module_360 0.59850691 0.38224425 0.59747506 0.00133592 0.00641239 
module_44 0.98185231 0.09182555 0.66795572 0.00143035 0.00643658 
module_91 0.44434491 0.06699763 0.61306558 0.00170707 0.00722992 
module_12 0.82851185 0.47678116 0.55288373 0.00204082 0.00816326 
module_211 0.87949581 0.04958244 0.2909799 0.00232902 0.00882576 
module_297 0.62698209 0.29473585 0.85644984 0.0034751 0.01250101 
seq_73 0.71895348 0.03954651 0.11385333 0.00381975 0.01250101 
module_275 0.91348908 0.08895663 0.56287536 0.00365876 0.01250101 
seq_146 0.01783219 0.00550793 0.05808128 0.00425302 0.0133138 
module_205 0.24517121 0.65949568 0.51743604 0.00553788 0.01661365 
module_77 0.04961332 0.52895328 0.08866945 0.00583753 0.01681209 
module_158 0.00125929 0.00202982 0.00054512 0.00633132 0.01753289 




Taxonomy for Significant Module Members and Specific Taxa 
 
Phylum Class Order Family Genus Species module 
seq_480 Bacteroidetes Bacteroidia Bacteroidales [Odoribacteraceae] Odoribacter 
 
module_49 
seq_32 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_49 
seq_265 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_49 
seq_121 Bacteroidetes Bacteroidia Bacteroidales [Odoribacteraceae] Odoribacter 
 
module_49 
seq_96 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides uniformis module_2 
seq_18 Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides module_2 
seq_29 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides uniformis module_2 
seq_79 Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides module_2 
seq_247 Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides module_2 
seq_21 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides uniformis module_2 
seq_5 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_2 
seq_98 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_34 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_39 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_27 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_12 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_1 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_7 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_8 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_119 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_123 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella 
 
module_0 
seq_56 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_6 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_93 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_2 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_70 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_206 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
seq_533 Bacteroidetes Bacteroidia Bacteroidales [Odoribacteraceae] Odoribacter 
 
module_156 
seq_447 Bacteroidetes Bacteroidia Bacteroidales [Odoribacteraceae] Odoribacter 
 
module_156 
seq_147 Bacteroidetes Bacteroidia Bacteroidales [Odoribacteraceae] Odoribacter 
 
module_156 
seq_51 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_1 
seq_290 Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae 
 
module_1 
seq_257 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_1 
seq_359 Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae 
 
module_1 
seq_110 Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae 
 
module_1 
seq_10 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_1 
seq_127 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_1 
seq_42 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_1 
seq_955 Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillospira 
 
module_284 
seq_380 Firmicutes Clostridia Clostridiales 
   
module_284 
seq_81 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_175 
seq_11 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_175 
seq_180 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Catenibacterium module_25 
seq_50 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Catenibacterium module_25 
seq_140 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Catenibacterium module_25 
seq_513 Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillospira 
 
module_25 
seq_457 Firmicutes Clostridia Clostridiales Lachnospiraceae Butyrivibrio 
 
module_25 
seq_80 Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
 
module_47 
seq_296 Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
 
module_47 
seq_561 Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
 
module_47 
seq_210 Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
 
module_47 
seq_401 Proteobacteria Betaproteobacteria Burkholderiales Alcaligenaceae Sutterella 
 
module_118 
seq_580 Proteobacteria Betaproteobacteria Burkholderiales Alcaligenaceae Sutterella 
 
module_118 
seq_168 Proteobacteria Betaproteobacteria Burkholderiales Alcaligenaceae Sutterella 
 
module_118 
seq_36 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella stercorea module_22 
seq_165 Firmicutes Clostridia Clostridiales Veillonellaceae Anaerovibrio module_22 
seq_378 Firmicutes Clostridia Clostridiales Lachnospiraceae 
 
module_22 
seq_482 Firmicutes Clostridia Clostridiales Veillonellaceae Anaerovibrio module_22 
seq_403 Firmicutes Clostridia Clostridiales Veillonellaceae Anaerovibrio module_22 
seq_839 Bacteroidetes Bacteroidia Bacteroidales [Paraprevotellaceae] 
 
module_160 
seq_259 Bacteroidetes Bacteroidia Bacteroidales [Paraprevotellaceae] 
 
module_160 
seq_648 Bacteroidetes Bacteroidia Bacteroidales [Paraprevotellaceae] 
 
module_160 
seq_76 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_5 
seq_4 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_5 
seq_57 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_5 
seq_164 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_5 
seq_24 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_5 
seq_15 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_5 
seq_31 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella stercorea module_161 
seq_99 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella stercorea module_161 
seq_505 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella stercorea module_161 
seq_59 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Catenibacterium module_360 
seq_219 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Catenibacterium module_360 
seq_49 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_44 
seq_148 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_44 
seq_361 Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillospira 
 
module_44 
seq_179 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella stercorea module_44 
seq_64 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae [Eubacterium] biforme module_91 
seq_299 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae [Eubacterium] biforme module_91 
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Table 3.3 (continued) 
 Phylum Class Order Family Genus Species module 
seq_226 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae [Eubacterium] biforme module_91 
seq_82 Firmicutes Clostridia Clostridiales Veillonellaceae Megasphaera  module_12 
seq_188 Firmicutes Clostridia Clostridiales Veillonellaceae Megasphaera  module_12 
seq_144 Firmicutes Clostridia Clostridiales Veillonellaceae Mitsuokella multacida module_12 
seq_288 Firmicutes Clostridia Clostridiales Veillonellaceae Mitsuokella multacida module_12 
seq_411 Firmicutes Clostridia Clostridiales Veillonellaceae Mitsuokella 
 
module_12 
seq_728 Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium 
 
module_211 
seq_101 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_211 
seq_197 Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides distasonis module_297 
seq_65 Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides distasonis module_297 
seq_73 Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium prausnitzii 
 
seq_61 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_275 
seq_52 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_275 
seq_146 Firmicutes Clostridia Clostridiales Ruminococcaceae 
  
seq_434 Firmicutes Clostridia Clostridiales 
   
module_205 
seq_517 Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillospira 
 
module_205 
seq_108 Firmicutes Clostridia Clostridiales Lachnospiraceae Blautia 
 
module_77 
seq_14 Firmicutes Clostridia Clostridiales Lachnospiraceae Blautia 
 
module_77 
seq_62 Firmicutes Clostridia Clostridiales Lachnospiraceae Blautia 
 
module_77 
seq_777 Proteobacteria Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae Desulfovibrio  module_158 
seq_331 Proteobacteria Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae Desulfovibrio  module_158 
seq_1041 Proteobacteria Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae Desulfovibrio  module_158 





Significance Table for Selected DADA2 and OTU Picking SCNIC Dataset for Julian-









Model p-value Model FDR 
p-value 
module_1 0.130981893 0.010773859 0.333194981 9.16E-18 6.05E-16 
module_3 0.404718536 0.01025307 0.42781567 6.73E-16 2.22E-14 
module_7 0.085488408 0.076202596 0.141810097 3.45E-15 7.59E-14 
module_25 0.28860562 0.013740689 0.499097158 9.01E-15 1.49E-13 
module_98 0.180812981 3.58E-05 0.151268718 6.48E-13 8.55E-12 
module_2 0.683311899 0.013085063 0.682521404 1.47E-12 1.62E-11 
module_0 0.965968563 0.003657584 0.607243956 3.38E-10 3.19E-09 
module_14 0.899937636 0.005619599 0.610862356 3.63E-09 2.99E-08 
module_13 0.150829935 0.431023507 0.121693997 1.27E-08 9.31E-08 
module_5 0.958655356 0.028987944 0.918140014 2.15E-07 1.42E-06 
module_12 0.887695659 0.009799237 0.44351714 5.95E-07 3.57E-06 
module_6 0.972775355 0.056925328 0.969782904 4.13E-06 2.27E-05 
module_26 0.980649543 0.086060865 0.94713893 1.69E-05 8.57E-05 
module_17 0.43623859 0.02392263 0.499110736 8.22E-05 0.000387686 
module_4 0.856182468 0.02232974 0.261720065 0.000178033 0.000783344 
842596 8.99E-05 0.00018033 2.14E-05 0.00030277 0.001175459 
module_33 0.989283056 0.031808904 0.217803676 0.000287568 0.001175459 
module_19 0.801213747 0.151245798 0.974901402 0.000604158 0.002215248 
denovo5139 0.946495076 0.210552522 0.868863298 0.00116103 0.004033052 
module_72 0.026997089 0.514669579 0.064663283 0.001224396 0.004040507 
849311 0.71021762 0.029509834 0.079312178 0.001416674 0.004452404 
module_34 0.816075876 0.553016179 0.498800379 0.002081951 0.006245853 
module_53 0.304242488 0.929258298 0.181667588 0.005413929 0.015535622 
827313 0.97113115 0.111554456 0.512196774 0.009739157 0.026782681 
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Table 3.5 
Taxonomy for Significant Module Members and Specific Taxa for DADA2 and OTU 
Picking 
 
Phylum Class Order Family Genus Species module 
850870 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_1 
844958 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides ovatus module_1 
849273 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_1 
846484 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_1 
denovo4213 Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides module_1 
849938 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_1 
denovo3422 Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides module_1 
367215 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Holdemania 
 
module_3 
840128 Firmicutes Clostridia Clostridiales Ruminococcaceae 
 
module_3 
591635 Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcus module_3 
628481 Firmicutes Clostridia Clostridiales Lachnospiraceae [Ruminococcus] module_3 
denovo969 Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillospira 
 
module_3 
593444 Firmicutes Clostridia Clostridiales Lachnospiraceae 
 
module_3 
denovo733 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_7 
445972 Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae 
 
module_7 
771558 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_7 
2055681 Bacteroidetes Bacteroidia Bacteroidales [Odoribacteraceae] Odoribacter 
 
module_7 
denovo7511 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_7 
210303 Bacteroidetes Bacteroidia Bacteroidales [Odoribacteraceae] Odoribacter 
 
module_25 
830129 Proteobacteria Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae Bilophila 
 
module_25 
624618 Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides distasonis module_25 
denovo5237 Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides module_98 
772282 Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae 
 
module_98 
531904 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_2 
274970 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Catenibacterium module_2 
denovo2051 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_2 
denovo4216 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_2 
532450 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_2 
172962 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella 
 
module_2 
denovo214 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_2 
562244 Proteobacteria Betaproteobacteria Burkholderiales Alcaligenaceae Sutterella 
 
module_0 
470369 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae [Eubacterium] biforme module_0 
540579 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella 
 
module_0 
355333 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Catenibacterium module_0 
846333 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
denovo3948 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella stercorea module_0 
denovo4115 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_0 
330294 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Catenibacterium module_0 
denovo4240 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella stercorea module_0 
179806 Bacteroidetes Bacteroidia Bacteroidales [Paraprevotellaceae] 
 
module_14 
4307094 Bacteroidetes Bacteroidia Bacteroidales [Paraprevotellaceae] [Prevotella] 
 
module_14 
denovo1758 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella 
 
module_14 
4300526 Firmicutes Clostridia Clostridiales Veillonellaceae Dialister 
 
module_14 
denovo3465 Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae 
 
module_13 
4336943 Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae 
 
module_13 
575041 Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae 
 
module_13 
842896 Bacteroidetes Bacteroidia Bacteroidales [Barnesiellaceae] 
 
module_13 
denovo5702 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides caccae module_5 
denovo5105 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides caccae module_5 
denovo502 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_5 
840832 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_5 
denovo4771 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 
 
module_5 
denovo1954 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_12 
denovo7505 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_12 
denovo3998 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_12 
1045110 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella copri module_12 
522231 Firmicutes Clostridia Clostridiales Veillonellaceae Anaerovibrio module_6 
denovo2065 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella 
 
module_6 
841946 Bacteroidetes Bacteroidia Bacteroidales 
  
module_6 
548775 Bacteroidetes Bacteroidia Bacteroidales [Paraprevotellaceae] CF231 
 
module_6 
658348 Firmicutes Clostridia Clostridiales Lachnospiraceae 
 
module_6 
denovo1464 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae Bulleidia p-1630-c5 module_26 
317892 Firmicutes Clostridia Clostridiales 
   
module_26 
806064 Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillospira 
 
module_26 
166794 Actinobacteria Coriobacteriia Coriobacteriales Coriobacteriaceae 
 
module_17 
656865 Firmicutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae [Eubacterium] biforme module_17 
denovo2778 Firmicutes Clostridia Clostridiales Ruminococcaceae Oscillospira 
 
module_17 
681419 Firmicutes Clostridia Clostridiales Ruminococcaceae 
 
module_4 
322258 Firmicutes Clostridia Clostridiales Ruminococcaceae 
 
module_4 
592857 Firmicutes Clostridia Clostridiales Ruminococcaceae 
 
module_4 
788963 Firmicutes Clostridia Clostridiales Ruminococcaceae 
 
module_4 
235212 Firmicutes Clostridia Clostridiales Ruminococcaceae 
 
module_4 
842596 Firmicutes Clostridia Clostridiales Lachnospiraceae Coprococcus 
  
denovo355 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella stercorea module_33 
denovo4830 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella stercorea module_33 
denovo3140 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella stercorea module_33 




Table 3.5 (continued) 
 Phylum Class Order Family Genus Species module 
denovo5139 Bacteroidetes Bacteroidia Bacteroidales [Paraprevotellaceae] Paraprevotella  module_19 
594044 Actinobacteria Actinobacteria Bifidobacteriales Bifidobacteriaceae Bifidobacterium longum module_19 
844941 Firmicutes Clostridia Clostridiales 
   
module_19 
1104433 Firmicutes Clostridia Clostridiales Lachnospiraceae Blautia 
 
module_72 
denovo3830 Firmicutes Clostridia Clostridiales Lachnospiraceae Blautia 
 
module_72 
849311 Firmicutes Clostridia Clostridiales Ruminococcaceae 
  
184067 Firmicutes Clostridia Clostridiales Veillonellaceae Mitsuokella 
 
module_34 
696259 Firmicutes Clostridia Clostridiales Veillonellaceae Megasphaera  module_34 
4307934 Actinobacteria Coriobacteriia Coriobacteriales Coriobacteriaceae 
 
module_34 
649588 Actinobacteria Coriobacteriia Coriobacteriales Coriobacteriaceae Slackia 
 
module_53 
585826 Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium 
 
module_53 





Significance Table for selected parameters for the DADA2 SCNIC for the Great Lakes 
data set 




p-value FDR adjusted p-
value 
module_4 25.5 1848 1.92E-08 4.64E-07 
module_1 1113.5 11282 1.93E-08 4.64E-07 
module_0 5677 793 1.93E-08 4.64E-07 
module_19 155 9 1.90E-08 4.64E-07 
module_88 79.5 348 3.15E-08 6.05E-07 
module_11 246.5 1453 5.76E-08 6.91E-07 
module_6 3573 1527 5.11E-08 6.91E-07 
module_22 924.5 255 5.67E-08 6.91E-07 
module_17 789.5 2013 9.25E-08 9.87E-07 
module_15 228.5 97 1.65E-07 1.59E-06 
module_5 416.5 5492 2.09E-07 1.73E-06 
module_2 347 1720 2.34E-07 1.73E-06 
module_23 45.5 286 2.33E-07 1.73E-06 
module_37 291.5 1018 3.68E-07 2.47E-06 
module_81 14.5 73 3.87E-07 2.47E-06 
6860327caf160bc04ed09a1ac307d738 13.5 52 4.31E-07 2.59E-06 
module_8 466.5 1162 4.60E-07 2.60E-06 
module_51 61.5 219 5.74E-07 3.06E-06 
e3a5b428512a602492fb8a3ade09abb7 146.5 360 8.90E-07 4.50E-06 
module_74 24 65 1.15E-06 5.51E-06 
module_55 667 2497 1.23E-06 5.63E-06 
module_14 290 1419 1.70E-06 7.41E-06 
module_49 10.5 44 1.78E-06 7.43E-06 
module_54 101.5 217 1.88E-06 7.54E-06 
module_21 361 761 2.09E-06 8.04E-06 
module_26 910.5 528 3.19E-06 1.18E-05 
6c5ecbe97f430f9a4f9b191c7854352b 676 1406 4.34E-06 1.54E-05 
16f5b8f8ebfd2dad6cb96509f5e1cb68 368.5 793 4.80E-06 1.65E-05 
module_9 908 4885 5.32E-06 1.76E-05 
0396ac0e424f05e181fb5065cf9088ee 10 32 6.78E-06 2.17E-05 
32df19e32d5c8ef5ee01010eaa55c21a 140 421 8.77E-06 2.72E-05 
ee7318027347060b6d95d8cae3d15d7e 24 82 9.61E-06 2.88E-05 
module_16 192 709 1.30E-05 3.67E-05 
module_27 245 1679 1.30E-05 3.67E-05 
module_86 19 48 1.99E-05 5.46E-05 
8d747141212432908ff661785e12d7b1 24 80 2.31E-05 6.16E-05 
module_66 361.5 814 2.80E-05 7.25E-05 
module_18 183 306 4.44E-05 0.00011216 
module_10 1136 276 6.39E-05 0.00015723 
module_73 32.5 74 0.00014743 0.00035383 
module_93 69 130 0.00016038 0.00037552 
ff096a871bc7d69bb4efc322ee80944c 11 21 0.00016463 0.00037629 
module_39 218 584 0.00023525 0.00052521 
bc09d6c51286f9fe50b6e6c929cb7668 13.5 23 0.00036537 0.00078925 
module_35 185 400 0.00036996 0.00078925 
module_69 44 65 0.00046812 0.00097694 
module_63 118.5 204 0.00064201 0.00131135 
3aa10f1398192c347760686a190f5ab2 23 50 0.00072075 0.0014415 
0.45_module_77 24.5 10 0.00087108 0.00170661 
0.45_module_29 264 527 0.00114874 0.00216234 
325b634500b29c4c5476bb90907013b2 77.5 126 0.00114774 0.00216234 
module_96 70 149 0.00118912 0.00219529 
c787e12203ae93b548e11daf33624c65 28 53 0.00137715 0.00249445 
module_56 62.5 177 0.00159941 0.00284339 
24b3d939d5299285745f439264fce9d7 23 48 0.00184171 0.00321462 
module_76 11.5 42 0.00242551 0.00415802 
bfb37f42b8cefdb4471327bca99cbac2 10.5 16 0.00248394 0.00418347 
module_44 59.5 135 0.00273405 0.00452532 
3aad2414349af58714c2c7d58a2f6c6c 9 13 0.00297124 0.00483456 
226d6e6f5b1230cb399756a03eb7a716 11 26 0.00335454 0.00536726 
module_82 22 42 0.00411372 0.00647406 
8ecd8f7eb9217ba33a2c0e60e8d0e77d 27.5 53 0.0061417 0.00950973 
module_33 621.5 1102 0.00677334 0.01032128 
module_48 224.5 319 0.00794616 0.01191924 
module_84 53.5 15 0.01215747 0.01795565 
module_98 216.5 304 0.01338415 0.01946785 
module_80 88.5 106 0.01791776 0.02567321 
module_30 153.5 354 0.02314739 0.03267867 





Taxonomy for Significant Module Members and Specific Taxa for DADA2 in the Great 









module_71 79.5 348 3.15E-08 1.17E-06 
module_1 1161 12256 1.93E-08 1.17E-06 
module_22 1153 348 5.76E-08 1.42E-06 
module_14 371.5 2151 1.04E-07 1.93E-06 
module_6 1211 2934 1.48E-07 2.19E-06 
module_108 34 103 1.86E-07 2.29E-06 
module_36 39.5 165 3.10E-07 2.55E-06 
module_4 372.5 1532 2.93E-07 2.55E-06 
module_52 68.5 162 2.77E-07 2.55E-06 
module_2 300 5746 5.14E-07 3.81E-06 
module_12 763 3869 5.75E-07 3.87E-06 
module_33 150 585 6.42E-07 3.96E-06 
module_87 158.5 384 8.43E-07 4.46E-06 
module_30 77.5 230 8.43E-07 4.46E-06 
module_48 37 87 1.10E-06 5.45E-06 
module_23 7.5 119 2.40E-06 1.11E-05 
module_13 856 4897 2.59E-06 1.13E-05 
module_18 533 1151 2.87E-06 1.18E-05 
module_121 40.5 96 3.51E-06 1.37E-05 
2421320 676 1406 4.34E-06 1.53E-05 
module_90 378 878 4.34E-06 1.53E-05 
module_72 35 95 5.29E-06 1.78E-05 
module_42 42.5 127 5.56E-06 1.79E-05 
module_62 6.5 36 7.82E-06 2.41E-05 
module_83 140 450 1.18E-05 3.49E-05 
module_58 12.5 46 2.41E-05 6.85E-05 
module_104 361.5 814 2.80E-05 7.66E-05 
module_15 48.5 201 3.87E-05 0.00010238 
module_89 24.5 93 4.43E-05 0.00011304 
module_10 334 562 5.10E-05 0.00012584 
module_43 51.5 101 6.38E-05 0.00015234 
module_46 36 85 0.00011872 0.00027453 
module_16 1235 847 0.00012969 0.00029082 
687414 11 21 0.00016463 0.00035831 
module_5 1614 5800 0.00018273 0.00038634 
module_73 61 117 0.00041655 0.00085623 
module_95 44 65 0.00046812 0.00093624 
module_123 17.5 39 0.00050783 0.00098894 
module_55 34 14 0.0005485 0.00104074 
933138 23 50 0.00072075 0.00133339 
module_0 14161.5 10161 0.00106551 0.00192312 
module_41 70 149 0.0011464 0.00201984 
module_3 3257 2262 0.00123794 0.00213041 
module_19 298 547 0.00133274 0.00224143 
module_112 85.5 134 0.00221585 0.00364384 
module_8 1957 1351 0.00304023 0.0048908 
bfb37f42b8cefdb4 
471327bca99cbac2 
11.5 16 0.00599114 0.00943285 
module_113 15.5 37 0.00674799 0.01040315 
module_86 15.5 24 0.00689185 0.01040809 
module_21 723 1249 0.01084206 0.01604625 
module_7 1354.5 659 0.01152288 0.01671948 
module_45 54.5 132 0.01186651 0.01688695 
module_40 60 29 0.01331096 0.01858511 
module_25 36 242 0.01788267 0.02450588 
module_120 11.5 21 0.02645681 0.03559643 
















module_0 7 0.0004 453.0724 0 0.019994 
module_2 3 0.0002 82.0032 0.0010044 0.3340051 
module_5 3 0.0018 74.038 0 0.1670022 
module_6 2 0.0003 0.0003 0 0 
module_7 2 0.0001 0.0001 0.0050018 0.0050018 
module_10 3 0 0.0004 0 0 
module_12 2 0.0003 0.0003 0.00199957 0.00199957 
module_16 3 0.0001 0.0005 0 0 
module_17 8 0.0003 1836.0823 0 0.0099921 
module_25 3 0.0008 21.9806 0 0.0039993 
module_26 3 0.0029 164.0053 0.0009946 0.0059938 
module_27 5 0 99.0666 0 0.0320053 
module_28 8 0.0012 413.0088 0 0.0060029 
module_29 2 0.0001 0.0001 0.0019993 0.0019993 
module_30 2 0.001 0.001 0.00299895 0.00299895 
module_34 2 0.0075 0.0075 0.003002 0.003002 
module_39 3 0.002 15.9739 0 0.0009969 
module_41 2 0.0105 0.0105 0 0 
module_43 4 0.0003 140.9793 0 0.007 
module_44 2 0.0002 0.0002 0.0030002 0.0030002 
module_45 3 1.00E-04 46.0055 0 0.0009996 
module_51 2 0.0001 0.0001 0 0 
module_55 2 0.0004 0.0004 0.0009996 0.0009996 
module_56 2 1.00E-04 1.00E-04 0 0 
module_57 2 0.0002 0.0002 0.00200135 0.00200135 
module_59 2 0.0004 0.0004 0.0010005 0.0010005 
module_63 3 0.0003 0.0012 0 0 
module_68 2 0.0006 0.0006 0 0 
module_69 5 0.0001 48.0039 0 0.0019997 
module_72 2 0.0024 0.0024 0 0 
module_76 4 0.0005 21.9816 0 0.0030005 
module_77 2 0.0001 0.0001 0 0 
module_78 2 0.0001 0.0001 0 0 
module_81 2 0.0012 0.0012 0 0 
module_84 2 0.0008 0.0008 0 0 
module_85 2 0.0004 0.0004 0 0 
module_86 4 0.0001 1.9968 0.00099966 0.08700026 
module_87 2 1.00E-04 1.00E-04 0 0 
module_88 2 0.0038 0.0038 0.00099998 0.00099998 
module_89 2 0.0005 0.0005 0 0 
module_94 2 0.0001 0.0001 0 0 
module_96 7 1.00E-04 1618.0747 0.0009946 0.0110062 
module_97 2 1.00E-04 1.00E-04 0 0 
module_98 2 0.0005 0.0005 0.00200057 0.00200057 
module_99 2 1.00E-04 1.00E-04 0 0 
module_100 2 0.0003 0.0003 0.00100003 0.00100003 
module_103 3 0 35.9767 0 0.06799915 
module_105 4 0.0001 79.9572 0 0.21300019 
module_108 3 0.0003 15.9733 0.0009978 0.0089975 
module_109 2 0.001 0.001 0.00199946 0.00199946 
module_112 4 0.0001 0.0006 0 0.0010007 
module_115 2 0.0002 0.0002 0 0 
module_119 2 0 0 0 0 
module_120 2 0.0013 0.0013 0 0 
module_121 2 0.0013 0.0013 0.0009997 0.0009997 
module_124 3 0.0004 21.9823 0 0.00600007 
module_126 2 0.0012 0.0012 0.0059988 0.0059988 
module_127 2 0.001 0.001 0.00500184 0.00500184 
module_130 2 0.0009 0.0009 0 0 
module_131 2 0.0011 0.0011 0.0009999 0.0009999 
module_139 2 0.0014 0.0014 0 0 
module_140 2 0.003 0.003 0.0019995 0.0019995 
module_141 2 0.0002 0.0002 0.0009995 0.0009995 
module_142 2 0.0003 0.0003 0 0 
module_151 2 0.0007 0.0007 0 0 
module_152 2 0.0008 0.0008 0 0 
module_153 2 0.0011 0.0011 0.00099998 0.00099998 
module_155 2 0.0002 0.0002 0.0009971 0.0009971 
module_156 2 0.0001 0.0001 0 0 
module_157 2 0.0017 0.0017 0 0 
module_160 2 0.0006 0.0006 0.003999 0.003999 
module_161 2 0.001 0.001 0.0009995 0.0009995 
module_162 2 0.0002 0.0002 0.0040005 0.0040005 
module_163 2 0.001 0.001 0 0 
module_164 4 0.0002 0.0047 0 0.0020011 
module_166 4 0.001 31.9508 0.00099954 0.01099834 
module_169 2 0.0015 0.0015 0 0 
module_176 4 0.0004 21.9827 0 0.0009995 
 95 











module_180 4 1.00E-04 15.9746 0.0009978 0.0059979 
module_181 2 0.0005 0.0005 0 0 
module_185 6 1.00E-04 567.1631 0 0.8210047 
module_189 3 0 1.9967 0 0.01200077 
module_191 2 0.0003 0.0003 0 0 
module_193 2 0.0001 0.0001 0.0010006 0.0010006 







SCNIC schematic and data flow. A. The basic process of SCNIC involves first identifying 
pairwise correlations between species and using them to build a correlation network. 
Modules of correlated features are identified and then summarized so that there is a 
decrease in the total number of features. B. The input to SCNIC comes in the form of a 
count table in BIOM format. The first step takes the table and generates a correlation 
table and network. The table is in a tab separated format and the network is in GML format 
and can be used to visualize the network in Cytoscape. Modules are detected and 
summarized in the final step which generates a module membership file indicating which 
features are in each module. The collapsed BIOM table contains the same total counts 
per sample as the original table, but with less features. All features not included in 
modules are retained with their original counts and all modules have a total count per 





Selecting a soft threshold for WGCNA. A. Similarity to scale free topology and mean 
connectivity at soft threshold levels between 1 and 20 for sparCC correlations from the 
Noguera-Julian data set processed with DADA2. B. Same data as panel A but with 
DADA2 and 99% OTU picking applied to the Noguera-Julian data set. C. Dendrogram 
and modules selected on the Noguera-Julian data set processed with DADA2. D. 
Dendrogram and modules selected on the Noguera-Julian data set processed with 





Consistency of association of modules with metadata across parameter sets. A. 
Distributions of associations of all ASVs passing the abundance filter which make up 
modules from the Noguera-Julian data set processed with DADA2. Broken up into 
positive results: the same and to_sig (to significance) categories showing the association 
staying the same or becoming significant. And negative: associations being significant in 
individual ASVs but not significant in the module is a negative result along with the 
significance of the interaction term changing. B. Plot of negative events across parameter 
sets from the Noguera-Julian data set processed with DADA2. C. Distribution of 
associations of all OTUs passing the abundance filter which make up modules from the 
Noguera-Julian data set processed with DADA2 and 99% OTU picking. Otherwise same 
as A. C. Scatterplot of only negative events across parameter sets from the Noguera-




Enrichment of modules in biological factors. A. p-value distributions of phylogenetic 
enrichments of modules across parameter sets from the Noguera-Julian data processed 
with DADA2. B. p-value distributions of functional enrichments of modules across 
parameter sets from the Noguera-Julian data processed with DADA2. C and D are 




Plots of significant differences with HIV and MSM for DADA2 processed SCNIC 
Summarized Table. All plots included had the model as significantly explaining the data 




Plots of significant differences with HIV and MSM for DADA2 and 99% OTU picking 
processed SCNIC Summarized Table. All plots included had the model as significantly 




Weighted Unifrac plots of the Great Lakes dataset. All are PCoA plots of unweighted 
Unifrac distance where the shape of the point represents the sampling site where it was 
taken. A. PCoA plot colored by lake of origin of the sample. B. PCoA plot colored by the 
depth of the sample. C. PCoA plot colored by the pH of the sample. D. PCoA plot colored 




Selecting soft threshold for WGCNA. A. Similarity to scale free topology and mean 
connectivity at soft threshold levels between 1 and 20 for sparCC correlations from the 
Great Lakes data set processed with DADA2. Based on this a soft threshold of 4 was 
selected. B. Same data as panel A but with DADA2 and 99% OTU picking applied to the 
Great Lakes data set. C. Dendrogram and modules selected on the Great Lakes data set 
processed with DADA2. D. Dendrogram and modules selected on the Great Lakes data 




Consistency of association of modules with metadata across parameter sets. A. 
Distributions of associations of all ASVs passing the abundance filter which make up 
modules from the Great Lakes data set processed with DADA2. Broken up into positive 
results: the same and to_sig (to significance) categories showing the association staying 
the same or becoming significant. And negative: associations being significant in 
individual ASVs but not significant in the module is a negative result along with the 
significance of the interaction term changing. B. Scatterplot of only negative events across 
parameter sets from the Great Lakes data set processed with DADA2. C. Distribution of 
associations of all OTUs passing the abundance filter which make up modules from the 
Great Lakes data set processed with DADA2 and 99% OTU picking. Otherwise same as 
A. C. Scatterplot of only negative events across parameter sets from the Great Lakes 




Enrichment of modules in phylogeny. A. p-value distributions of phylogenetic enrichments 
of modules across parameter sets from the Noguera-Julian data processed with DADA2. 
B. p-value distributions of functional enrichments of modules across parameter sets from 




Plots of significant differences between lakes for DADA2 processed SCNIC Summarized 
Table. All plots included had the model as significantly explaining the data (model FDR 




Plots of significant differences between lakes for DADA2 and 99% OTU picking 
processed SCNIC Summarized Table. All plots included had the model as significantly 




Correlation network generated from Spearman correlation on untargeted LC/MS 
metabolomics of the plasma. A. Correlation network where edges are correlations with a 
R value > .75. Nodes are compounds and node color represents module membership. B. 
Distribution of module sizes found in correlation network. C. The largest module 






USING GENOMIC INFORMATION TO IDENTIFY METABOLIC RELATIONSHIPS 
BETWEEN MICROBES 
The host-associated microbiome can influence many aspects of human health and 
disease through its metabolic activity. Examples include microbe-host co-metabolism of 
dietary choline/carnitine to TMAO as a driver of heart disease (Wang et al., 2011), 
microbial production of branched chain amino acids as a contributor to insulin resistance 
(Pedersen et al., 2016b), and microbial production of 12,13-DiHOME as a driver of 
CD4+ T cell dysfunction associated with childhood atopy (Fujimura et al., 2016). A key 
way of exploring which compounds might mediate relationships between microbial activity 
and host disease is untargeted metabolomics (e.g. mass spectrometry) of host materials 
such as stool, plasma, urine, or tissues. These analyses result in the detection and 
relative quantitation of hundreds to thousands of compounds, the sum of which is referred 
to as a “metabolome”. Host-associated metabolomes represent a complex milieu of 
compounds that can have different origins, including the diet of the host organism and a 
variety of environmental exposures such as pollutants.  In addition, the metabolome 
contains metabolic products of these compounds, i.e. metabolites, that can result from 
host and/or microbiome metabolism or co-metabolism (Shaffer et al., 2017). 
One way to estimate which metabolites in host samples originate from host versus 
microbial metabolism is to use metabolic networks described in databases such as KEGG 
(Kanehisa et al., 2017). Metabolic networks capture the relationship between metabolites, 
the enzymes that produce them, and the genomes of organisms (both host and microbial) 
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that contain genes encoding those enzyme and provide a framework for relating the 
genes present in the host and colonizing bacteria, and the metabolites present in a 
sample (Figure 4.1). 
The metabolic network is a directional with a flow starting from nodes representing 
the organisms present in a community and edges connecting to the genes in the 
organism’s genomes. Genes connect to the chemical reactions that the proteins that they 
encode catalyze, which connect to the compounds the reactions consume (incoming 
edges) and produce (outgoing edges). We trace up the metabolic network from 
compound to organism to determine the possible origin of a metabolite. For example, in 
Figure 4.1, we can infer that the microbiome could have generated compound 9 because 
of the presence of gene 4 in the genome of Bacteria 2. However, compound 9 could also 
have been produced by the host because of the presence of gene 5 in the human 
genome. In contrast, compound 8 could only be produced by the bacteria present and not 
the host. 
Here I generated this network along with imputed genomes from 16S sequences 
to determine if microbes can potentially produce or degrade compounds which are 
associated with disease or correlated with detected microbes. I first used this to find 
associations between microbes and metabolites in children with autism. In this dataset 
there were specific hypotheses which allowed for a targeted analysis. In the second 
analysis I generalized this process to develop a tool for Annotation of Molecular Origin 
via Networks (AMON) and show the origin of plasma compounds from stool microbes and 
the host can be predicted from gene sets. 
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4.1 Determining if Intestinal Bacterial Could Produce Stool NMR Compounds in a 
Study of Autism Spectrum Disorders 
Here fecal microbial metabolites and microbiome differences in children with and 
without autism spectrum disorders (ASD) were studied (Kang et al., 2018). The fecal 
microbiome was measured via 16S rRNA sequencing and the fecal metabolome was 
measured via nuclear magnetic resonance spectroscopy (NMR). There were 21 children 
recruited for the study with ASD and 23 neurotypical controls. NMR detected 59 
metabolites with isopropanol being significantly more abundant in ASD individuals than 
controls (FDR adjusted p-value < .05). p-cresol was more highly abundant in individuals 
with ASD (unadjusted p-value = .04) and GABA was less abundant (unadjusted p-value 
= .077) although these results were only trending toward significance. In the fecal 
microbiome there was a reduction of Prevotella copri in ASD children (unadjusted p-value 
= .02) as well as Faecalibacterium prausnitzii and Haemophilus parainfluenzae (FDR 
adjusted p-values < .05). The predicted genomes of the microbes in the stool were used 
to find if detected compounds could be produced by the measured microbes. 
4.1.1 Results 
To integrate the microbiome and metabolome data I used two approaches. First I 
identified correlations between microbes and metabolites and then used genomic 
information to determine whether microbes present could produce metabolites they 
correlate with. Second, the ability of microbes present in the intestinal microbiome to 
potentially produce metabolites which were associated with ASD was determined. Both 
approaches required determining the ability of a microbe to produce a metabolite via 
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multiorganismal metabolic networks. I used PICRUSt (Langille et al., 2013) to predict the 
genomes associated with the detected 16S rRNA sequences. KEGG is used to predict 
the reactions and compounds and generate a metabolic network. 
In the first integration, for correlations between the microbiome and metabolome 
data the genomic information was used to provide further evidence for the correlations. 
Spearman correlation was calculated between all pairs of microbes and compounds. All 
correlations with a FDR adjusted p-value of less than 0.1 were used as edges in the 
network and nodes were the microbes and metabolites connected by the edges (Figure 
4.2). Of the 17 nodes, 5 were microbes and 12 were compounds. The operational 
taxonomic unit (OTU) 173883, assigned to the genus SMB53 and order Clostridales has 
8 significant correlations with compounds. Of these, 6 are amino acids and two are nucleic 
acids. None of the metabolites present in the network were associated with ASD or of 
specific interest. 
I used KEGG to determine whether compounds in the correlation network could 
be produced or degraded by the OTUs they were correlated with. The reactions in the 
KEGG entry for each compound and then the KOs associated with each KEGG reaction 
were used to connect genes to compound. These were then compared with the KOs each 
genome was predicted to encode. Interestingly, all microbe-compound pairs had a 
potential production or degradation relationship (Table 4.1). Of the correlations, 9 had 
potentially productive relationships and 15 had degradative relationships. 
In the second integration approach, I found microbes which could produce or 
degrade metabolites of interest because of their association with ASD. The compounds 
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were isopropanol, which was the compound significantly associated with ASD, and p-
cresol, GABA, and glutamate which have previously been associated with ASD. The 
PICRUSt predicted metagenomes were used to find KOs associated with ASD. There 
were 211 KOs significantly associated with ASD (FDR adjusted p-value < 0.1). I used the 
multiorganismal metabolic network to determine that 1 of the significant KOs can 
potentially degrade GABA and 2 could produce it. No other significant KOs were able to 
produce or degrade any other compounds of interest. The two significant pathways (FDR 
adjusted p-value < 0.1) were basal transcription factors and ether lipid metabolism, both 
of which were decreased in abundance with ASD.  Neither pathway includes genes which 
are producers or degraders of compounds of interest. 
To further investigate these compounds, I used the multiorganismal metabolic 
network to determine which detected microbes could produce or degrade each compound 
of interest. The KOs that could produce or degrade each metabolite were determined and 
then the microbes with these KOs were found. There were no genes which could 
potentially produce or degrade isopropanol. There was one gene which could produce p-
cresol, present in 385 OTUs, and none which could degrade it. 6 genes could potentially 
produce GABA and were present in 291 OTUs. 4 genes could degrade GABA and were 
present in 42 OTUs. Differences in relative abundance of p-cresol producers, GABA 
producers and GABA degraders were measured using the Mann-Whitney U test (Figure 
4.3). There are significantly more p-cresol producers in autistic individuals than 
neurotypical individuals (p-value < .05) and this pattern was also true in GABA producers 
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(p-value < .05). For GABA degraders there was a higher abundance in neurotypical 
individuals than in autistic individuals (p-value < .05). 
4.1.2 Discussion 
This exploratory analysis provided interesting insights to further investigate. While 
no metabolites that were associated with ASD in this or previous studies were found in 
the microbe-metabolite correlation network, interesting potential relationships between 
microbes and metabolites were present. Notably the network suggested a particular 
microbe that may influence amino acids and nucleotides. The OTU 173883, assigned 
taxonomy SMB53, is correlated with 8 different compounds 6 of which are amino acids. 
Additionally, this microbe has genes which could produce 4 of these compounds and 
degrade all but two. SMB53 is of the family Clostridiaceae and other members of this 
family are known amino acid fermenters (Elsden and Hilton, 1979; Kim et al., 2008; 
Nanninga and Gottschal, 1985). SMB53 is positively correlated with all these which could 
suggest a productive relationship but only has genes to produce half of them and could 
degrade all but two. A positive correlation could alternatively be interpreted as a 
consumptive relationship where the microbe is able to thrive when the compound 
increases in abundance. It is interesting this microbe only has genes which could explain 
the production of half of these positive relationships. At the same time 6 out of 8 had 
potential degradation genes which one normally associates with negative correlations. 
Of the significant correlations detected, all but 2 were positive and of those 13 
positive correlations only 7 had genes which could potentially produce that compound. A 
positive correlation between a microbe and compound is often viewed as a potential 
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productive relationship (Freitag and Prosser, 2009; Danielsson et al., 2017). There are 
many explanations for why there are not microbes with genes to produce these 6 
compounds such as the lack of coverage of PICRUSt as well as the lack of database 
information which underlies this. These relationships could also imply indirect 
associations where the product of the reaction is a substrate for a further reaction which 
is rapidly done (Tang et al., 2013). Both negative correlations had more than one gene 
which could degrade those compounds and at least one gene which could produce it. 
This does not point to a clear the role of these bacteria in these metabolic relationships. 
Although it would be ideal if compounds associated with ASD were present in this 
network, that was not found. If compounds associated with ASD or otherwise of interest 
had significant correlations with microbes that were also associated with ASD, then this 
information could be used to make hypotheses of the roles of the specific microbes and 
compounds in the disease. If this could be supported with genomic data then a metabolic 
relationship could be established which could be tested using traditional microbiology 
techniques. Knockout experiments could be done to verify the ability of a microbe to 
produce or degrade a compound of interest and the knockout could further be used to 
colonize a germ free animal to find the effect of that gene and compound on a host 
associated bacterial community. These analyses set out a framework that could generate 
these hypotheses which could be applied to any other disease system or other phenotype 
of interest. 
Investigating the metabolic relationships between microbes and compounds was 
done with specific metabolites of interest as well. The compounds of interest were 
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isopropanol, the only metabolite found to be associated with ASD, and three metabolites 
previously associated with ASD: GABA (Horder et al., 2018; Ma et al., 2005; Chao et al., 
2010), glutamate (Horder et al., 2018) and p-cresol (Elaine Y. Hsiao et al., 2013; Altieri et 
al., 2011). There were no genes found in KEGG which could produce or degrade 
isopropanol so I could not include this in any further analysis. There were 6 genes 
predicted to be encoded by detected bacteria which could potentially produce GABA and 
4 which could degrade it. There was one gene which could produce p-cresol and none 
which could degrade it. Glutamate had 57 genes which could produce it and 35 which 
could degrade it. This high abundance of genes which can produce or degrade glutamate 
is not surprising as it is an amino acid which is essential to protein metabolism. 
The metagenome and the pathway abundances, predicted by PICRUSt, were 
associated with ASD and could potentially produce or degrade any metabolites of interest. 
Of 211 genes associated with ASD one is a potential GABA producer and two were 
potential degraders. These genes were all more abundant in autistic individuals than 
neurotypical. This suggests that GABA regulation by the microbiome, as seen in other 
studies (Mazzoli and Pessione, 2016), may be affected by ASD but not clearly in one 
direction. There were no genes which produce or degrade the other compounds which 
were significantly associated with ASD. The only two pathways significantly differentially 
abundant were unrelated to any of the compounds of interest.  
The list of genes which could produce or degrade these compounds was used to 
find OTUs which were producers or degraders of the compounds of interest.  All microbes 
could both produce and degrade glutamate so there were no specific differences in 
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production and degradation between groups. GABA had both producers and degraders 
present and p-cresol only had producers. All three of these groups were significantly 
different between autistic and neurotypical groups. Producers of p-cresol were more 
abundant in autistic individuals. This aligns with the higher levels of p-cresol in the feces 
of autistic individuals and points to a potential role of gut bacteria in this finding (Kang et 
al., 2018). GABA producers were more abundant in autistic individuals and degraders 
were more abundant in neurotypical individuals. This is counter to the finding that GABA 
could be less abundant in children with autism but contributes to the idea that microbes 
could have a role in GABA regulation. 
4.2 AMON: Annotation of molecular origins via networks 
To generalize the prediction of whether a compound could be produced by the 
microbiome I developed a tool for the Annotation of Molecular Origins via Networks 
(AMON). AMON is an open source tool that is designed to use the KEGG metabolic 
network to predict what metabolites could be generated by a set of genes. AMON takes 
as input lists of KEGG KO (KEGG Orthology) identifiers that are predicted to be present 
in different potential sources (e.g. the metagenome of a host-associated microbiome or 
the genome of host organism) and a list of KEGG compound IDs, such as from an 
annotated metabolome (Figure 4.4).  AMON uses the multi-organism metabolic network 
constructed with information in KEGG to produce a table indicating which compounds 
(from the entire set of KEGG compounds and from the list of those annotated to be 
present in the metabolome) could be produced by each of the different provided KO sets 
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and a file for input to KEGG mapper (https://www.genome.jp/kegg/mapper.html) which 
can be used to overlay this information on KEGG pathway diagrams. 
AMON uses the hypergeometric test to measure enrichment of KEGG pathways 
in metabolites predicted to originate specifically from each source environment that are 
present in the metabolome. Specifically, the set of metabolites predicted to be 
produced by the list of KO identifiers provided by the user is tested for enrichment of 
metabolites present in KEGG pathways relative to the background set of all 
compounds in all KEGG pathways that had at least one metabolite predicted to be 
produced by the provided gene sets. It produces a summary figure (Venn diagram) 
illustrating predicted metabolite origins. 
AMON is built to be flexible as to the type of technology and informatics 
methods used to obtain the list of KOs present in each source sample and compounds 
present in a metabolome. As shown in our case study below, 16S rRNA data can be 
used to predict the KO list using PICRUSt (Langille et al., 2013), which uses whole 
genome sequence information to predict KOs present. Other ways to produce this list 
of KOs include annotation of genes present in a shotgun metagenome, e.g. using tools 
such as HUMAnN (Abubucker et al., 2012). The host KOs can be acquired from KEGG 
using the extract_ko_genome_from_organism.py script, which downloads the KOs 
from the KEGG API or parses them from a KEGG FTP file and makes a list of KOs 
present in that file. 
AMON does not require the user to purchase a KEGG license. For individuals 
who have purchased a KEGG license, files containing KO and reaction information 
provided by KEGG can be loaded into AMON. As another option, AMON can also 
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download the required information using the publicly available KEGG API 
(https://www.kegg.jp/kegg/rest/), although this method is comparatively slow and limits 
maximum dataset size based on the limits of the KEGG API. The KEGG API is only 
available for use by academics. 
AMON is available both in the pypi repository (https://pypi.org/project/amon-bio) 
and on github (https://github.com/lozuponelab/AMON). 
4.2.1 Case Study 
We used AMON to relate the stool microbiome (as assessed with 16S rRNA gene 
sequencing) to the plasma metabolome (as assessed with untargeted LC/MS), in a cohort 
of HIV positive individuals (n=37) and HIV-negative controls (n=22). These data represent 
a subset of the cohort described in (Armstrong et al., 2018) and are paired with 
metabolome data as a part of a study described at ClinicalTrials.gov (Identifier: 
NCT02258685). The overall goal of our case study was to use AMON to determine the 
degree to which annotated compounds in the plasma metabolome of our study cohort 
may have been produced by bacteria present in fecal samples, the host, either (i.e. both 
are capable of production), or neither (i.e. neither the human or the fecal microbiome are 
predicted to be capable of producing the observed metabolite).  
4.2.2 Results 
We used PICRUSt to determine the genome content of the OTUs detected in the 
fecal samples. PICRUSt drops from the analysis OTUs that do not have related reference 
sequences in the database and produces an estimate of the nearest sequenced taxon 
index (NSTI) which measures how close those sequences are to sequenced genomes 
(those more closely related to genomes have more power to make predictions regarding 
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gene content). Since human gut bacteria are well represented in genome databases, only 
0.7% of total reads of the detected sequences were dropped because of not having a 
related reference sequence in the database. Furthermore, the average NSTI across 
samples was 0.08, indicating that most OTUs were highly related to an organism with a 
sequenced genome. We applied PICRUSt to the 16S rRNA dataset with only OTUs 
present in more than 11 of 59 samples included. The 267 remaining OTUs were predicted 
to contain 4,409 unique KOs using PICRUSt. We used the KEGG list of KOs in the human 
genome to represent human gene content. 
We used the lists of gut microbiome and human KOs to AMON to produce a list of 
compounds generated from the gut microbiome and the human genome. Of the 4,409 
unique KOs that PICRUSt predicted to be present in the gut microbiome, only 1,476 
(33.5%) had an associated reaction in KEGG. Those without associated reactions may 
represent orthologous gene groups that do not perform metabolic reactions (such as 
transporters), or that are known to exist but for which the exact reaction is unknown, 
showing gaps in our knowledge (Figure 4.5A). Using information in KEGG, AMON 
predicted these KOs to produce 1,321 unique compounds via 1,926 unique reactions. 
The human genome was predicted to produce 1,376 compounds via 1,809 reactions. 
Our metabolomics assays detected 5,971 compounds, of which only 1,018 (17%) 
could be putatively annotated with KEGG compound identifiers via a database search; 
only 471 (6%) of the 5,971 detected compounds were associated with a reaction in 
KEGG. Of these 471 annotated compounds in the plasma metabolome with associated 
KEGG reactions, 189 were predicted to be produced by enzymes in either human or stool 
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bacterial genomes. 40 compounds were exclusively produced by bacteria, 58 exclusively 
by the host, and 91 by either human or bacterial enzymes (Figure 4.5B). The remaining 
282 compounds may be 1) from the environment, 2) produced by microbes in other body 
sites or 3) host or gut microbial products from unannotated genes. 
We used AMON to assess enrichment of pathways in the detected human and 
bacterial metabolites using the hypergeometric test (Figure 4.6B, Table 4.2). The 41 
compounds predicted to be produced by stool bacteria and not the host were enriched in 
xenobiotic degradation pathways, including nitrotoluene and atrazine degradation, and 
pathways for amino acids metabolism, including the phenylalanine, tyrosine and 
tryptophan biosynthesis pathway and the cysteine and methionine metabolism pathway. 
The metabolite origin data was visualized using KEGG mapper for the phenylalanine, 
tyrosine and tryptophan biosynthesis pathway (Figure 4.6B). This tool helps to visualize 
the host-microbe co-metabolism and which genes are important for compounds that may 
have come from multiple sources. For instance, Figure 4.6B allows us to see that Indole 
is a compound found in our metabolome that could only have been produced by bacterial 
metabolism via the highlighted enzyme (K01695, tryptophan synthase). Also, Tyrosine is 
a compound found in our metabolome that could have been synthesized by a variety of 
enzymes found only in bacteria, only in humans, or in both and so further exploration 
would be needed to understand origins of this compound. The 51 compounds which were 
detected and predicted to be produced by the human genome were enriched in pathways 
that include bile secretion, steroid hormone biosynthesis and gastric acid secretion. 
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4.2.3 Discussion 
Taken together, these analyses show that AMON can be used to predict the origin 
of compounds detected in a complex metabolome, such as stool. Our case study shows 
the specific application of predicting origins of plasma compounds as being from the fecal 
microbiome versus the host. However, this tool can be used to compare any number of 
different sources – e.g. from the microbiomes of different body sites or compounds that 
may come directly from plants consumed in the diet. Also, the outputs of AMON can be 
used in conjunction with lists of metabolites that were determined to significantly differ 
with disease state or correlate with other host phenotypes to predict origins of metabolites 
of interest. 
Although our example uses PICRUSt to predict compounds of bacterial origin 
using 16S rRNA sequence data, AMON requires a list of KEGG Orthology identifiers as 
input and so could also be used with shotgun sequencing data. This can allow for a more 
thorough interrogation of host microbiomes that account for strain level variation in 
genome content and opens its application to environments with less understood 
genomes. 
The pathway enrichment of compounds predicted to be unique to the gut 
microbiome and the host provide a level of validation for these results. The pathways 
enriched with compounds predicted to only be from microbes are consistent with known 
roles for gut bacteria in degrading various xenobiotics (Maurice et al., 2013; Lu et al., 
2015; Das et al., 2016; Saad et al.; Clayton et al., 2009) and for influencing amino acid 
(Neis et al., 2015; O’Mahony et al., 2015) and vitamin metabolism (Streit and Entcheva, 
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2003). Likewise, the pathways enriched with compounds predicted to be human only 
include host processes such as taste transduction and bile secretion. Further, since the 
microbial community measured was from the human gut and the metabolome came from 
plasma, these results suggest that these microbial metabolites can translocate from the 
gut into systemic circulation. This is consistent with the gut microbiome being linked with 
many diseases that occur outside of the gut. Examples include interactions between the 
gut and brain via microbially derived compounds such as serotonin (O’Mahony et al., 
2015), and branched chain amino acids from the gut microbiome as a contributor to insulin 
resistance (Pedersen et al., 2016b). 
Although our application is specifically designed to work with the KEGG database, 
similar logic could be used for other databases such as MetaCyc (Caspi et al., 2014). Our 
tool also does not apply methods such as gap-filling (Thiele et al., 2014; Orth and Palsson, 
2010) and metabolic modeling (Orth et al., 2010; Mendes-Soares and Chia, 2017) in its 
estimates. The goal is not to produce precise measurements of the contributions of the 
microbiome and host to the abundance of a metabolite. Rather, AMON is designed to 
annotate metabolomics results to give the user an understanding of whether specific 
metabolites could have been produced directly by the host or its microbiomes. If a 
metabolite is identified by AMON as being of microbial origin and is associated with a 
phenotype, this result should motivate the researcher to perform follow up studies. These 
can include confirming the identity of the metabolite, via methods such as tandem mass 
spectrometry, and performing experiments to confirm the ability of microbes of interest to 
produce the metabolite. 
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4.3 Limitations 
All the analyses presented here have one major flaw in the limitations of the 
genomic databases that they rely on. PICRUSt only gives gene assignments for OTUs 
with sufficiently close sequenced genomes and the quality of assigned genomes for OTUs 
is limited by how close the nearest sequenced genome is. When we do not find a gene 
that can degrade or produce a compound we do not know that such a gene not present 
in that microbiome. Absence of a gene can be the result of the microbe not having a close 
relative with a sequenced genome with that gene or of poor genome annotation. Strain 
level variation that could never be detected by 16S rRNA sequencing exists as well 
(Poretsky et al., 2014). The problem of missing sequenced relatives gives some problems 
in these gut microbiome samples but would cause a much larger problem in environments 
were fewer genomes are cultivated like marine or soil habitats. This limitation could 
potentially be overcome by using a shotgun metagenomic sequencing and assembly 
based approach. Metagenome assembled genomes could be used as directly measured 
taxonomic and functional units which would be better annotated than PICRUSt predicted 
metagenomes. 
However, this analysis also highlights limitations in this approach due to issues 
with annotation of both metabolites and the enzymes that may produce them. Overall, it 
is striking that of 5,971 compounds in the LC/MS data, only 471 could be linked to 
enzymatic reactions in KEGG. For example the human genome is known to contain 
approximately 20,000 genes (Ezkurdia et al., 2014); however, there are only 7286 KOs 
annotated in KEGG. These KOs only predict the creation of 1376 unique compounds 
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while the Human Metabolome Database 4.0 contains 114,100 (Wishart et al., 2018).  Part 
of this discrepancy is because multiple species of lipids are, generally, reduced to a single 
compound in KEGG.  For example, while KEGG includes a single phosphatidylcholine 
(PC) lipid molecule in the Glycerophospholipid pathway, in fact, there are over 1,000 
species of PCs. It is also important to note that metabolite annotations are based on peak 
masses and isotope ratios, which can often represent multiple compounds and/or in-
source fragments; our confidence in the identity of these compounds is only moderate. 
The situation is even worse for less understood microbial communities such as 
marine and soil environments, where even fewer genes detected are of known function. 
Because of these gaps in our knowledge of metabolite production, efforts to identify 
microbially produced metabolites that affect disease should also use methods that are 
agnostic to these knowledge-bases. These include techniques such as 1) identifying 
highly correlated microbes and metabolites to identify potential productive/consumptive 
relationships that can be further validated 2) molecular networking approaches which take 
advantage of tandem mass spectroscopy data to annotate compounds based on similarity 
to known compounds with related MS/MS profiles (J. Watrous et al., 2012) or 3) coupling 
LC/MS runs with data from germ-free versus colonized animals (Wang et al., 2011; 
Rothhammer et al., 2016; Elaine Y. Hsiao et al., 2013) or antibiotic versus non-antibiotic 
treated humans (Tang et al., 2013; Antunes et al., 2011).  Because AMON takes only KO 
identifiers and can pull database information from the KEGG API or user provided KEGG 
files, it will become increasingly useful as KEGG improves as well as the the peak 
annotation process in metabolomics pipelines. 
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AMON does not recapitulate all features that are shown in the initial analysis of the 
ASD cohort. AMON could be expanded to not only determine whether sets of KOs could 
generate a compound but also if they could degrade it. This would allow the detection of 
relationships where a compound could be absent as the result of possible consumption 
by the microbes present. This could also give researchers a better idea of pathways of 
reactions where a microbial community may be able to perform a series of reactions from 
a starting compound. Patterns such as this could explain patterns of changes in 
abundance. 
In these analyses the metabolic potential of the microbes present in a community 
is looked at in bulk across samples. This work could potentially provide deeper insights 
by looking at the microbiome and metabolome of groups or by breaking it down to the 
individual level. The production or degradation of a compound could be specific to a set 
of microbiomes or a group of microbiomes could be enriched in both the compound and 
gene, or organism with that gene, which can produce or degrade it. This sample specificity 
is available in the data and could be taken advantage of. 
The analyses presented here do not account for co-metabolism between the host 
and microbes. An example of this is the production of trimethylamine N-oxide (TMAO) 
from dietary choline (Wang et al., 2011). The gut microbiome produces trimethylamine 
(TMA) from choline which is then modified by the human host to TMAO. Our tool would 
list TMAO as a host compound and its precursor TMA as a microbiome derived compound 
but would not indicate that TMAO could overall not be produced from dietary substrates 
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unless a microbiome was present. Further inspection of metabolic networks may be 
needed to decipher these co-metabolism relationships. 
4.4 Summary 
When researchers are seeking to integrate microbiome and metabolome data, 
identifying the origin of metabolites measured is an obvious route. Here I have shown that 
the origin of compounds can be putatively identified. With predicted genomes from 16S 
rRNA sequencing data I was able to predict the ability of OTUs to produce or degrade an 
array of metabolites. The compound origin data was then used to find associations with 
a disease phenotype and then the method of finding the compound origin was generalized 
to create a tool for other researchers to use. 
In the ASD data set I was able to find compounds of interest whose producers or 
degraders were associated with the disease phenotype. No single OTUs were correlated 
with any of the compounds we were interested in before that analysis, but the correlations 
found did have genes which could explain them metabolically. With compounds of 
interest, genes which could produce or degrade them could be identified and both the 
relative abundance of these genes as well as the microbes that encode them were 
associated with ASD. 
I sought to generalize this ability to determine the producers of metabolites and 
made a tool to do this called AMON. AMON facilitates the annotation of metabolomics 
data by tagging compounds with their potential origin, either as bacteria or host. I showed 
the results of AMON on a human gut 16S rRNA sequencing and LC/MS measured plasma 
metabolomics study. With these data I found that the metabolome is enriched in 
 128 
compounds putatively from the gut microbiome which are associated with known bacterial 
specific function and the metabolome is enriched in compounds putatively produced by 
the human host which are associated with known human specific functions. AMON allows 
researchers to develop hypotheses about the metabolic involvement of microbes in 
disease that can be tested in the lab. It is novel in that it automates a previously manual 
approach 
4.5 Methods 
4.5.1 Subject recruitment, data acquisition of 16S rRNA and NMR metabolomics 
44 children were recruited where 21 were neurotypical and 23 had ASD. All 
individuals in the study were between 4 and 17. Participants in the study did not use 
antibiotics and antifungal medications for at least one month before samples were 
collected. Samples were collected at home and frozen before shipment to Arizona State 
University. 
DNA was extracted from stool using the PowerSoil DNA extraction kit. 16S rRNA 
sequencing was done by amplifying the V2-V3 region followed by pyrosequencing using 
the Genome Sequencer FLX-Titanium System as previously outlined (Wolcott et al., 
2009). QIIME was used to split libraries and pick 97% closed reference OTUs based on 
the greengenes 13_5 data base (Caporaso et al., 2010; DeSantis et al., 2006b). A total 
of 563 OTUs remined after rarefying to 6,011 sequences per sample and removing OTUs 
present in less than 22 samples. 
Metabolites were extracted for 1H-NMR metabolomics by suspending in water and 
centrifuging and filtering. Samples were mixed with a reference mix and send to Pacific 
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Northwest National Laboratory for 1H-NMR analysis. This was done using Varian Direct 
Drive 600 MHZ spectrometer. Results were analyzed using Chenomx based on spectral 
intensities and were compared to known spike ins. The abundance of metabolites was 
normalized relative to per gram dry-weight feces. The NMR data was filtered to remove 
compounds present in less than 22 samples after which 54 compounds remained. 
For more details on these methods please see (Kang et al., 2018). 
4.5.2 Building a correlation network between microbiome and metabolome data 
Spearman correlation was used to correlate between all pairs of features in the 
OTU and NMR tables. The p-values from the correlation analysis were corrected using 
the Benjamini-Hochberg FDR procedure. A network was made from these pairwise 
correlations where microbes and metabolites are nodes and edges were pairs of 
microbes and metabolites where the adjusted p-value was less than 0.1. 
4.5.3 Determining if OTUs can produce or degrade compounds 
The PICRUSt program was used to determine predicted genomes for each 
detected closed source OTU. The genes which can produce or degrade compounds of 
interest were determined starting with the compound. The KEGG API was used to find 
the reactions which were associated with the compound (Kanehisa et al., 2017). The 
genes that were associated with each reaction was found also via KEGG. Whether a 
compound was degraded or produced by a reaction was determined based on which side 
of the equation associated with the reaction the metabolite was on. 
4.5.4 Using PICRUSt to predict and test sample metagenomes 
For analyses of full predicted metagenomes, the PICRUSt 
predict_metagenomes.py script was used to predict the metagenomes of each sample, 
 130 
in terms of KOs, from the OTU table after it was rarefied. The KO table were filtered to 
exclude KOs present in less than 9 samples. Across all samples a total of 4,396 KOs 
were predicted to be present. Additionally the categorize_by_function.py was used with 
level 3 to determine the abundance of the KEGG pathways represented by the predicted 
metagenomes. The pathway table were filtered to exclude pathways present in less than 
9 samples after which 253 pathways remained. The Mann-Whitney U test was used to 
find significant differences in abundance between autistic and neurotypical individuals. 
The p-values from both tests were multiple testing corrected using the Benjamini-
Hochberg FDR procedure. 
4.5.5 Determining differential abundance of producers and degraders of compounds 
The producers and degraders of compounds were determined. An OTU is 
considered a producer of a compound if it has at least one gene that can produce that 
compound and a degrader if it has at least one gene which can degrade that compound 
in its genome. The relative abundance of producers or degraders of a compound was 
determined by summing the relative abundances of all producing or degrading OTUs 
within each sample. The Mann-Whitney U test was then used to test for differential 
abundance between neurotypical and autistic individuals. 
4.5.6 Case Study Dataset 












Thymine 0.66 2 0 
Uracil 0.66 5 0 
Alanine 0.56 5 3 
Leucine 0.55 0 1 
Valine 0.55 0 1 
Tyrosine 0.55 0 7 
Phenylalanine 0.55 1 7 
Isoleucine 0.54 0 1 
179911 Coprococcus 
Formate 0.61 5 2 




Lactate 0.59 0 1 
Glycerol 0.57 3 2 
Valine 0.54 0 2 
199698 Bacteroides Aspartate -0.58 1 14 
177319 Oscillospira Glycerol -0.55 2 2 
OTUs and the compounds they are correlated with. R value is from Spearman 
correlation. The column KOs which produce is the number of KOs in the PICRUSt 
predicted genome for that OTU which can catalyze reactions which have that compound 
as a product. The column KOs which degrade is the number of KOs in the PICRUSt 
predicted genome for that OTU which can catalyze reactions which have that compound 


























Ubiquinone and other terpenoid-
quinone biosynthesis 
76 6 2.86E-06 4.40E-04 1 2.36E-01 4.90E-01 
Protein digestion and absorption 47 4 4.28E-05 3.30E-03 0 4.39E-01 5.45E-01 
Biotin metabolism 11 2 9.26E-05 3.56E-03 0 1.26E-01 4.44E-01 
Phenylalanine, tyrosine and 
tryptophan biosynthesis 
27 3 7.13E-05 3.56E-03 0 2.82E-01 4.90E-01 
Cysteine and methionine 
metabolism 
56 3 1.25E-03 3.83E-02 0 4.98E-01 5.81E-01 
Nitrotoluene degradation 27 2 1.49E-03 3.83E-02 0 2.82E-01 4.90E-01 
Benzoate degradation 64 3 2.05E-03 4.20E-02 0 5.45E-01 6.08E-01 
C5-Branched dibasic acid 
metabolism 
32 2 2.46E-03 4.20E-02 0 3.25E-01 4.90E-01 
Terpenoid backbone biosynthesis 32 2 2.46E-03 4.20E-02 0 3.25E-01 4.90E-01 
Butanoate metabolism 40 2 4.66E-03 7.18E-02 0 3.88E-01 5.24E-01 
Biosynthesis of siderophore group 
nonribosomal peptides 
13 1 5.29E-03 7.41E-02 0 1.47E-01 4.53E-01 
Histidine metabolism 44 2 6.10E-03 7.83E-02 1 9.93E-02 4.02E-01 
Purine metabolism 92 3 7.59E-03 9.00E-02 1 3.08E-01 4.90E-01 
Sphingolipid metabolism 25 0 1.94E-01 3.29E-01 8 5.33E-12 8.21E-10 
Phosphatidylinositol signaling 
system 
27 0 2.08E-01 3.34E-01 4 1.46E-05 6.47E-04 
Primary bile acid biosynthesis 47 0 3.35E-01 4.00E-01 5 1.81E-05 6.47E-04 
Bile secretion 98 0 5.74E-01 5.86E-01 7 1.95E-05 6.47E-04 
Steroid hormone biosynthesis 99 0 5.78E-01 5.86E-01 7 2.10E-05 6.47E-04 
Inositol phosphate metabolism 39 0 2.87E-01 3.79E-01 4 9.34E-05 2.40E-03 
Vascular smooth muscle 
contraction 
25 0 1.94E-01 3.29E-01 3 2.05E-04 4.52E-03 
Fc epsilon RI signaling pathway 11 0 9.06E-02 3.03E-01 2 2.62E-04 5.05E-03 
Fat digestion and absorption 12 0 9.85E-02 3.03E-01 2 3.47E-04 5.93E-03 
Amoebiasis 13 0 1.06E-01 3.03E-01 2 4.47E-04 6.88E-03 
Pathways in cancer 20 0 1.59E-01 3.28E-01 2 1.68E-03 2.35E-02 
Arachidonic acid metabolism 75 0 4.79E-01 5.16E-01 4 2.01E-03 2.57E-02 
Ether lipid metabolism 23 0 1.80E-01 3.28E-01 2 2.54E-03 3.01E-02 
Linoleic acid metabolism 26 1 2.05E-02 1.62E-01 2 3.63E-03 3.99E-02 
Biosynthesis of unsaturated fatty 
acids 
54 0 3.74E-01 4.27E-01 3 3.95E-03 4.06E-02 
Secondary bile acid biosynthesis 32 0 2.42E-01 3.55E-01 2 6.58E-03 6.33E-02 
Gap junction 11 0 9.06E-02 3.03E-01 1 7.44E-03 6.37E-02 
Prostate cancer 11 0 9.06E-02 3.03E-01 1 7.44E-03 6.37E-02 
Cholinergic synapse 12 0 9.85E-02 3.03E-01 1 8.86E-03 7.18E-02 
Vitamin digestion and absorption 38 1 4.17E-02 2.07E-01 2 1.06E-02 7.79E-02 
Taste transduction 13 0 1.06E-01 3.03E-01 1 1.04E-02 7.79E-02 
Gastric acid secretion 14 0 1.14E-01 3.13E-01 1 1.20E-02 8.42E-02 
Tryptophan metabolism 81 2 3.16E-02 1.74E-01 3 1.63E-02 9.82E-02 
Glycerophospholipid metabolism 46 1 5.88E-02 2.66E-01 2 1.79E-02 9.82E-02 
Glycosylphosphatidylinositol 
(GPI)-anchor biosynthesis 
16 0 1.29E-01 3.28E-01 1 1.56E-02 9.82E-02 
Pancreatic secretion 17 0 1.37E-01 3.28E-01 1 1.76E-02 9.82E-02 
Salivary secretion 17 0 1.37E-01 3.28E-01 1 1.76E-02 9.82E-02 
Nicotinate and nicotinamide 
metabolism 
44 0 3.17E-01 3.97E-01 2 1.59E-02 9.82E-02 
Table of results of hypergeometric testing. All results where adjusted p-value < .1 in 






The network analysis and data flow of AMON. A) A simple multi-organism metabolic 
network. Blue nodes represent genomes, red nodes represent genes, orange nodes 
represent reactions and yellow nodes represent compounds. Edges between blue and 
red nodes indicate that the bacterial genomes contain the indicated genes and edges 
between red and orange nodes indicate the reactions which the genes can mediate. 
Yellow to orange edges connect reactants to a reaction and orange to yellow edges 
connect the reactions to its products. This network can be traversed to connect products 





The correlation network between NMR measured metabolites and OTUs. Compounds 
are rectangles and microbes are hexagons. Blue rectangles are amino acids and green 
rectangles are nucleic acids. Yellow hexagons are OTUs assigned to the Clostridales 
order and the red hexagon is from the Bacteroides genus. Edges represent Spearman 
correlations with an FDR adjusted p-value less than 0.1 and are weighted by absolute R 




The abundance of OTUs which can produce or degrade metabolites of interest. All 
comparisons are significant using the Mann-Whitney U test p-value < .05. GABA 
degraders are more abundant in autistic individuals and GABA producers are more 
abundant in Autistic individuals. In Autistic individuals p-cresol producers are also more 
abundant.  




This schematic shows the flow of data through the AMON tool. The required input is a 
list of KEGG orthology (KO) identifiers which will be used with the KEGG database to 
build a metabolic network and determine the possible metabolites produced. This 
information is output to the user along with a pathway enrichment analysis to show 
functionality in the produced metabolite and a KEGG mapper file for visualization of 





The results of a case study running AMON with 16S rRNA sequencing data from stool 
and PICRUSt to predict the metagenome along with the KEGG human genome and an 
LC/MS untargeted metabolome. A) A flow diagram showing how much data is lost 
between parts of analyses at all data levels. B) A Venn diagram showing overlaps in 
compound sets. The red circle shows compounds detected with untargeted LC/MS with 
an annotated KEGG compound ID. The green and purple circles show compounds that 
the metabolic network tells us could have been produced by the bacteria present in the 





Enrichment of pathways and a single enriched pathway colored with metabolite origin. 
A) A heatmap showing the p-values associated with a pathway enrichment analysis with 
KEGG pathways. The first column is p-values for enrichment of KEGG pathways in 
compounds that were detected via untargeted LC/MS of plasma and we predict could 
be generated by members of the fecal microbiome. The second column is the same but 
for compounds that we predicted could have been generated by the human host. B) 
This pathway map is colored by putative origin of the compound, which are circles, and 
presence of the reaction, which are rectangles. Dark blue is a compound or gene with a 
bacterial origin, yellow is a compound or gene with a human origin, orange ¬outlined 
compounds are detected in the metabolomics. Circles or rectangles could be of human 




USING MICROBIOME AND METABOLOME DATA TO UNDERSTAND THE EFFECT 
OF HIV AND LIPODYSTROPHY ON THE GUT MICROBIOME 
While the lifespan of individuals who have HIV and undergo treatment with 
antiretroviral therapy (ART) has been steadily increasing (Weber et al., 2013) there are 
comorbidities, especially for those who were treated with earlier protease inhibitors 
(Gallant et al., 2017). HIV positive status is associated with metabolic abnormalities such 
as hypertriglyceridemia, low high-density lipoprotein cholesterol, and insulin resistance 
(Pao et al., 2008). Lipodystrophy is a metabolic disease that occurs in individuals who 
were treated with protease inhibitors and is characterized by atrophy of the face and 
extremities with occasional increases in visceral fat. The causes behind the occurrence 
of lipodystrophy are not completely understood. 
No studies have been done to measure the effect of the gut microbiome in 
lipodystrophy. The gut microbiome has a large impact on metabolism and the largest 
single impact on the plasma metabolome (Torell et al., 2015). The composition of the gut 
microbiome is associated with a variety of metabolic diseases and shifts have been 
observed with type II diabetes (Qin et al., 2012; Forslund et al., 2015) and metabolic 
syndrome (Vijay-Kumar et al., 2010; Zhang et al., 2010; Vrieze et al., 2012). A role for the 
gut microbiome could exist in lipodystrophy etiology. 
Many studies have been done on the shifts in gut microbiome in HIV (Vujkovic-
Cvijin et al., 2013; Lozupone et al., 2013; Dillon et al., 2014) but recent studies have cast 
doubt on this. They have shown that what was thought to be a HIV-associated 
composition is more strongly connected to high risk sexual behavior in men who have 
 140 
sex with men (MSM) (Noguera-Julian et al., 2016; Armstrong et al., 2018). The shift from 
high levels of Bacteroides to Prevotella that was seen seems have been a result of the 
high number of MSM individuals in HIV positive populations. To understand a role of the 
microbiome in lipodystrophy, MSM status needs to be considered. 
The metabolome is a functional end point which shows the sum of effects from 
the human host and the microbiome. The plasma metabolome has been associated with 
both HIV (Cassol et al., 2013; Scarpelini et al., 2016) and familial forms of lipodystrophy 
(Visser et al., 2011; Peinado et al., 2011). No studies have been done associating the 
metabolome with ART induced lipodystrophy. There also have been no studies on the 
effect of MSM status on the plasma metabolome. By measuring both the microbiome 
and the metabolome our knowledge of the functional potential of the microbes present 
in the gut can be used to better understand the effect of microbes on the metabolome. 
By measuring both the microbiome and metabolome on the same samples, an 
association of microbes with disease and hypotheses regarding microbial metabolic 
products that may drive disease phenotypes can be generated. Here, the microbiome 
and metabolome have been measured on a cohort of individuals with and without HIV 
and an additional cohort of individuals with HIV both with and without lipodystrophy. I 
have used various integration techniques to explore these data to determine 1) whether 
associations of the microbiome and metabolome with these disease states exist and 2) 





5.1 Strong Associations Exist Between the Metabolome and Lipodystrophy 
5.1.1 Results 
5.1.2.1 The cohort 
A cohort was recruited to investigate the potential impact of gut microbiome 
composition and the plasma metabolome on lipodystrophy and HIV status (Table 5.1). A 
total of 59 samples across four groups were used to perform two separate comparisons. 
First a group of individuals with lipodystrophy who were HIV positive and on long term 
ART (N=12) were compared to individuals without lipodystrophy who were also HIV+ and 
on long term ART (N=15). To find associations with HIV both HIV positive, ART naïve 
individuals (N=10) and HIV negative, ART naïve individuals (N=22) were recruited. With 
these separate analyses associations of microbes and metabolites with Lipodystrophy 
and untreated HIV can be determined. The sizes of these cohorts precluded the ability 
to include MSM status as a factor in the analysis although both sets of individuals were 
matched based on MSM status. 
5.1.2.2 Pathways are enriched in compounds associated with Lipodystrophy and HIV 
The plasma metabolome of all individuals in the cohort was measured via 
untargeted liquid chromatography and mass spectroscopy (LC/MS) metabolomics, 
which detected 7,864 compounds. 94 compounds had significantly different 
abundances (FDR adjusted p-value < .05) between the HIV+ and HIV- individuals. 
These compounds represented 64 unique KEGG compound IDs. 78 compounds were 
significantly different (FDR adjusted p-value < .05) between the individuals with and 
without lipodystrophy. These compounds represented 54 unique KEGG compound 
IDs. To test for enrichment all compounds with Kyoto Encyclopedia of Genes and 
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Genomes (KEGG) annotations significantly associated with each comparison were 
used to perform a pathway enrichment analysis. This identified 16 pathways which 
were significantly enriched with compounds associated with lipodystrophy and 4 which 
were associated with HIV status. Three of the pathways enriched in lipodystrophy and 
two in HIV are involved in lipid processing. In lipodystrophy two of the enriched 
pathways, regulation of autophagy and Fc gamma R-mediated phagocytosis, are 
involved in immune interactions. 
5.1.2.3 No significant associations with Lipodystrophy or HIV in the gut microbiome 
Based on the results of chapter III, the gut microbiome data was processed with 
either DADA2 alone or DADA2 and 99% OTU picking before applying SCNIC using the 
naïve module making method with a .35 minimum R value for edge creation. This 
reduced the number of features from 2,348 to 2,135 ASVs when DADA2 was used and 
from 1,918 to 1,704 OTUs when DADA2 and 99% OTU picking were used. These data 
were then stratified to determine associations between microbes and modules of 
microbes with lipodystrophy and HIV using ANCOM (Mandal et al., 2015). After doing 
this there were no ASVs, OTUs or modules which were associated with either 
lipodystrophy or HIV. 
5.1.2.4 Correlations between the microbiome and metabolome 
Correlations between the microbiome and the metabolome were measured to 
identify potential interactions. In order to limit the number of comparisons, only 
compounds from the metabolomics which were annotated with a KEGG ID were used 
(2,825 compounds). The DADA2 and DADA2 with 99% OTU picking data were correlated 
with the filtered metabolomics data set using Spearman correlation. When DADA2 was 
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used to process the data, there are 8 modules of ASVs which are significantly correlated 
with compounds (FDR adjusted p < .1) with an additional 4 correlations trending towards 
significance (FDR adjusted .1 < p < .2) (Figure 5.2). When OTU picking is applied after 
DADA2, there are only two significant associations between modules of microbes and 
compounds (FDR adjusted p < .2). None of the compounds with a significant correlation 
to an ASV, OTU or module were associated with either HIV or lipodystrophy. The data 
as processed with DADA2 only was used for further investigation of the correlations. 
5.1.2.5 Compounds can be produced by correlated microbes 
AMON was used to predict the ability of modules to produce or degrade the 
compounds they are correlated with. Of the 12 compounds with significant or trending 
correlations, 3 have reactions associated with them in the KEGG database all of which 
are lipids typically found in cell membranes. The lipid 
PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/21:0), a phosphatidate, was significantly negatively 
correlated with module 15 which contains genes that can produce and degrade this 
compound. While this compound is not associated with HIV or lipodystrophy the 
compound is in the glycerolipid metabolism pathway, which is associated with 
lipodystrophy status in the metabolomics data, and the glycerophospholipid metabolism 
pathway, which was associated with lipodystrophy and HIV status. This compound can 
also be produced by the human genome. 
Ganglioside GM3 was significantly negatively correlated with module 15 as well 
but the module had no genes which could generate or degrade it. Module 0 was 
negatively correlated with the phosphatidylinositol PI(18:1(9Z)/0:0) and the module had 
genes which could both produce and degrade it and it could be produced by the human 
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genome. This compound is in the glycerophospholipid pathway which was associated 
with lipodystrophy and HIV status. 
5.1.2.6 Modules are enriched in pathways that are shared with correlated compounds 
Few correlations could be directly explained by genome information. To find 
additional database explainations pathway enrichment of modules in genes was 
measured. Running this enrichment analysis with the genes present in all genomes 
would yield an enrichment in commonly shared pathways. To find unique genes I 
calculated the probabilities of genes not occurring by chance in a genome based on the 
genome table predicted by PICRUSt 2 (Langille et al., 2013). Then the probability of a 
gene occurring across genomes in the module was calculated. 
Genes with a probability of less than .05 of occurring across the module were 
used for the pathway enrichment analysis (Figure 5.3). Module 15 was enriched with 
Thiamine metabolism which is not associated with any of the compounds it is correlated 
with. Module 0 is correlated with phosphatidylinositol and is not enriched in any 
pathways which phosphatidylinositol is a member of. 2-Dimethylamino-5,6-
dimethylpyrimidin-4-ol does not have a pathway annotation and is correlated with 
module 10. Module 10 is enriched in the amino sugar and nucleotide sugar metabolism 
pathway. 
5.1.2 Discussion 
The plasma metabolome has a stronger association with both lipodystrophy and 
HIV than the gut microbiome (Figure 5.1). Many compounds significantly associated with 
both HIV status and lipodystrophy in the metabolome. The strongest association was 
with lipodystrophy. This is seen in the pathway enrichment analysis where 17 pathways 
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were enriched with significant compounds associated with lipodystrophy while only 4 
were enriched with compounds associated with HIV status. While the effects of 
lipodystrophy on the plasma metabolome have been studied using animal models (Visser 
et al., 2011; Peinado et al., 2011), the effects of ART induced lipodystrophy on the 
plasma metabolome is less understood and literature search found no other 
metabolomics studies conducted in humans. Lipid metabolism pathways such as 
glycerolipid, glycerophospholipid and sphingolipid metabolism were all enriched as well 
as cell membrane lipid pathways glycosylphosphatidylinositol-anchor biosynthesis and 
phosphatidylinositol signaling system. 
A previous study found associations between HIV status and the metabolome and 
these are at least in part replicated in our results (Cassol et al., 2013). Both found 
metabolites in the lineolic acid and glycerophospholipid pathways which were 
associated with HIV infection status. Our cohort is small but unlike previous studies is 
balanced for MSM status which is known to have a large effect on the gut microbiome 
compared to HIV status (Noguera-Julian et al., 2016; Armstrong et al., 2018). The small 
sample made an analysis controlling for MSM status as part of our statistical model 
impossible, but the cohort was balanced. The results seen in previous studies could be 
driven by an uneven balance of MSM status between groups, as happened in earlier gut 
microbiome studies (Lozupone et al., 2013; Dillon et al., 2014; Vujkovic-Cvijin et al., 
2013). An analysis on a larger cohort would allow the use of linear modelling to tease 
apart MSM and HIV effects on the metabolome. 
After summarizing correlated features to increase power, no significant 
associations with lipodystrophy or HIV status could be found in the microbiome. This is 
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in line with previous studies of the gut microbiome in the context of MSM and HIV status 
where MSM had a much stronger effect than HIV (Noguera-Julian et al., 2016; Armstrong 
et al., 2018). The lack of an association with lipodystrophy was not expected and does 
not support the original hypothesis that the gut microbiome would differ with 
lipodystrophy, although our negative result may be caused by the small sample size. 
While there was no correlation between any microbes and the metabolites that 
were associated with disease, relationships between correlated microbes and 
metabolites could be predicted based on microbial genomes. Of 3 compounds that had 
significant, or trending toward significant, correlations and reaction information related 
to compound, two could have been produced or degraded by a microbe in the module. 
The KEGG IDs assigned to both compounds include a wide class of lipids and so are 
not specific to the compound which was detected and are both very common cell 
membrane components. The ability to produce and degrade these compounds is not 
surprising. 
Of the 7,864 compounds detected only 2,825 had KEGG annotations. The 
common metabolites and functions, like the production and degradation of cell 
membrane components, will be more likely to be found. Not being specific to the well 
annotated subset of compounds and functions means more potential associations are 
found. The glycerolipid pathway was significantly enriched in metabolites associated 
with lipodystrophy and these lipid components, while not specifically associated, point 
to a pattern of mixed effect on the metabolism of lipids. Compounds like 2-
Dimethylamino-5,6-dimethylpyrimidin-4-ol are not well annotated but the known 
structure of the compound, an aminopyrimidine, and the pathways that are enriched in 
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rare genes from the module it is associated with, amino sugar and nucleotide sugar 
metabolism, can suggest a possible relationship. It is not annotated in either the 
compound entry in KEGG or the predicted genomes of the ASVs. This relationship may 
be worth further investigation to understand if the organisms in this module could 
produce or degrade it. 
An unexpected result from this study was the increase in strength of correlations 
found by using DADA2 only as compared to when using DADA2 and 99% OTU picking. 
The most significant compounds were primarily the same across both microbiome 
processing techniques but correlations had higher R squared values and lower p-values 
when OTU picking was not applied. This suggests correlations are better explained by 
the exact sequence variants found by DADA2 than when variants were further 
summarized by 99% OTU picking. Therefore, these effects seem to be ASV specific. The 
summarization by OTU picking decreases the number of features in the microbiome 
table. The specify of the correlations when ASVs are used is stronger than the increase 
in power that is provided by having fewer taxonomic units. 
5.2 Limitations 
A limitation of this study is the small sample size. With four groups and 60 total 
participants in the study there is relatively little power to detect significant differences 
associated with HIV or lipodystrophy as well as correlations that exist between the two 
groups. This is a small preliminary analysis of a larger cohort. When this larger cohort 
has been sequenced and had metabolomes measured these analyses can be repeated. 
The increased power may allow the detection of more significant associations and 
correlations. Because of this more correlations may be able to be explained using 
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genomic database information and some of the microbes and metabolites may also be 
associated with disease. This scenario would make it possible to make mechanistic 
hypotheses explaining associations with disease which could be tested with in vitro or 
in vivo experiments. 
A more serious limitation is the limited annotations of compounds and microbial 
genomes. When using untargeted mass spectroscopy metabolomics, without further 
tandem mass spectroscopy, the data available to assign an annotation is the mass and 
the pattern of isotopic peaks. The annotations made are only medium confidence and 
most peaks are not annotated. Compound identifications would be better with tandem 
mass spectroscopy and molecular networking techniques. Many compounds that are 
annotated with a KEGG ID do not have reaction, orthology or pathway information. These 
further annotations allow the compound to be plugged into the community metabolic 
network to connect to microbes or other genomes which could produce or degrade 
them. Without this the compound identification is of little use. 
Annotation of microbial genomes is also limiting. Here the gut microbiome is being 
studied. The microbes in the gut microbiome are very well studied compared to other 
environments, such as soil. Tools that predict genomes form 16S rRNA sequencing like 
PICRUSt can provide good genomes in these well studied communities. But not all 
diversity has been cataloged and PICRUSt cannot detect variations that exists at sub-
ASV levels. To address these concerns shotgun metagenomics can be used. Assembling 
genomes from metagenomics would give gene content specific to each sample. This 




Here I have shown a deeply integrated analysis of microbiome and metabolome 
data that was used to understand the role of the microbiome in lipodystrophy, a 
metabolic disease which is a comorbidity of HIV. This is the first study measuring the 
effects of ART associated lipodystrophy on the plasma metabolome and many pathways 
were enriched with compounds associated with lipodystrophy. The compounds that 
were associated with HIV overlapped with those found associated with HIV in a previous 
study. Gut microbiome composition could not be associated with either lipodystrophy 
or HIV status. This cohort was matched for MSM status so this matches with recent 
studies finding little association between the gut microbiome and HIV when considering 
MSM status. 
To find if the microbiome potentially made contributions to these metabolome 
associations, correlations between the microbiome and the metabolome were 
measured. Stronger correlations were found when the microbiome data was processed 
with DADA2 alone, as compared to when processed with DADA2 with 99% OTU picking. 
This indicates metabolome correlations could be driven by sub-99% OTU level variation. 
No metabolites that were significantly associated with HIV or lipodystrophy were 
correlated with modules of microbes or microbes not included in modules by SCNIC. 
Potential interactions between the microbiome and metabolome were further 
investigated. Using AMON, two modules were found with the potential to produce and 
degrade metabolites with which they were negatively correlated. Functions of modules 
not well annotated by PICRUSt were predicted. This was done by finding enrichment of 
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pathways in rare genes from modules. One correlation was found which could be 
explained by this enrichment. 
This study is underpowered, which could explain the lack of associations found 
in the microbiome. A larger cohort is being assembled which will alleviate this issue. A 
lack of annotation affects this analysis. These shortfalls are in compound identification, 
compound functional annotation, microbial genome assignment and microbial gene 
function annotation. Despite this, correlations between the microbiome and metabolome 
were found which are explained by functional relationships between microbes and 
compounds. This study did not find direct associations of microbes with disease that 
were correlated with compounds also associated with disease, but it provides a 
framework for future analyses. The same analysis strategy could be applied to other well-
studied microbiomes and metabolomes or extended for use with shotgun metagenome 
data. 
5.4 Methods 
5.4.1 Cohort recruitment 
All study participants were recruited from University of Colorado Hospital with an 
approved IRB protocol (CoMIRB 14-1595). 59 subjects were split across four groups. 
The groups of individuals who were HIV positive and ART naïve (N=10) as well as HIV 
negative and ART naïve (N=22) were used to test for associations with HIV status. The 
lipodystrophy, HIV positive and ART treated group (N=12) and the group of individuals 
without lipodystrophy who were HIV positive and ART treated (N=15) were used to find 
an association with lipodystrophy status. 
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5.4.2 Metabolomics Data Acquisition and Processing 
The metabolomics data used was described in sections 3.6.7-3.6.10. 
5.4.3 Metabolomics differential abundance and pathway enrichment analyses 
The metabolomics data was filtered to remove compounds that were not present 
in at least 20% of samples and log normalized. The groups with and without 
lipodystrophy were tested against each other for differential association with 
lipodystrophy and the ART naïve HIV positive and negative groups were tested against 
each other for association with HIV. A t-test was used and compounds which had a False 
Discovery Rate (FDR) multiple testing corrected p-value less than 0.05 were considered 
significant. For each group the KEGG IDs of significant compounds were used to 
calculate pathway enrichment using mBrole (López-Ibáñez et al., 2016) with the full set 
of compounds detected in this study as the background data set. A pathway was 
considered significantly enriched when the FDR adjusted p-value was less than 0.05. 
5.4.4 16S sample extraction, sequencing and processing 
Stool samples from individuals were collected at home in a commode specimen 
collector within 24 hours of the clinic visit in which blood was drawn. Stool samples were 
stored at -20°C during transit and at -80°C prior to DNA extraction with the MoBIO kit 
and preparation for barcoding sequencing using the Earth Microbiome Project protocol 
(http://www.earthmicrobiome.org/protocols-and-standards/16s/). The 16S rRNA gene 
V4 region of stool microbes was sequenced using MiSeq (Illumina), denoised using 
DADA2 (Callahan et al., 2016) and binned into 99% Operational Taxonomic Units (OTUs) 
using VSEARCH (Rognes et al., 2016) and the greengenes database (version 13_8) via 
QIIME 2 (Bolyen et al., 2018). 
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Genome content in terms of KEGG Orthology (KOs) was predicted for each 
sequence, from both DADA2 and 99% OTU picking, using PICRUSt 2 (Langille et al., 
2013) with HMMER (Eddy, 1998), EPA-NG (Barbera et al., 2018),  gappa (Czech and 
Stamatakis, 2018) and castor (Louca and Doebeli, 2018). 
SCNIC was used to summarize the data generated by both DADA2 alone and 
DADA2 with subsequent 99% OTU picking. The sparCC correlation metric was used 
(Friedman and Alm, 2012) and the naïve method was used for module detection using a 
minimum R threshold of 0.35. ANCOM (Mandal et al., 2015) to determine differential 
abundance for the SCNIC processed data both with and without OTU picking. 
5.4.5 Correlating between microbiome and metabolome data 
SCNIC was also used to calculate correlations between the microbiome and 
metabolome data. The metabolome data was filtered to only include compounds which 
had KEGG annotations. The microbiome tables with both processing methods and the 
metabolomics table were filtered to remove all features which were not present in at least 
30 samples (50%). Spearman correlation was used. Edges were made between 
microbes and metabolites if the p-value of the correlation, after FDR correction, was less 
than 0.2. 
5.4.6 Determining metabolite origin with AMON 
To determine if modules of microbes could produce the compounds which they 
are correlated with I used AMON (Shaffer et al., 2018). AMON was applied to the gene 
list predicted by PICRUSt 2 from each module that was significantly correlated to any 
metabolite. The results of AMON were used to assess the potential of each module to 
produce the correlated compounds. 
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5.4.7 Measuring pathway enrich rare genes in 16S modules 
Genes unlikely to occur throughout modules by chance were determined. The 
probability of gene existing in a specific genome was calculated given the abundance of 
that gene across genomes, and the number of genes in that genome, using the Wallenius 
noncentral hypergeometric distribution. If a gene was not present in a genome then it 
was assigned a probability of 1. Then for each module the probabilities of each gene 
were multiplied across all genomes in the module which gives the probability of a gene 
occurring across the module. Genes with a probability less than 0.05 were rare and used 








HIV+, ART- HIV-, 
ART- 
N 12 15 10 22 
Sex (Male) 10 (83.3%) 22 (73.3%) 10 (100%) 
18 
(81.8%) 
Age (Years) 55.4 ± 6.4 48.7 ± 8.5 35.9 ± 9.8 35.7 ± 9.2 
MSM 5 (41.7%) 4 (26.7%) 6 (60.0%) 
14 
(63.6%) 
IVDU 1 (8.3%) 0 0 0 
BMI 
(kg/m2) 
26.1 ± 2.9 25.8 ± 3.1 23.1 ± 3.9 25.4 ± 3.3 
CD4 
(cells/uL) 
712 ± 334 
(187-1200) 
690 ± 337 
(177-1417) 






12 ± 12 (0-40) 
396 ± 1364 
(0-5314) 
129,722 








Heatmap of p-values from pathway enrichment analysis with compounds associated 





Correlation network between modules and compounds from 16S rRNA stool microbiome 
and plasma metabolome. Orange nodes are ASVs, labeled by most specific taxonomic 
assignment, and have an edge connecting to a white node which is the module that 
these ASVs are a part of. Yellow nodes are compounds labeled with the name of the 
compound. Edges between modules and compounds represent significant correlations. 
Green edges are positive correlations and red edges are negative correlations. The width 
of edges represents the strength of the association with wider edges representing strong 





Heatmap showing the enrichment of pathways in genes not expected to be shared 




CONCLUSIONS AND FUTURE DIRECTIONS 
The microbiome field has become very adept at finding associations between large 
numbers of features and some potential perturbation, such as disease, across ‘omics 
techniques. What has proved more difficult is finding why this association occurs. This is 
especially prevalent in microbiome research. We have found associations between the 
gut microbiome and a wide variety of disease but few actionable results. The difficultly of 
turning associations with disease into understating of how disease affects microbial 
communities and vice versa lies in our lack of understanding of the interactions between 
these microbes and with their host. 
Ten years ago all were invited to the marriage of metagenomics and metabolomics 
(Turnbaugh et al., 2008) and progress in integrating these data types and elucidating the 
function of key small-molecules that are produced by the microbiome is being made. 
Understanding the metabolic capabilities of the microbes that inhabit all areas of the 
human body will be key to determining their effects on health and disease. To advance 
this knowledge, more work remains to be done. 
While 16S rRNA can be used to survey the composition of microbial communities, 
its ability to predict metabolic effects is limited both by the incomplete knowledge present 
in bacterial genomic databases and strain level variation. Metagenomic sequencing gives 
knowledge of the genes present, but the majority of these genes still have unknown 
function. KEGG is still the most used database for orthologous gene group assignment 
and is the most comprehensive database for linking orthologous gene groups to reactions 
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and annotated compounds (Kanehisa et al., 2017). KEGG has moved to a subscription 
service model since 2011 and difficult to integrate into new open source tools. MetaCyc 
(Caspi et al., 2014) is free to use and redistribute but is missing features from KEGG such 
as a universal gene orthology. As the gaps in these databases are filled through genome 
sequencing and functional studies, our power to understand the functional potential of 
host associated microbial communities will increase. 
Metabolomics has perhaps even greater challenges than the evaluation of 
microbial community structure and function using DNA and RNA sequencing. Extraction 
techniques are not standardized and subject to technical variability. Peak extraction and 
annotation of mass spectroscopy data is challenged by multiple metabolites matching to 
the same mass (Kohler et al., 2016). Current best practices do not give confident results 
without further experimental validation and quantification which is not currently possible 
on the scale of detected metabolites in untargeted experiments. 
As the technology for untargeted mass spec metabolomics becomes more mature, 
these issues will become less prominent allowing understanding of metabolomes across 
studies. Paired with an increased biochemical understanding of the function of genes 
encoded by microbiomes, the ability to develop a mechanistic understanding of how 
microbial communities influence the host via their metabolic activities will be enhanced. 
To rapidly advance microbiome and metabolome integration to understand roles for 
microbial metabolism in diverse disease contexts, advanced yet “user friendly” methods, 
such as SCNIC and AMON, for multi-omic integration need to be developed. 
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Even with these formidable challenges, many studies have identified key microbes 
and their enzymes and metabolites that can be targeted therapeutically in the context of 
varied diseases (Elaine Y Hsiao et al., 2013; Haiser et al., 2013). A key challenge in the 
field is to move many of these novel discoveries from the bench to the bedside. By 
understanding the metabolic interplay between microbiome and host, novel prebiotics and 
probiotics can be explored, as well as personalized treatment of disease that capitalize 
on knowledge of microbiomes and their interactions with the host (Kearney and Gibbons, 
2018). 
The work here has shown progress in creating tools (SCNIC and AMON) that will 
allow for a deeper understanding of the interactions between the microbiome and the 
metabolome. It also lays out strategies for analyzing these data so that functional 
associations with disease can be identified (Chapter V). The most significant limiting 
factor in understanding these communities is the difficulty of identifying the compounds 
or genes present in a community or genome and then understanding the functionality of 
that compound or gene. While identification problems will be alleviated with further 
improvements in technology and software, our understanding can only be improved by 
building our base of knowledge. This will come in the form of sequencing more genomes 
and performing more biochemical experiments to understand the roles of known and 
novel genes. 
Once this knowledge is built, microbiome-based medicine will advance. Current 
techniques for treating the microbiomes come in the form of either transplants of microbial 
communities or specific pre- or probiotics. Fecal matter transplants have proven effective 
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in the treatment of recurrent C. difficile infection (Quraishi et al., 2017; Tariq et al., 2018) 
but of limited effectiveness in other disease systems such as inflammatory bowel disease, 
Chron’s disease and ulcerative colitis (Paramsothy et al., 2017; Narula et al., 2017; Cao 
et al., 2018). Most probiotic treatments use either Bifidobacterium or Lactobacillus 
species or and most prebiotic studies use fermentation products of these same microbes 
(Quigley, 2012; Floch et al., 2015; Sánchez et al., 2017). In these studies, there is often 
not a hypothesis of why these microbes or microbial products would be helpful aside from 
a general pattern of dysbiosis associated with the disease system in which they are 
applied. Clinical trials have shown the effectiveness of these to be mixed (Kukkonen et 
al., 2007; Wickens et al., 2008; Radke et al., 2017; Quraishi et al., 2017; Ghouri et al., 
2014). 
To move microbiome medicine forward we must move to rationally designed pre- 
and probiotics (Kearney and Gibbons, 2018). If we understand a microbial community 
and why it is in a healthy state or why it has shifted with disease, then we can shift that 
community. By integrating microbiome and metabolome we believe this understanding 
will be possible. If we can find and explain relationships between microbes, metabolites 
and disease we can manipulate them in a targeted way. Selected bacteria with known 
metabolic function can be given as probiotics either alone or with other microbes they 
are dependent on. This can be paired with prebiotics to support the growth and 
establishment in the community of these beneficial microbes or changes in diet that 
provide the nutrients for the same purpose. Once we have a deep understanding of 
these communities then we can engineer them to improve human health.  
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